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Sex hormones form the gonads and stress hormones from the adrenals are responsible for 
maintaining sexual development and regulating cellular responses to stress, respectively. It is 
becoming evident that endocrine signalling networks do not exist in isolation. Instead they are 
integrated, allowing the cell to respond to multiple signals from the environment. However, most 
studies addressing the effects of hypothalamic pituitary gonadal (HPG) and hypothalamic pituitary 
adrenal (HPA) hormonal feedback to the pituitary have been limited to the isolated actions of 
individual hormones. In this study we focus on the interplay of adrenal and gonadal hormone 
feedback regulating target receptor mRNA and protein expression in a pituitary gonadoptrope cell 
line, and discuss how crosstalk signalling may contribute to differential gene expression. The 
transcriptional effects of progesterone (P4), and estrogen (E2) from the gonads, and cortisol from 
the adrenals, and gonadotropin-releasing hormone (GnRH) from the hypothalamus, are mediated by 
the progesterone receptor (PR), estrogen receptor (ER), glucocorticoid receptor (GR) and 
gonadotropin-releasing hormone receptor (GnRHR), respectively. Therefore, the aim of this study 
was to investigate the effect of P4, E2, the synthetic GR agonist dexamethasone (Dex), and 
gonadotropin-releasing hormone (GnRH), on ER, PR, GR and GnRHR levels in gonadotrope cells. 
Combinations of some hormones were also used in an attempt to simulate the interplay of signalling 
events present under physiological conditions. The LβT2 mouse pituitary precursor gonadotrope cell 
line was used as a model system. Cells were initially characterised for basal steroid receptor (SR) 
mRNA and protein expression using conventional PCR and western blot techniques. Results show 
expression of ERα, PR (A+B) and GRα mRNA, and GRα protein. PR (A+B) protein expression was not 
detected using western blot techniques, while no conclusive results were obtained for ERα protein 
expression. Reporter assays reveal GR-mediated transactivation in response to agonist treatment, 
but no PR- or ER-mediated transactivation in response to agonist. Quantitative real-time PCR 
analysis provided strong evidence that receptor mRNA is ligand-dependently regulated in response 
to Dex, P4 and GnRH. Specifically, Dex was shown to regulate GnRHR, ERα and GRα mRNA levels; P4 
was shown to regulate ERα and GRα mRNA levels; and GnRH treatment was shown regulate GnRHR, 
ERα, PR (A+B) and GRα mRNA levels in the LβT2 cell line. Combination treatments of Dex + GnRH 
appeared to act additively in regulating GnRHR and GRα mRNA. E2 priming appeared to modulate 
the Dex responsiveness on target GnRHR, ERα and GRα genes, suggesting cross talk between the ER 
and GR signalling pathways. Furthermore, both E2 and GnRH priming were shown to modulate 
hormone response element (HRE)-reporter gene activity. Finally ligand-dependent effects of Dex and 
GnRH on GRα mRNA levels appeared to be consistent with changes in GRα protein levels. 















and GnRH, suggesting GnRHR signalling is greatly influenced by HPA and HPG crosstalk. Furthermore, 
ER and GR expression were shown to be down-regulated in response to GnRH, Dex and P4, 
suggesting that hypothalamic, adrenal and gonadal feedback, respectively, all play an important role 
on relative LβT2 steroid receptor levels. Whether these hormonal effects are also exhibited in vivo in 
primary gonadotrope cells remains to be determined. Although no mechanisms were established; 
the study does lay a platform for further research into novel HPG and HPA crosstalk mechanisms 
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HYPOTHESES & STRATEGIES 
The central hypothesis of this study is that hormone-specific receptor (GnRHR, ER, PR, and GR) 
mRNA and protein levels are regulated in response to hormone treatments in the LβT2 cell line. 
To assess this hypothesis, a number of aims were formulated and strategies were explored. 
a) HORMONE TREATMENTS INFLUENCE GnRHR mRNA EXPRESSION IN 
THE LβT2 CELL LINE 
i) Effects of Dex and GnRH on GRE-mediated transcription 
A previous study performed by Kotitschke et al., (2009) has shown that Dex, GnRH and combinations 
thereof increase the transcriptional activity on a GRE promoter in the LβT2 cell line. Therefore, it is 
necessary to reproduce this published result in the current cell line before exploring novel signalling 
pathways.  
This was tested by examining the effect of saturating Dex and GnRH (100 nM) and combination 
treatments thereof on GR-mediated transactivation on a TAT-GRE-luc reporter construct in the LβT2 
cell line. Assuming the hypothesis, a ligand-dependent trend in GRE-reporter activity will be 
observed with hormone treatments. 
ii) Effects of Dex and GnRH on endogenous GnRHR expression in the LβT2 cell 
line 
Further results obtained by Kotitschke et al., (2009) have shown that the effects of Dex and GnRH on 
GRE-luc reporter activity are also observed on endogenous GnRHR mRNA expression in the LβT2 cell 
line. Therefore, to determine whether the cell line is responding according to the literature, this 
result needed to be reproduced in the hands of the current author. 
This was tested using real-time PCR and GnRHR-specific primer pairs to examine ligand-induced 
effects on endogenous GnRHR mRNA expression levels in the LβT2 cell line. Assuming the 
hypothesis, expression of endogenous GnRHR mRNA, relative to vehicle, will follow a reproducible 
ligand-dependent trend, in relation to treatment with Dex, GnRH and combinations thereof 















iii) Effects of E2 and P4 signalling on endogenous GnRHR expression in the LβT2 
cell line 
Considering the outcome of (ii), the LβT2 cell line was to be used to further explore novel signalling 
pathways regulating GnRHR mRNA levels. 
E2 and P4 signalling has been shown to regulate a number of gonadotrope responses via the HPG 
signalling axis (Ng et al., 2009; Sleiter et al., 2009). Furthermore, recent publications further support 
GnRHR and PR/ER crosstalk-signalling (An et al., 2009; Chen et al., 2009) in regulating target gene 
expression in LβT2 cells. Therefore, it was hypothesised that ER- and PR-mediated signalling 
pathways would regulate GnRHR mRNA expression levels.  
To assess this hypothesis, a similar approach was used as described in (ii). Relative expression levels 
of GnRHR mRNA in response to treatment with E2 (0.2 nM) and P4 (100 nM) and subsequent 
combinations thereof was investigated with real-time PCR.  
b) SR- AND GnRHR-MEDIATED SIGNALLING INFLUENCES ERα, PR (A+B) 
AND GRα EXPRESSION AND FUNCTION IN THE LβT2 CELL LINE 
i) SR- and GnRHR-mediated signalling influences ERα mRNA and protein 
expression levels  
According to the literature ERα mRNA is down-regulated in reproductive tissues including breast 
cancer (Alexander et al., 1990) and uterus cells (Hsueh et al., 1990) in response to P4 treatments. 
These effects may be due to the presence of an AP-1 site (Tang et al., 1997) and a half-PRE site 
(Amicis et al., 2009) in the ERα promoter. Furthermore ligand-dependent responses on ERα 
expression levels have been shown to be mediated by the PR (Amicis et al., 2009). 
Therefore, the hypothesis is that ERα mRNA and protein levels are regulated in response to 
treatment with Dex, P4, GnRH, E2 and combinations thereof in the LβT2 cell line. 
The strategy to test this hypothesis was to use real-time PCR and ERα-specific primer pairs to 
investigate the transcriptional effects of ligand treatment on endogenous ERα mRNA expression. 















otherwise stated, the ligands Dex, P4, E2 (0.2 nM) and GnRH and combinations thereof were used at 
saturating concentrations of 100 nM.  
Assuming the hypothesis is true, a reproducible and ligand-dependent trend was anticipated with 
varying ERα mRNA and protein levels in the LβT2 cell line.  
ii) SR- and GnRHR-mediated signalling influences PR (A+B) mRNA and protein 
expression levels  
Studies have shown the PR-B and PR-A promoters are up-regulated in response to E2, even though 
no consensus palindromic estrogen response element (ERE) can be found in their respective 
promoters (Kastner et al., 1990). In primary pituitary gonadotrope cells, PR mRNA expression is 
found to be up-regulated in response to prolonged treatments with 0.2 nM E2 (Turgeon and Waring, 
2006). Furthermore, in rat pituitary cells PR mRNA is up-regulated in response to E2, and down-
regulated in response to progesterone (Turgeon and Waring, 2000). 
Therefore the hypothesis is that PR (A+B) mRNA and protein levels are regulated in response to 
treatment with Dex, P4, GnRH, E2 and combinations thereof in the LβT2 cell line. 
The strategy to test this hypothesis was to use real-time PCR and PR-(A+B)-specific primer pairs to 
study the transcriptional effects of ligand treatment on endogenous PR-B mRNA expression. Protein 
levels were assessed by western blotting with PR-B-specific antibodies.  
Assuming the hypothesis is true, a reproducible and ligand-dependent trend will be observed in 
response to differential PR-B mRNA and protein expression levels in the LβT2 cell line.  
iii) SR- and GnRHR-mediated signalling influences GRα mRNA and protein 
expression levels  
In the literature GR mRNA and protein is down-regulated in response to glucocorticoids (Burnstein et 
al., 1990; De Silva et al., 1993). These transcriptional effects may be mediated by a half-GRE or a cis-
element resembling an NF-κB site in the GRα promoter region (Breslin et al., 2001) 
Therefore the hypothesis is that GRα mRNA and protein levels are regulated in response to 















The strategy to test this hypothesis was to use real-time PCR and GRα-specific primer pairs to 
examine the transcriptional effects of ligand treatment on endogenous GRα mRNA expression. 
Protein levels were assessed by using western blotting and a GRα-specific antibody.  
Assuming the hypothesis is true, a reproducible and ligand-dependent trend will be observed with 
regard to varying GRα mRNA and protein levels in the LβT2 cell line.  
c) THE EFFECT OF LIGAND-INDUCED RESPONSES ON HRE-luc EXPRESSION 
IN THE LβT2 CELL LINE. 
A central question of this part of the study was to assess whether ligand-activated ER, PR and GR are 
functionally active and can regulate promoter activity in the LβT2 cell line.  
This was tested by measuring SR-specific agonist transactivation on an HRE-luc-reporter construct. 
The functionality of SRs was assessed by monitoring HRE-luc activity in response to SR-specific 
agonist treatments, at saturating concentrations (100 nM). Differences in relative HRE-reporter 
activity between vehicle and treated LβT2 cells will confirm the hypothesis that ligand-activated SRs 
can modify HRE-reporter activity in LβT2 cells. Assuming the null hypothesis, no differences in HRE-
reporter activity would be seen for ligand pre-treatments relative to control, suggesting ligand 


















1.1  Hypothalamic pituitary signalling 
The hypothalamus is a small region of the brain that is responsible for integrating both 
nervous and endocrine signalling systems. It interprets signals from the nervous system to 
regulate the pituitary. The pituitary gland controls the majority of several endocrine organs 
in the human body. This interaction between the hypothalamus, pituitary and other 
endocrine glands is known as the hypothalamic-pituitary-endocrine axis, which controls all 
endocrine activity. 
The pituitary gland consists of two components, the posterior and the anterior pituitary. The 
posterior pituitary originates from neural tissue, containing neural axons from the 
hypothalamus. The anterior pituitary comprises of glandular cells, consisting of a 
heterogeneous mixture of cell types, each specialised in synthesising and secreting key 

















Figure 1.1 (A-C): The anatomy of the hypothalamus and pituitary. A: Representations of the cellular 
make up of the anterior and posterior pituitary. B: Schematic representation of the capillary network 
responsible for mediating the transportation of posterior pituitary hormones into the blood 
circulation. C: Schematic representation of the portal system mediating the transportation of 
hypothalamic hormones to their designated cell targets in the anterior pituitary [adapted from 
Purves (2004)]. 
 
1.1.1  Gonadotropes and gonadotrope cell lines 
1.1.1.1 Cell types of the anterior pituitary 
The anterior pituitary consists of a heterogenous population of differentiated endocrine 
cell-types, each responsible for the production of different hormones and the control of 
different endocrine signalling axes. The corticotropes differentiate first during pituitary 
development (Horn et al., 1992) and produce a precursor peptide, pro-opiomelancortin 















(ACTH), endorphin and enkephalin. Other cell types that differentiate later are the 
thyrotropes, which secrete thyroid-stimulating hormone (TSH), somatotropes, responsible 
for growth hormone production, lactotropes, which produce prolactin (PRL), and the 
gonadotropes, which produce the gonadotropin luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) (Horn et al., 1992).  
1.1.1.2 Gonadotrope cell lines 
Within the anterior pituitary, gonadotropes make up 6-15% of the total cell population 
(Hyde et al., 1982; Ibrahim et al., 1986). In the past, experiments investigating the function 
of the gonadotrope’s in reproduction have been performed in vivo or in primary pituitary 
cultures. However, the heterogeneity of the anterior pituitary cell population limits the 
interpretation of results derived from these studies. Furthermore, primary pituitary cells 
cannot be maintained in continuous culture, creating practical problems for experimental 
design. Therefore it was necessary to engineer immortalised pituitary cell lines, specifically 
gonadotrope cell-types, to use as model systems for the investigation of gonadotrope 
endocrine signalling. As a result, Dr. P. Mellon developed the αT3-1 and LβT2 cell lines and 
characterised them. 
Numerous studies assessing GnRHR, gonadotropin signalling and gene expression have been 
carried out in the αT3-1 (Duval et al., 1997a; Duval et al., 1997b; White et al., 1998; Norwitz 
et al., 2002) and the LβT2 cell lines (Thackray et al., 2009; An et al., 2009; Chen et al., 2009; 
Kotitschke et al., 2009).  All these studies have been shown to hold physiological relevance 
in interpreting molecular mechanisms of gene expression and regulation. 
1.1.1.3 The αT3-1 cell line 
The αT3-1 clonal cell line was created by targeted tumourigenesis in transgenic mice, using 
the promoter of the human glycoprotein hormone α-subunit (α-GSU) gene (Windle et al., 
1990). These cells represent precursor gonadotrope cells retaining some gonadotrope 
functions, including the expression of functional gonadotropin-releasing hormone receptor 
(GnRHR) and GnRHR-mediated responsiveness to gonadotropin-releasing hormone (GnRH) 
treatments. Additionally, they express several activin receptor subunits, as well as the β-















express, synthesise and secrete the gonadotropin hormone α-subunit, but they do not 
express either of the gonadotropin hormone-specific β-subunits, LHβ and FSHβ (Windle et 
al., 1990). 
1.1.1.4 The LβT2 cell line 
Like the αT3-1 cells, the LβT2 cell line was generated by targeted tumourigenesis. However, 
in this instance the rat LHβ promoter was used, generating a clonal cell line representing a 
more mature and differentiated gonadotrope cell (Turgeon et al., 1996). These cells express 
functional GnRHR, the gonadotrophin hormone α-subunit and β-subunits LHβ and FSHβ 
(Turgeon et al., 1996; Pernasetti et al., 2001) and have been reported to express functional 
steroid receptors including the progesterone receptor (PR), estrogen receptor (ER) and 
glucocorticoid receptor (GR) (An et al., 2009; Chen et al., 2009; Kotitschke et al., 2009). In 
addition, this cell line also expresses activin and activin receptors, as well as inhibin and 
follistatin, therefore displaying all the hallmarks of fully differentiated gonadotrope cells 
(Pernasetti et al., 2001). 
1.1.2  The hypothalamic-pituitary-gonadol axis (HPG) 
The mammalian HPG axis controls reproduction, including sexual development, puberty, 
gametogenesis, pregnancy and menopause.  The axis is governed by the pulsatile secretion 
and binding of the hypothalamic decapeptide gonadotropin-releasing hormone (GnRH) to 
the gonadotrope cell surface (Figure 1.2) (Levine and Ramirez, 1982). It activates the GnRH 
Receptor (GnRHR), a 328 amino acid G-protein coupled receptor, essential for maintaining 
serum gonadotropins (Burns and Matzuk, 2002). This is achieved through regulating the 
synthesis and release of the two heterodimeric glycoproteins gonadotropin hormones 
luteinizing hormone (LH) and follicle stimulating hormone (FSH).  Changes in the amplitude 
and frequency of GnRH pulses have differential effects on the rate on gonadotropin 
synthesis, resulting in differential secretion patterns of the gonadotropins, thereby 
regulating downstream hypothalamic pituitary gonadol signalling (Shupnik, 1996). 
The gonadotropin hormones are composed of a common α subunit and specific β subunits, 
namely luteinizing hormone β (LHβ) and follicle stimulating hormone β (FSHβ) (Gharib et al., 















inhibits both gondadotropin hormone production and gonadal function in mammals (Mason 
et al., 1986). Naturally occurring mutations in the GnRHR gene, resulting in GnRH resistance, 
have been found in patients with hypogonadotropic hypogoandism (HHG) (de Roux and 
Milgrom, 2001). Symptoms of HHG include delayed onset of puberty, absence of secondary 
sexual characteristics or low sex hormone levels (Seminara et al., 1998; Millar et al., 2004). 
Furthermore clinical studies have shown that the pulsitile administration of GnRH is able to 
induce ovulation and restore fertility in HHG woman (Seminara et al., 2000). These studies 
highlight the importance of GnRHR-mediated signalling with regards to the regulation of 
reproduction, and reveal why GnRHR agonists and antagonists are widely used in the clinical 
treatment of infertility and hormone dependent diseases (Neill, 2002). 
The pulsitile release of both LH and FSH is central to endocrine signalling (Figure 2), and 
regulation of follicular development, ovulation and steroidgenesis in females, and 
spermatogensis, testicular growth and steroidogenesis in males (Burns and Matzuk, 2002). 
Both are secreted into the blood stream from the pituitary and bind to their respective G-
protein coupled receptors, FSH receptor (FSHR) and LH receptor (LHR), present in gonadal 
















Figure 1.2: The HPG signalling axis. A model representing the major regulatory hormones and 
endocrine organs involved in HPG signalling. Arrows indicate the points of regulation mediated by 
hormones along the HPG axis. Arrows indicated positive (+) or negative (-) feedback effects of 
hormones. Abbreviations GnRH, LH and FSH are Gonadotropin-releasing hormone, Leuteinizing 
hormone and follicle stimulating hormone, respectively [figure adapted from Fernandes (2007)] 
 
Gonadotrophins regulate the production of steroids by inducing the expression of gonadal 
steroidogenic enzymes responsible for the synthesis of various steroid hormones including 
testosterone, progesterone and estrogen (Burns and Matzuk, 2002). These steroid 
hormones then feedback on the hypothalamus and pituitary, in turn regulating GnRH, LH 















Matzuk, 2002). This negative feedback is evidence for a complex signalling network that 
integrates and regulates HPG signalling.  
Furthermore, the role of hormones and steroid receptors (SRs) in mediating negative 
feedback signalling is supported in transgenic mice studies, where alterations in SR activity 
or steroid biosynthesis result in problems with sexual function.  Estrogen Receptor α (ERα) 
knockout mice exhibit female infertility that is associated with ovarian cyst formation 
(Schomberg et al., 1999), as disruption of estrogen (E2) feedback signalling results in 
continuous gonadotropin subunit mRNA expression at the level of the pituitary (Scully et al., 
1997) and elevated LH levels in serum (Couse and Korach, 1999; Hess et al., 1997). 
Additional studies on transgenic mice with abrogated E2 production reveal a female 
phenotype resembling that of ERα knockout mice, where high LH and FSH serum levels lead 
to infertility through ovarian cyst formation and inhibition of follicular development (Fisher 
et al., 1998). The male phenotypes exhibit infertile characteristics brought about through an 
arrest in early spermatogenisis, germ cell apotosis, Leydig cell hyperplasia and high LH levels 
(Robertson et al., 1999).  
1.1.3  The hypothalamic pituitary adrenal axis (HPA) 
The mammalian HPA axis is activated in response to stress, and regulates the synthesis of 
the endogenous glucocorticoid cortisol, secreted from the adrenal cortex. During a time of 
inflammation, lymphocytes/macrophages are activated. This leads to the production of 
inflammatory cytokines, including tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-
1β). These cytokines induce the expression of pro-opiomelanicortin (POMC), the pre-cursor 
of corticotrophin-releasing hormone (CRH). CRH from the hypothalamus induces the 
synthesis and secretion of adrenocorticotropic-releasing hormone (ACTH) in corticotrope 
cells in the anterior pituitary. ACTH enters into the blood circulation system, and stimulates 
the adrenal cortex, resulting in the synthesis and secretion of glucocorticoids (Figure 1.3) 
(Smoak and Cidlowski, 2004). Glucocorticoids are anti-inflammatory hormones which affect 
various cell types including the hypothalamus, corticotropes, gonadotropes, T-cells, 
macrophages, eosinophils, neutrophils, mast cells, endothelial and epithelial cells 
















Figure 1.3: The HPA signalling axis. A model representing the major regulatory hormones and 
endocrine organs involved in HPA signalling. Arrows indicate the points of regulation mediated by 
hormones along the HPG axis. Arrows indicated positive (+) or negative (-) feedback effects of 
hormones. Abbreviations CRH, POMC and ACTH are corticotropin-releasing hormone, pro-
opiomelanicortin and adrenocorticotropic hormone, respectively [figure adapted from Boetticher 
(2008)]. 
 
Glucocorticoids exert their anti-inflammatory effects through interrupting pro-inflammatory 
gene expression, cytokine-mediated signalling pathways and promoting apoptosis in certain 
immune cell types (Smoak and Cidlowski, 2004). Glucocorticoids are internally regulated 
















1.1.4  HPG-HPA cross-talk 
In times of stress, the sympathetic nervous system and HPA signalling allows an organism to 
mobilize all of the body’s resourses. Crosstalk signalling between HPG and HPA endocrine 
signalling pathways has been shown to modulate GnRH expression in the hypothalamus 
(Ferin, 1999; Berga et al., 1989; Chandran et al., 1994; Dubey and Plant, 1985), and has been 
associated with a reduction in LH secretion from the anterior pituitary (Figure 1.4) (Berga et 
al., 1989; Baldwin et al., 1991). 
 
Figure 1.4: HPA/HPG crosstalk. A model representing the major regulatory hormones and endocrine 
organs involved in HPG-HPA crosstalk signalling. Arrows indicate the points of regulation mediated 
by hormones along HPG and HPG axes. Arrows indicated positive (+) or negative (-) feedback effects 
















HPG and HPA crosstalk has also shown to positively influence GnRHR expression levels in 
mouse gonadotrope models, through mechanisms mediated by the GR and GnRHR (Figure 
1.4) (Kotitschke et al., 2009). These results presented by Kotitschke et al, reveal a molecular 
insight into how endocrine signalling within the body is functionally integrated to regulate 
hypothalamic pituitary endocrine signalling. Therefore, factors including metabolism, stress 
and immune function can influence HPG signalling through receptor crosstalk (Navratil et 
al., 2009; Kotitschke et al., 2009), supporting the concept that all hypothalamic-pituitary 
signalling axes are functionally integrated and bi-directionally regulated to maintain 
















 1.2  G-protein coupled receptor family 
G-protein coupled receptors (GPCR) form the largest group of membrane receptors involved 
in membrane signalling events, and encode for the largest gene family in most mammals 
(Flower,  1999).  These cell surface receptors are able to detect a wide array of extracellular 
stimuli; including peptide and non-peptide neurotransmitters, steroid hormones, growth 
factors, lipids, ions, odorant molecules and light (Marrinissen and Gutkind, 2001). They 
mediate signal transduction though G-protein interaction and downstream effector protein 
activation (Marrinissen and Gutkind, 2001). 
1.2.1  GPCR protein structure 
GPCRs share a common central domain comprised of 7-transmembrane α-helices, 
connected by 3 extracellular and 3 intracellular loops.  The carboxy (C)-terminal is 
intracellular and the amino (N)-terminal is extracellular (Bockaert & Pin, 1999). These 
domains contribute to the specific properties of ligand recognition, receptor activation, G-
protein binding and intracellular signal transduction (Kakar et al., 1993). 
1.2.2  Rapid G-protein-mediated signalling 
GPCR-mediated signal transduction is not dependent on a single biochemical pathway, but 
rather the integration of an intricate network of rapid intracellular signalling pathways. 
Signals are mediated through heteromeric G-proteins, consisting of a Gα-subunit tightly 
bound with GDP, and associated with Gβγ-subunits. Depending on the class of G-protein 
coupled to the GPCR, a wide variety of effecter proteins and signalling cascades may be 
activated in response to a signalling event (Figure 1.5) (Marrinissen and Gutkind, 2001; 
Nerves et al., 2002).  
In response to agonist binding, GPCRs undergo a conformational change that allows the 
exchange of GDP for GTP on the Gα subunit (Figure 1.5). Upon GTP binding, the Gα subunit 
dissociates from the GPCR and the Gβγ dimer (Marinissen and Gutkind, 2001). Here the GTP 
bound Gα, and Gβγ subunits can activate many downstream effecter proteins and 















et al., 2002). Both α and βγ subunits are responsible for the ligand-induced, GPCR-mediated 
signal transduction. 
More than 20 Gα subunits are known, and can be divided into four main classes depending 
on the type of effecter proteins and signalling pathways activated, and include Gαs; Gαi; Gαq 
and Gα12/13 (Kraus et al., 2001). 
Figure 1.5: The G-protein coupled receptor (GPCR) signalling network. Activation of the GPCR by 
ligands leads to the dissociation of the GDP-bound Gα-subunit and the tightly associated Gβγ-subunits 
which are able to interact with a diverse array of effector molecules involved in signal transduction 
pathways to regulate key biological responses [from Marinissen and Gutkind (2001)]. 
 
The Gαs subunit has been shown to activate adenylyl cyclases which increase intracellular 
levels of the second messenger cyclic adenosine monophosphate (cAMP), resulting in the 
activation of protein kinase A (PKA) (Beebe et al., 1994; Birnbaumer, 1992). In contrast, the 















and phospholipases (PLs) (Birnbaumer et al., 1992; Naor et al., 2000). Gαq subunits mainly 
activate phospholipase C (PLC), increasing the intracellular concentration of diacylglycerol 
(DAG) and inositol (1,4,5)-triphosphate (IP3) to induce Ca2+ mobilization and the activation 
of protein kinase C (PKC) (Noar et al., 2000; Ostrom et al., 2000). Gβγ dimers mediate 
signalling pathways that activate phosphoinositide-3 kinase (PI3K), components in the 
mitrogen-activated protein kinase (MAPK) pathways and PLC (Naor et al., 2000; Hur and 
Kim, 2002). All the diverse signalling cascades mediated by G-proteins can directly affect 
gene transcription and result in a number of specific biological responses. 
The diverse array of signalling proteins that GPCRs are able to interact with provides insight 
into how GPCRs are able to be involved in so many diverse and specific signalling pathways. 
For this reason, GPCR signalling mediates and regulates most biological functions including 
reproduction, metabolism and cell proliferation, cell differentiation and cell development 

















1.3  The gonadotropin-releasing hormone receptor (GnRHR)  
The GnRHR was first identified in gonadotropes of the anterior pituitary (Hyde et al., 1982). 
The primary structure of GnRHR was first determined in 1992 through sequencing GnRHR 
cDNA isolated from an immortalised murine gonadotrope cell line (αT3-1) (Tsutsumi et al., 
1992; Reinhart et al., 1992). To date the sequences of mammalian GnRHRs include species 
such as rat (Eidine et al., 1992), sheep (Brooks et al., 1993), bovine (Kakar et al., 1993), 
human (Chi et al., 1993) and other non-mammalian species have been described (Millar et 
al., 2004). All these receptors have been designated as type I GnRHRs, with the mammalian 
type I GnRHR lacking a C-terminal tail, setting it apart from non-mammalian GnRHRs and 
other GPCRs (Willar et al., 1999). The primary structure of the human GnRHR is represented 
in Figure 1.6.
Figure 1.6: The amino acid structure of the GnRHR. Figure shows the ligand and sites of mutations 
(dark circles) on the human GnRHR that are associated with human disease. Glycosylation sites are 
















Functional type I GnRHR has been detected in reproductive tissues including the pituitary, 
endometrium, ovary, placenta, uterus and breast. The type I GnRHR has also been detected 
in other non-reproductive tissues including the prostate gland, liver, heart, skeletal muscle, 
kidney and peripheral blood mononuclear cells (Kakar and Jennes, 1995; Limonta et al., 
2003; Imai and Tamaya, 2000; Imai et al., 1994). Moreover the receptor is also expressed in 
melanoma and breast tumour cells, highlighting its involvement in cell proliferation (Moretti 
et al., 2002).  
The accumulating evidence in the literature showing the wide spread expression of GnRHR 
in various extra-pituitary mammalian tissues and cells including reproductive tissues and 
non-reproductive tissues, suggests a functional role for GnRH and its receptor as an 
important autocrine and/or paracrine regulator in extra-pituitary tissues (Cheng and Leung, 
2005; Hapgood et al., 2005). In male reproductive tissues GnRH acting, via its receptor, has 
been shown to be involved in spermatogenesis, testis maturation (Cheung and Hearn, 2003) 
and sperm oocyte interaction (Morales, 1998). In female reproductive tissues GnRH and its 
conjugate receptor has been shown to regulate the menstrual cycle (Raga et al., 1998), 
ovarian steroidogenesis (Guerrero, et al 1993) and the maintenance of pregnancy (Rama & 
Rao et al., 2001). Besides reproductive roles, GnRH is also involved in cell proliferation 
(having anti-proliferative properties) and apoptosis (Cheng and Leung, 2005). 
Activation of GPCRs is typically followed by their desensitization and internalization, which 
involve processes of rapid agonist induced phoshorylation by both second messenger-
dependent protein kinases and G protein-coupled receptor kinases (Ferguson. 2001). 
Studies have shown that the mammalian GnRHR does not undergo rapid homologous 
desensitization or exhibit agonist-induced phosphorylation (Willars et al., 1999). This 
supports the concept that mammalian GnRHRs lack serine and threonine residues on the C-
terminal tail which are phosphorylated in response to desensitization. Therefore the 
mammalian GnRHR internalizes slowly via clathrin-coated vesicles and occurs independently 
of β-arrestin and dynamin (Heding et al., 1998). This unusual resistance to desensitization is 
essential in mediating GnRHRs anti-proliferative properties with regard to sustained ligand 















1.3.1 GnRHR gene structure  
The structures for the mouse (Zhou and Sealfon, 1994), rat (Reinhart et al., 1997), human 
(Fan et al., 1995), pig (Jiang et al., 2001) and sheep (Campion et al., 1996) GnRHR I genes 
have been characterised. In these species, the GnRHR I gene has a high degree of sequence 
homology within the coding regions, and consist of 3 exons separated by 2 introns. The 
intron exon boundaries are conserved across species, but the sizes of the introns, as well as 
the sequence and length of 5’ and 3’ untranslated regions (UTRs) differ across species 
(Figure 1.7). Exon 1 encodes the N-terminal tail and the transmembrane helices (TM) 1, 2, 3 
and part of 4. Exon 2 encodes the rest TM 4 and TM 5. Exon 3 encodes TM 6 and 7 (Figures 
1.6 and 1.7) (Fan et al., 1994). The GnRHR gene exists as a single copy gene and encodes a 

















Figure 1.7: Structural organization of the GnRHR I gene in human, mouse, rat and sheep. Exons (I, II 
& III) are represented by blocks, with portions containing coding sequences shown as dark blocks, 
and untranslated regions (UTR) shown as light blocks. Sizes of coding, and non-coding portions of 
exons are indicated above and represented in kilobasepairs. Introns are represented by solid lines, 
with sizes indicated below, and represented as kilobase pairs [figure adapted from Hapgood et al., 
(2005)].  
1.3.2  GnRHR promoter 
The 5’ flanking region of the mouse GnRHR gene has been cloned and the major 
transcriptional start site has been identified 62 nucleotides upstream of the ATG 
translational start site (Albarracin et al., 1994). While no TATA or CAAT sequences were 
found in the mouse GnRHR promoter region, several minor transcriptional start sites where 
identified (Figure 1.8) (Albarracin et al., 1994). Albarracin et al. (1994) further showed that a 
1.2 Kb mouse GnRHR genomic fragment attached to a luciferase reporter gene appeared to 















pituitary- and gonadotrope-responsive, as low expression occurred in the transfected 
placental cell line JEG-3 and the kidney fibroblast cell line CV-1 (Albarracin et al., 1994; 
Kaiser et al., 1997). 
Sequencing analysis (Figure 1.8) revealed a consensus activator protein-1 (AP-1) element at 
the position -336/-330 relative to the transcriptional start site (Albarracin et al., 1994; Kaiser 
et al., 1997). A gonadotrope-specific element (GSE) like sequence at position -15/-7 has 
been identified as a binding site for the orphan nuclear steroidogenic factor-1 (SF-1) (Kaiser 
et al., 1997; Duval et al., 1997a). Other researchers have identified a tripartite enhancer 
element that regulates cell specific expression comprised of a binding site for SF-1 at -244/-
236 bp (Duval et al., 1997b), a consensus AP-1 site at -336/-330 bp and an element referred 
to as GnRHR activating sequence (GRAS) at -391/-380 bp relative to translational start site 
(Duval et al., 1997a). GRAS was found to contain overlapping functional elements and 
binding sites for SMAD, AP-1 and FoxL2 proteins (Ellsworth et al., 2003; Norwitz et al., 
2002). In addition a region designated Sequence-underlying Responsiveness to GnRH-1 
(SURG-1) has been identified including binding sites for Oct-1 and nuclear factor Y (NF-Y) 
(Kam et al., 2005). Furthermore a region termed DARE (down-stream activin regulatory 
element) was found to contain binding sites for LHX2, a member of the LIM homeodomain 
family (Cherrington et al., 2005), as well as an ATTA element located at -360 bp in the 
proximal GnRHR promoter where LHX3 was shown to bind in vitro and in vivo (McGillivray et 
















Figure 1.8: Regulatory elements of the GnRH-R I promoter region for the human and mouse gene.  
Shaded boxes indicate TATA elements, striped boxes indicate CCAAT elements. Functional cis-
elements that have been characterised are shown in the black boxes. Putative elements which have 
been identified by promoter sequence analysis are shown in white boxes. Transcriptional start sites 
are indicated by arrows and the ATG shows the translational start site. The mouse site GRAS 
contains binding sites for SMAD, AP-1 and FoxL2 proteins. Figures are not drawn to scale [from 
Hapgood et al., (2005)]. 
 
1.3.3 GnRHR-mediated signalling 
Type I GnRHR is responsible for mediating the effects of GnRH signalling in the pituitary and 
is essential in maintaining gonadotropin serum levels, ensuring fertility (Burns and Matzuk, 















signalling cascades that regulate the synthesis and secretion of LH and FSH gronadotropins 
(Wen et al., 2010). 
With regards to the GnRHR ligand, two GnRH isoforms have been found (Neill et al., 2001), 
GnRH I and GnRH II, which differ by three amino acids (Burns and Matzuk, 2002). Both 
isoforms have specific affinities for their corresponding receptors. They differ in their tissue 
expression patterns, potential action, however, have been described in several species 
including humans (White et al., 1998; Burns and Matzuk, 2002). GnRH II is expressed in 
several regions of the brain, including the amygdale, caudate nucleus, hippocampus and 
thalamus, as well as the kidney, bone marrow, prostate, endometrium and ovary (Cheon et 
al., 2001; Kang et al., 2001). Although in vitro experiments indicate GnRH II has anti-
proliferative effects on ovarian carcinoma cells (Choi et al., 2001), functional 
characterisation of GnRH II and its receptor remain unreported in the literature, therefore 
the role of GnRH II signalling in gonadotropin physiology remains unknown. A second type II 
GnRHR has been shown to be ubiquitously expressed and down-regulated in multiple tumor 
cell lines, suggesting its involvement in inhibiting cell proliferation and prompting cell 
differentiation (Neill et al., 2001) 
The nature of G protein-coupled signalling initiated by the GnRHR largely depends on 
cellular context. For example, it has been demonstrated that the human GnRHR couples to 
Gαq in Chinese hamster ovary-K1 and COS-7 cells (Stanislaus et al., 1998), whereas it couples 
to Gαs in the placenta (Cheng et al., 2000). In mouse pituitary cell lines, the GnRHR activates 
four MAPK cascades’ including the ERK1/2, the c-Jun amino-terminal (JNK), the p38 MAPK 
and the big MAPK (BMK1/ERK5) pathways to various extends by PKC, Ca2+, and tyrosin 
kinase-dependent mechanisms (Levi et al., 1998; Roberson and Mulvaney, 1999; Kraus et 
al., 2001). These signalling cascades mediate the GnRH-targeted gene transcription in rat 
and mice models (Weck et al., 1998; Saunders et al., 1998; Vasilyev et al., 2002; Call and 
















1.3.4 Regulation of GnRHR mRNA expression 
Glucocorticoids have been shown to directly influence GnRHR expression in immortalised 
gonadotrope cell lines, with the ligand-dependent activation of the GR inducing both GRE 
reporter-promoter transactivation in αT3-1 cells (McGillivray et al., 2007) and endogenous 
GnRHR gene expression in LβT2 cells (Kotitschke et al., 2009; von Boetticher, 2008). 
The transcriptional effect of GnRH regulating endogenous GnRHR expression has been 
studied by research groups (Ellsworth et al., 2003). Previous studies from the Hapgood lab 
have shown that continuous treatment with 100 nM GnRH increases the expression of a 
synthetic transfected mouse GnRHR reporter-promoter construct by 2.5-fold (Sadie, 2006), 
while continuous 8 hour treatments of 100 nM GnRH was also shown to up-regulate 
endogenous LβT2 GnRHR mRNA expression (Kotitschke et al., 2009; Sadie, 2006). 
In a physiological context, GnRH is released in a pulsatile manner from the hypothalamus to 
regulate the expression and secretion of the gonadotropin hormones FSH and LH (Levine 
and Ramirez, 1982). Studies performed by Bedecarrats et al., (2003) have shown that the 
pulsatile stimulation with GnRH (1 pulse every 30 min) for 10 hours resulted in a 2-fold 
increase in GnRHR promoter activity and a 2-fold increase in GnRHR numbers on the cell 
surface (Bedecarrats and Kaiser, 2003). Taken together, these findings suggest that the 
GnRHR is transcriptionally regulated by both pulsatile and continuous treatment of GnRH in 
LβT2 cells. 
Finally a studied performed by Kotitschke et al., (2009) revealed that Dexamethasone (Dex) 
and GnRH co-treatments act synergistically in up-regulating endogenous LβT2 GnRHR mRNA 
expression. The study further showed that the effects of Dex and GnRH co-treatment on 
GnRHR expression are mediated by GR and GnRHR crosstalk, and involves a combination of 
genomic and non-genomic signalling events to enhance GnRHR promoter activity 
















1.4   Nuclear receptor family 3C: steroid hormone receptors 
Nuclear steroid receptors play a vital role in gene expression and regulating aspects of 
physiology, including in reproduction, stress, metabolism and immune function.  
Nuclear receptors are ligand-inducible, sequence-specific, DNA-binding proteins that 
recognise palindromic hormone response elements (HREs) in promoter regions of target 
genes to regulate gene transcription. They belong to a sub-class of the nuclear receptor 
super family 3, based on their primary sequence and mechanism for HRE-mediated 
transactivation (Carson-Jurica et al., 1990). Upon ligand-binding and receptor dimerization, 
these receptors adopt a head to head orientation when bound to the DNA, allowing for 
necessary interactions between basal transcription machinery and additional co-activators 
to drive chromatic transcriptional activity (Lu et al., 2006; Mangelsdorf et al., 1995). 
The glucocorticoid, estrogen, progesterone, androgen and mineralocorticoid (GR, ER, PR, AR 
and MR) receptors all belong to this subclass of modulating receptors, as they share primary 
and tertiary structural similarity, as well as gene regulatory mechanisms. 
1.4.1  Common domains and structure of nuclear receptors 
Nuclear receptors are modular proteins all consisting of 3 common domains, an N-terminal 
domain (NTD), a highly conserved DNA-binding domain (DBD) and a C-terminal or ligand-
binding domain (LBD). Within these domains are at least 2 transcriptional activation sub-
















Figure 1.9: The functional domains of nuclear steroid receptors. The domains AF-1 (N-terminal 
domain), DBD (DNA-binding domain), HR, (hinge region), LBD (ligand binding domain) and AF-2 (C-
terminal domain) are represented. Domains where multiple protein-protein interactions occur are 
shown with arrows. Co-activators include steroid receptor co-activator (SRC) 1/2/3 and the 
p300/CREB-binding protein (CBP). Co-repressors include histone deacetylases (HDACs). Areas where 
phosphorylation (P) and ubiquitation (U) occur are shown [figure adapted from Zhou and Cidlowski, 
(2005)]. 
 
AF1 (Figure 1.9, A) resides in the NTD and is important for full transcriptional activity of the 
SRs (Mangelsdorf et al., 1995; Kumar et al., 2003). This domain interacts directly with basal 
transcription machinery and multiple cofactors involved in regulating transcriptional activity 
(Dahlman-Wright et al., 1995; McEwan et al., 1993), and contain multiple Ser/Thr 
phosphorylation sites which are modified by various protein kinases (Weigel, 1996; Lange et 
al., 2000; Rochette-Egly et al., 2003).  
The central DBD (Figure 1.9, B) consists of 66-68 highly conserved amino acids and 9 
perfectly conserved cysteine residues. This primary sequence forms two zinc finger α-helix 
motifs, where zinc is coordinated into tetrahedral geometry by four cystines, resulting in 
correct orientation of two conserved α-helixes. Upon head-to-head homodimerization, one 















sequence recognition of HREs (Lu et al., 2006). The other α-helix is important for protein-
protein interaction for steroid receptor dimerization (Dahlman-Wright et al., 1991; Lu et al., 
2006).  
On the N-terminal side of the LBD there is a flexible hinge region (Figure 1.9, C) that is 
responsible for ligand-binding and ligand-induced changes in conformational states. Upon 
ligand-activation, a nuclear localisation sequence is exposed in this region that promotes 
nuclear transportation (Picard & Yamamoto 1987). 
The LBD (Figure 1.9, D) consists of 11 α-helixes and 4 β-sheets which fold into a three-
dimensional ligand binding pocket (Zu et al., 2006). There are three structural features that 
ensure ligand selectivity. First is a unique hydrogen bond network between receptor and 
bound ligand that establishes specific ligand recognition. Second is the shape of the ligand 
and the topology inside the binding pocket which enhances selectivity. Third is the relative 
position of the binding pocket within the receptors’ LBD.  Variations in these three factors 
contribute to ligand-specific binding characteristics of each SR (Zu et al., 2006). 
The AF-2 sub-domain is found on the C-terminal end of the LBD (Figure 1.9, E). This co-
activator binding cleft on the surface of the LBD has been shown to recruit a wide variety of 
co-activators that determine transcriptional activity. Specific charged residues and 
intermolecular interactions facilitate relative cofactor recruitment of each SR. (Williams and 
Sigler, 1998; Matais et al., 2000; Bledsoe et al., 2002; Li et al., 2005). A common leucine-rich 
LxxLL motif is found among AF-2 sub-domains for most of the SRs, which is believed to 
mediate the interactions between SRs and co-activators (Lonard and O’Malley, 2005), 
whereas the AR contains an FxxLF motif. This motif has been found to interact with multiple 
co-activators including steroid receptor coactivator-1 (SRC-1) (or NcoA-1), SRC-2 (TIF-2 or 
GRIP-1, NcoA-2), SRC-3 (RAC3, ACTR, AIB1,P/CIP and TRAM) (Heery et al., 1997; Le Douarin 
et al., 1996; Savkur and Burris, 2004; Torchia et al., 1997), and the p300/CBP “docking 

















1.4.2  Classical nuclear signalling by steroid receptors 
The genomic actions of SRs in mediating gene transcription have been examined 
extensively. Upon binding steroid, SRs in target cells become activated through a process 
involving conformational changes, dissociation from protein chaperones, nuclear transport 
and binding to palindromic steroid hormone response element (HRE) sequences in gene 
target promoters (Figure 1.10) (Tsai et al., 1994). Once directly or indirectly bound to the 
DNA, SRs can mediate their transcriptional regulation through transactivation or 
transrepression mechanisms. 
The majority of unbound SRs reside in the cytoplasm, where they are found in a complex 
with chaperone proteins including heat shock proteins (HSP90, HSP70), immunophilins, and 
p23 (Pratt et al., 2003). These interactions are required for proper protein folding and the 
assembly of a stable SR-HSP heterocomplexes, promoting ligand binding and maintaining 
cytosolic location (Zu et al., 2006).  
Upon ligand-binding, the receptor undergoes a conformational change that causes 
dissociation from chaperones and translocation to the nucleus (Weigel and Moore, 2007). 
Here it binds directly to promoter regions of target genes though HRE-protein interactions. 
HREs consist of inverted DNA sequence repeats of TGTTCT for the GR PR and AR, and TGACC 
for the ER (Parker, 1990). SRs can also indirectly interact with the DNA through protein (SR)-
protein (transcription factor) interactions. 
SRs can modulate gene transcription independent of HRE binding through protein-protein 
(transcription factor-SR) interactions, referred to as tethering. These interactions can disrupt 
or activate expression of target genes by blocking or enhancing the assembly of 
transcription machinery to the promoter respectively. Examples of transrepression and 
transactivation models are seen with the protein-protein interaction of the GR with nuclear 
factor–kappa B (NFκB) present in cytokine promoters, and the binding to Stat 5 on the 















DNA-bound SRs alter the transcriptional activity of target gene promoters, through the 
recruitment of co-activator or co-repressor proteins. These co-factors are devoid of DNA-
binding characteristics, and are recruited through protein-protein interactions via the AF-1 
and AF-2 sub-domains of SRs. Several co-activators form a bridge between DNA-bound SRs 
and the transcriptional initiation complex, and facilitate RNA polymerase II activity 
(Meckenna et al., 1999; Meckenna et al., 1999; Meckenna et al., 2002; Auboeuf et al., 
2002). 
Figure: 1.10. Mechanisms for classical SR action. SR monomers complex with chaperone proteins 
such as heat shock proteins (hsp) 90, p23 and immunophilins (X & Y). After hormone binding, the 
receptor undergoes a conformational change, dissociates from chaperones, and translocates to the 
nucleus where it binds to DNA through HRE interactions and/or interacts with other proteins 
including co-activators (CoA) or transcription factors (TF) to regulate transcription. Aspects of SR 
function shown to be regulated by posttranslational modifications (i.e. phosphorylation) are 
highlighted in red. Sub-cellular localisation of SRs is a dynamic process, with both nuclear 
translocation and export modulated by phosphorylation. Phosphorylation can also affect DNA-
binding affinity of SRs, interactions with other transcription factors and transcriptional activity. SR 
















Three groups of co-activators have been found to interact with SRs. The first are the p300 
and homologous cAMP-response element binding protein (CBP), which form the central 
position and serve as macromolecular “docking platforms” for SRs, CREB, AP-1, NFκB, p53, 
Ras-dependent growth factor, and signals inducers and activators of transcription (STATs). 
Second is the pS300/CBP-associated factor (p/CAF), which is a broad transcription factor 
that interacts with p300/CBP complex. Third are the p160 family of co-activators; SRC-1, 
SRC-2 and SRC-3, which interact with the AF-2 domain of SRs through signature LxxLL motifs 
located on the co-activators. These co-activators have intrinsic histone acetyltransferase 
activity (HAT) promoting chromatin decondensation, thereby allowing access for the 
transcription initiation complex (Nicolaides et al., 2010; Mckenna et al., 2002; Auboeuf et 
al., 2002; Heery et al., 1997: Beato et al., 2000) All these factors are responsible for 
stabilizing the transcription initiation complex, and promote RNA polymerase II activity. 
Post translational modifications including phosphorylation, acetylation, and ubiquitination 
can affect SR stability, turnover, sub-cellular localisation, ligand affinity, DNA-binding, 
protein-protein interactions, specificity and extent of target gene-promoter activity 
(Nicolaides et al., 2010; Weigel and Moore, 2007a; Weigel and Moore, 2007b). The AR, GR, 
ER and PR have all been shown to be phosphorylated on multiple sites along the AF-1 sub-
domains through the activity of specific kinases. Therefore SR activity can be modulated in a 
phosphorylation-dependent manner brought about through non-genomic signalling 
cascades (Red arrows in Figure 1.10) (Weigel and Moore, 2007). 
Steroid hormones have also been reported to stimulate non-genomic signalling events 
including second messenger production, ion channels, and protein kinase cascades. These 
actions happen on a time scale of seconds, and are not affected by inhibitors of gene 
transcription (Limbourg and Lia, 2003; Losel et al., 2003). These rapid effects of steroid 
hormones have been mimicked with cell impermeable steroid-protein conjugates, 
suggesting the event is initiated at the cell membrane and is distinguishable from the 
classical nuclear actions of steroids (Cato et al., 2002; Norman et al., 2004; Valverde and 
Parker, 2002; Cheskis, 2002; Watson and Gametchu, 1999; Losel and Wehling, 2003; Revelli 















gene transcription, have been termed non-genomic, as opposed to steroids’ conventional 
















1.5   The estrogen receptor (ER) 
The ER ligand 17β-estradiol (E2) is an important neurotrophic factor in brain development 
and differentiation, and has a primary role in transmitting feedback to GnRH neurons in the 
hypothalamus and to lactotropes in the pituitary (Edwards, 2006). The ovary is the major 
site of synthesis and secretion for E2, and is tightly regulated by the HPG signalling axis 
(Figure 1.2). E2 regulates the synthesis and secretion of a number of pituitary hormones 
that play vital roles in HPG signalling and HPG signalling feedback. E2 regulates GnRH 
expression and secretion in the hypothalamus, and is involved in the transcriptional 
regulation of gonadotropin hormones LH and FSH in gonadotrope cells through negative 
feedback mechanisms (Ng et al., 2009). E2 also has simulative effects on lactotrope 
proliferation (Lieberman et al., 1978; Lieberman et al., 1981), mediated by hormone-bound 
ERα up-regulating multiple growth factors, growth factor receptors and proteins involved in 
cell cycle progression (Katzenellenbogen et al., 2009).  
The effects of E2 are mediated by their intracellular receptors. The major ER isoform is a 66 
kDa protein termed ERα, which is essential in regulating both reproductive (Pfaff et al., 
1994), and non-reproductive processes including: skeletal physiology (Frank. 1995), tumour 
development and growth (Auchus et al., 1994), and cardiovascular function (Farhat et al., 
1996). This intracellular receptor has been found in a number of mammalian tissues 
including male and female reproductive tracks, female mammary glands, bone, the 
cardiovascular system and regions of the brain including the hippocampus, hypothalamus, 
preoptic area, amygdale, cerebellum, cerebral cortex and pituitary gonadotropes (including 
LβT2 and GN11 cell lines) (Couse et al., 1997; Ng et al., 2009; Edwards, 2006). 
1.5.1  The ERα gene and protein structure 
The cDNA for ERα was first cloned in 1986 (Green et al., 1986) and the genomic sequence 
was later described (Ponglikitmongkol et al., 1988). The ERα gene consists of 8 exons 
spanning 140 kb of chromosome 6 (Gosden et al., 1986). The ERα cDNA shows a high level 
of sequence homology between human and chicken (Krust et al., 1986), rat (Koike et al., 















Evidence has shown that there are multiple promoters present upstream to the ERα gene 
(Treilleux et al., 1997; Hodin et al., 1989; Kastner et al., 1990), highlighting the potential for 
tissue-specific regulation and the control of ER variant mRNA expression. Several attempts 
to characterise the ERα promoter has been performed mainly in breast cancer and HeLa cell 
lines (Treilleux et al., 1997; Schuur et al., 2001; deConinck et al., 1995; Cohn et al., 1999; 
McPherson et al., 1999; Tanimoto et al., 1999; Penolazzi et al., 2000). These studies show 
the presence of an AP-1 site (Tang et al., 1997), a half-PRE site (Amicis et al., 2009), and a 
palindomic binding site for the estrogen receptor transcription factor (ERF-1) (McPherson et 
al., 1997). ERF-1 has been shown to be a member of the AP-2 family of developmentally 
regulated transcription factors and is likely involved in regulating the expression of genes 
characteristic of the breast cancer phenotype (McPherson et al., 1997; McPherson et al., 
1999). 
The ERα promoter has been shown to be down-regulated in response to E2 in MCF-7 cells, 
while up-regulated in response to E2 in T47D, ZR-75 and EFM-19 cells (Donaghue et al., 
1999). This suggests that the transcription factors present within a cell; rather than the 
selective use of a specific promoter, determines whether ERα mRNA expression is increased 
or decreased in response to E2 (Donaghue et al., 1999; Castles et al., 1997; Pakdel et al., 
1989; Treilleux et al., 1997).  ERα promoters have no TATA-box, CCAAT-box or GC-box 
sequences. Multiple transcription start sites have been identified (Kos et al., 2001), with 
three half EREs being located and shown to be responsible for the E2 inducibility of the ERα 
promoter (Treilleux et al., 1997). 
Many studies have shown that the ERα promoter region is a large and complex regulatory 
promoter, comprised of many cis-elements. However, many questions still remain 
unanswered with regard to the function of multiple promoters, suggesting that further 
research is required in order to assess how the ERα promoter is regulated at the level of 
pituitary gonadotropes. 
Two major ER isoforms that mediate the genomic effects of E2 in mammalian tissues, 
referred to as the ERα and ERβ, are encoded by two different genes (Kuiper et al., 1996). 
The LBD and DBDs of the two ER isoforms are well conserved both at the amino acid level 















Both isoforms recognise similar HREs and respond similarly to E2. However, there are 
differences in DNA-binding affinity and specificity for pharmacological ligands (Cowley and 
Parker, 1999). Although ERα and ERβ are co-expressed in target tissues, they also exhibit 
differential tissue expression patterns and are functionally distinct, with ERα being the more 
potent transcriptional activator. Cells lines that express both ERs appear to show ERβ having 
the role of an attenuator for ERα activity (Hall and McDonnell. 1999). 
  
Figure 1.11: Primary structure comparison between the two estrogen receptor isoforms α and β. 
LBD (Ligand-binding domain); DBD (DNA-binding domain); HR (hinge region); and AF (transcriptional 
activation domains 1 and 2) are shown. The percentages indicate the amino acid sequence homology 
between specific domains of the ERα and ERβ. Illustration not to scale [adapted from Edwards 
(2006)]. 
 
An additional isoform of the ER termed truncated estrogen receptor product-1 (TERP-1) has 
no independent activity, yet it can stimulate the activity of conventional ERα at low ratios 
and inhibit the activity of ERα and ERβ in the pituitary at high ratios of 1:1 or greater 
(Resnick et al., 2000). The expression of TERP-1 is limited to the pituitary (Friend et al., 1995; 
Demay et al., 1996). All three ER isoforms have been found in rat, mice and humans species 
















1.5.2   Regulation of ER mRNA expression by hormones 
The anti-estrogenic action of progesterone (P4) has previously been established, with 
liganded PR recruiting specific repressor complexes to the ERα promoter region and down-
regulating ERα expression in MCF-7 breast cancer cells (Amicis et al., 2009). This P4-
mediated inhibition of ERα mRNA expression in reproductive tissues has been shown by a 
number of research groups in breast cancer cells (Read et al., 1989; Alexander et al., 1990), 
and in the uterus (Mester et al., 1974; Hsueh et al., 1990). Futhermore PR-B has been shown 
to recruit a repressor complex containing nuclear receptor co-repressor (NCoR) to a half-PRE 
site on the ERα gene promoter region in MCF-7 human breast cancer cells (Amicis et al., 
2009). 
Studies have shown that E2 regulates ERα mRNA expression in reproductive tissues 
(Donaghue et al., 1999; Castles et al., 1997; Treilleux et al., 1997). In most cases E2 has been 
shown to up-regulate ERα mRNA expression in reproductive cell lines including T47D, ZR-75 
and EFM-19 cells (Donaghue et al., 1999). It is this auto-regulation of ER expression which may 
contribute to its over-expression in some breast cancer tumors (Castles et al., 1997). On the other 
hand, E2 has been shown to down-regulate ERα mRNA expression in MCF-7 cells (Donaghue et al., 
1999) and down-regulate ERα and ERβ mRNA expression in primary rat pituitary cells (Schreihofer et 
al., 2000). Schreihofer et al., (2000) also showed that TERP-1 mRNA expression was increased in 
response to E2, further suppressing ER-mediated acftivity in the rat pituitary (Schreihofer et al., 
2000).  
1.5.3   ER-mediated signalling 
The ER is known to mediate gonadotrope signalling. The effects of estrogen have been 
shown to directly repress GnRH expression in GT1-7 neurons via mechanisms dependent on 
ER protein (Roy et al., 1999). The ERα has also been shown to be activated ligand-
independently in response to GnRH treatment in the LβT2 cell line (Chen et al., 2009). Chen 
et al., (2009) further showed the GnRHR-mediated phophorylation of the ERα coincides with 
an increase in binding to the co-activator, p300/CBP-associated factor (PCAF) and 















Interestingly E2 has been shown to affect GR-mediated signalling in MCF-7 and T47D breast 
cancer cells (Zhang et al., 2009). Zhang et al., showed that E2 does not effect GC-induced GR 
nuclear translocation, but instead reduced ligand-induced GR phosphorylation at Ser-211, 
associated with the active form of GR. The research group further showed an increase in 
protein phosphatise 5 (PP5) expression (mediating the dephosphorylation of GR at Ser-211), 
in response to E2 (Zhang et al., 2009). This study suggests a crosstalk between estrogen and 
glucocorticid signalling, with estrogens indirectly regulating GR activity.  
1.5.4  Rapid non-genomic actions of E2 
The rapid non-genomic effects of E2 were first identified in 1967 (Szego and Davis, 1967),  
and these rapid effects were mimicked by cell impermeable steroid-protein conjugates, 
suggesting a plasma membrane initiated event distinguishable from intracellular or nuclear 
actions of E2 (Cato et al., 2002).  For this reason, a candidate orphan GPCR was thought to 
mediate the rapid effects of E2. The orphan G-protein coupled receptor 30 (GPR30) has 
been shown to localise either to the plasma membrane (Filardo et al., 2000) or to the 
endoplasmic reticulum (Revankar et al., 2005). 
A recent study showed that E2 failed to bind to GPR30, and a GPR30 agonist (G1) did not 
stimulate oestrogen actions in mammary gland or reproductive organs (Otto et al., 2008). 
Therefore, these results suggest that GPR30 is not an ER. 
On the other hand, there is increasing evidence that the nuclear ER translocates to the cell 
membrane to mediate the non-genomic effects of E2. Studies of isolated cells from 
combined ERα and ERβ knockout transgenic mice show a lack of all E2 binding at the plasma 
membrane, and failed to respond to E2 by rapidly activating signal transduction pathways 
(Pendram et al.,2006). The ER can interact with a wide variety of signalling proteins capable 
of initiating kinase cascades, thereby influencing biological responses. The ERα was found to 
interact with caveolin-1 through Serine 522 (Razandi et al., 2003), further supporting the 
role of ER in non-genomic signalling. Caveolin-1 is a required structural protein for ERα to 
interact with caveolae rafts at the plasma membrane (Razandi et al., 2002). It is also 
believed that caveolin-1 mediated membrane localisation allows ERα and ERβ to associate 
with, and activate Gα and Gβγ proteins to activate Ca















activate proximal kinases (Src, PI3K) and distal kinases (ERK) (Kumar et al., 2007). It is these 
signals that are proposed to result in the rapid non-genomic effects of E2, including the 
post-translational phosphorylation of many other signalling proteins, modulating cell 
















1.6  The progesterone receptor (PR) 
Broadly speaking, the major roles of P4 in mammals are 1) in the uterus and ovary: 
regulating the release of mature ooctyes, facilitation of implantation, and the maintenance 
of pregnancy; 2) in the mammary gland: lobular and alveolar development in preparation of 
milk secretion, and suppression of milk protein synthesis; and 3) in the brain: mediation of 
signals that are require for sexual behaviour and the indirect regulation of key HPG target 
genes (Graham and Clarke, 1997). 
The actions of P4 are mediated through the binding to its conjugate receptors, the full 
length PR-B and N-terminally truncated PR-A isoforms (Figure 1.12) (Kraus et al., 1993). The 
PR isoforms are members of the type I sub-family of the nuclear hormone receptors 3C 
family, and are classified as ligand-activated transcription factors (Carson-Jurica et al., 1990). 
1.6.1   The PR gene and protein structure 
The single-copy human PR gene uses separate promoters and transcriptional start sites to 
produce the two isoforms PR-B and PR-A (Kastner et al., 1990), which are identical except 
for an additional 165 amino acids present only in the N-terminus of PR-B (Figure 1.12). 
Although the separate promoters of PR-A and PR-B are E2 inducible, they do not contain any 
consensus palindromic estrogen esponse elements (EREs). While a “half-palindromic” ERE 
might be involved in the E2 responsiveness in the promoter for A, no candidate ERE could 
















Figure 1.12: Primary structure comparison between the PR isoforms B and A. LBD (Ligand 
binding domain); DBD (DNA binding domain); HR (hinge region); and AF (transcriptional 
activation domains 1 and 2) are shown. The percentage indicates the amino acid sequence 
homology between the PR-B and PR-A. Illustration note to scale. Adapted from Edwards, 
2006. 
 
PR-B and PR-A are 116 kDa and 97 kDa proteins, respectively, which interact with specific 
PREs in the promoter regions of target genes including c-myc (Moore et al., 1997), fatty acid 
synthetase (Chalbos et al., 1987), FSH (An et al., 2009) and the mouse mammary tumour 
virus (MMTV) promoter (Haraguchi et al., 1997). While PR-B tends to be a stronger activator 
of target genes, PR-A can act as a dominant repressor of PR-B activity (Vegeto et al., 1993), 
suggesting that high PR-A expr ssion may reduce P4 responsiveness of PR-B. The repressive 
role of PR-A has also been shown to diminish the responsiveness of the GR, ER, MR and AR 
to their appropriate ligands (McDonnell et al., 1994; McDonnell and Goldman. 1994) 
Each PR isoform contains a C-terminal ligand binding domain, a DNA-binding domain, a 
hinge region, and at least two AF sub-domains, located in the lignad-binding domain (AF-1) 
and in the N-terminal domain (AF-2). The N-terminal of the PR-B contains an additional AF-3 
sub-domain within the unique 164-amino acid upstream segment, which contributes to the 
stronger transcription activity of PR-B (Giangrande et al., 1999; Li and O’Malley, 2003). 
PR-B contains a total of 14 known phosphorylation sites (Zhang et al., 1994; Zhang et al., 
1995; Zhang et al., 1997). Serines at positions 81, 162, 190 and 400 are defined as “basal” 















345 are ligand-inducible phosphorylation sites that are maximally phosphorylated 1-2 hours 
after P4 treatment (Zhang et al., 1995). Although the role of PR phosphorylation is not fully 
understood, it may influence co-factor interactions and PR turn-over (Lange et al., 2000). 
Additionally MAPK-dependent Ser294 phosphorylation has been shown to be required for 
rapid nuclear translocation of unliganded PR, suggesting MAPK signalling may regulate PR 
activity by altering nucleo-cytoplasmic shuttling (Qui et al., 2003).  
Both PR isoforms are expressed in the female reproductive tract, mammary gland, brain, 
pituitary gland and specifically in gonadotrope cells (Mangal et al., 1997; Soyal et al., 2005). 
The PR isoforms are major regulators of the HPG signalling axis by differentially regulating 
the transcription of the two gonadotropins (LH and FSH) (Figure 1.2) during the menstrual 
cycle (Thackray et al., 2006; Lu et al., 2006). PR-A and PR-B are co-expressed in most target 
tissues. However, their ratio can vary considerably depending on cell type or physiological 
conditions, suggesting differential PR expression contributes to cell-specific response 
(Shyamala et al., 1998). Transgenic mice models have shown that PR-A has a predominant 
physiological role in mediating the actions of P4 in the uterus and ovary, whereas PR-B is 
more important in the mammary gland and pituitary (Mulac-Jericevic et al., 2000; Mulac-
Jericevic et al., 2003) 
1.6.2  PR-mediated signalling 
Studies have highlighted the importance of P4 signalling in the regulation of LβT2 responses. 
For instance, the Mellon Lab has shown with over-expressed PR protein, the differential 
effects of P4 treatments on both LHβ and FSHβ expression in the LβT2 cell line (Thackray et 
al., 2006a; Thackray et al., 2006b). P4 was shown to inhibit basal and GnRH-induced 
induction of LHβ, while FSHβ was shown to be up-regulated in response to P4 treatments. 
Both these responses occur in a homone- and receptor-dependent manner, yet the 
mechanisms of liganded PR differ. In the case of LHβ repression, the PR was shown not to 
bind to the DNA directly, but rather recruited to the LHβ promoter region through protein-
protein interactions with transcription factors (Thackray et al., 2006a). FSHβ expression was 
induced via direct binding of the liganded PR to the FSHβ promoter region (Thackray et al., 















ensures differential regulation of the gonadotropin genes. P4 signalling has also been shown 
to modulate GnRH signalling at the level of the hypothalamus, as seen with P4’s negative 
effects of GnRH release (Slieter et al., 2009; Skinner et al., 1998).  
In the brain, PR expression has been linked with lordosis behaviour (behaviour associated 
with sexual reproduction). Transgenic mice with no functional PR show a complete lack of 
lordosos response after hormone administration (Lydon et al., 1995). This is further 
supported as sexual behaviour can be abrogated by direct delivery of antisense PR 
oligonucleotides to the cerebral ventricle of the rat brain (Mani et al., 1994). P4 is also 
known to stimulate γ-aminobutyric acid (GABA) signalling pathways in specific areas of the 
brain. The P4 mediated increase in GABA receptor binding sites contributes to lordosis 
behaviour in rats, suppression of aggressive behaviour and induction of the release of GnRH 
(Maggi and Perez, 1984; De Bold and Frye, 1994). 
PR-B has shown to be ligand-independently activated through GnRHR signalling (An et al., 
2009). In this study the authors show PR phosphorylation is mediated by GnRH treatments 
to increase co-activator affinity and promote PRE reporter-promoter and endogenous FSHβ 
expression in LβT2 cells (An et al., 2009). Another independent study in αT3-1 cells showed 
GnRH treatments resulted in the same ligand-independent activation of the PR, increasing 
SRC-3 interaction and luciferase expression on a PRE-luciferase reporter construct (An et al., 
2006). 
1.6.3  Regulation of PR mRNA expression by hormones 
The expression of both PR isoforms has been shown to be up-regulated in response to E2 in 
MCF-breast cancer cells (Milgrom et al., 1973), while P4 has been shown to repress PR 
expression in many reproductive tissues. Furthermore, P4 exposure was able to oppose the 
effect of E2-mediated PR expression (Milgrom et al., 1973). 
In primary pituitary gonadotrope cells, PR expression was found to be up-regulated in 
responses to pro-longed 0.2 nM E2 treatments (Turgeon and Waring, 2006). In rat pituitary 















(Turgeon and Waring, 2000). However in LβT2 cells, PR mRNA expression was not regulated 
in response to the same E2 treatments (Turgeon and Waring, 2006).  
1.6.4  The membrane-bound progesterone receptor (mPR) 
In 2003, a new family of progesterone receptors unrelated to nuclear receptors, but instead 
characteristic of GPCRs, was discovered (Zhu et al., 2003; Zhu et al., 2003). Non-genomic 
actions of progesterone have been reported in several tissue types, including the brain, 
kidney, intestine, testis and ovaries (Losel and Wehling, 2003). Rapid progesterone 
responses are also evident in cell types that lack nuclear or classical PR, such as T-
lymphocytes, platelets and the rat corpus luteum (Bar et al., 2000; Park-Sarge et al., 1995). 
Examples of non-genomic actions of P4, that suggest the involvement of receptors besides 
the nuclear PR, include the acrosome reaction in sperm characterised by a rapid increase of 
intracellular Ca2+ (Blackmore et al., 1991; Luconi et al., 2004), and initiation of oocyte 
maturation in amphibians and fish (Maller, 2001; Thomas et al., 2004). 
The first α isoform of a membrane-bound progesterone receptor (mPR) was cloned from the 
ovary of spotted sea trout and was reported in be involved in initiating the oocyte 
maturation in response to P4 (Zhu et al., 2003). Thereafter an additional two isoforms of 
mPR (mPRβ & mPRγ) were identified (Zhu et al.,2003). All three isoforms have been found in 
a number of vertebrate species including human, mouse, pig, frog, and fish (Zhu et al., 
2003). 
The molecular structure of the membrane bound progesterone receptor (mPR) reveals 
GPCR like topology, having 7-transmembrane domains, an extracellular N-terminal and 
intracellular C-terminal domains (Figure 13) (Tang et al., 2005). Yet based on amino acid 
sequence homology, the mPRs belong to a larger, highly conserved family of proteins 
termed the Progestin and AdipoQ Receptor (PAQR) family (Tang et al., 2005). According to 
this nomenclature, mPRα, β and γ are designated PAQR 7, PAQR 8 and PAQR 5, respectively 
(Tang et al., 2005). This conserved family of proteins include 11 mammalian members that 
have been termed PAQRs because its members are thought to be progesterone or 
adiponectin receptors. However, in this conserved family, only mPR-related receptors are 















related receptors, are found in animal, plant and fungi (Fernandes et al., 2005; Thomas et 
al., 2007). 
 
Figure 1.13: Amino acid sequence comparison between seatrout mPRα and the three putative 
human mPRs. Numbers above the box indicate the percentage sequence identity of amino acids in 
each domain between the sea trout mPR and the human mPRs. Solid gray indicate extracellular 
domains, solid black indicate transmembrane domains, white indicate cytoplasmic domains 
[addapted from Zhu et al., (2003)]. 
 
The expression of each human mPR isoform appears to be tissue specific. The α-isoform is 
predominantly expressed in reproductive tissues including the placenta, uterus, testis and 
ovaries. The β isoform is exclusively expressed in neural tissues throughout the brain and 
spinal cord, but has not been shown in the pituitary. The γ isoform is expressed in the 
kidney and gastrointestinal track (Zhu et al., 2003).  
The binding affinities of mPRs towards P4 were initially determined using bacterially 
expressed recombinant mPR proteins (Zhu et al., 2003), which showed specific binding of 
P4. An additional study supported this finding, showing that MDA-MB-231 cells transfected 
with human mPRα exhibit high-affinity binding for P4 (Thomas et al., 2007). The synthetic 
progestins and antiprogestins, which have relatively high affinities for nuclear PRs, display 
little to no competitive binding to mPRs (Thomas et al., 2007). These differences in selective 
binding between mPR and nuclear PR (nPR) reveal that non-genomic progesterone signalling 















The link between tissues where P4 levels have an influential role, and the expression pattern 
of the mPRs (especially the α-isoform), suggests that mPRs may be involved in P4-
dependent signal transduction in vivo. Zhu et al., showed that expression of the sea trout 
mPRα in human MDA-MB-231 breast cancer cells rapidly activated the MAPK (ERK1/2) 
signalling cascade and lowered cAMP levels in response to P4. In addition, the effect of P4 
cAMP levels were partially blocked by pre-incubations with pertussis toxin (an exotoxin 
which prevents G proteins from interacting with GPCRs). This suggests that the sea trout 
mPRα couples to an inhibitory G-protein (Zhu et al., 2003). However, contradictory reports 
have been published regarding mPRα’s ability to regulate cAMP levels through ERK1/2 
activation (Kriestsch et al., 2006). 
The concept that mPRs couple with G-proteins has been based on a number of pertussis 
toxin-sensitivity assays and co-immunoprecipitation studies (Zhu et al., 2003; Zhu et al., 
2003; Thomas et al., 2007; Karteris et al., 2006; Hanna et al., 2006).  Therefore, as putative 
GPCRs, mPRs may couple to a diverse array of signalling cascades, including Ca2+ fluxes. P4 
has been reported to induce rapid Ca2+mobilization in different target cells, including 
myocytes and sperm (Thompson et al., 2004; Blackmore et al., 1991). In support of this 
notion, the over-expression of ovine mPRα in CHO cells revealed a P4-dependent release of 
Ca2+ from the endoplasmic reticulum (Ashley et al., 2006).  
Therefore, as putative GPCRs, mPRs can be considered as novel pharmaceutical targets, 
which could lead to the design of more specific and effective drugs in controlling 
contraception and further reproductive disorders. However, much scepticism has been 
reported in the literature concerning the functional and mechanistic role of mPRs in 

















1.7  The glucocorticoid receptor 
Glucocorticoids play a vital role in inducing many biological responses involved in growth, 
reproduction, metabolism, immune and inflammatory reactions, as well as central nervous 
system and cardiovascular function (Tilbrook et al., 2000; Zhou and Cidlowski. 2005). 
Glucocorticoids regulate carbohydrate, protein and fat metabolism, and play a vital role in 
the protection of glucose-dependent tissues such as the brain and heart during stressful 
situations (Katzung, 2004; Goodman et al., 2006). Immune responses are also modulated 
through GR action; regulating the activity of peripheral leukocytes, suppressing the 
production of cytokines and chemokines, and changing the life span of immune cells (Lu et 
al., 2006). Therefore glucocoriticoids represent one of the most widely used therapies for 
many immune and inflammatory diseases including acute and chronic asthma, rheumatoid 
arthritis as well as in cancer treatment (Rhen and Cidlowski, 2005). 
The endogenous ligand to the GR in humans is cortisol. The synthesis and secretion of 
glucocorticoids by the adrenal cortex is tightly regulated by the hypothalamic-pituitary-
adrenal (HPA) axis (Figure 1.3). Like all HP-endocrine signalling, this axis is sensitive to 
negative feedback through circulating steroid hormones and glucocorticoids (Lu et al., 
2006). 
1.7.1  The GR gene and promoter structure 
The human GR (hGR) cDNA was first isolated by cloning in 1985 (Hollenburg et al., 1985). 
The hGR gene consists of 9 exons and is located on chromosome 5. At least three separate 
promoters have been identified for the mouse GR gene (Figure 1.14) (Strahle et al., 1992). 
The utilization of these separate promoters gives rise to five separate transcripts, encoding 
different 5’-untranslated first exons (Figure 1.14). The proximal GR-promoter region (1B and 
1 C) is very GC-rich, contains a CpG island characteristic of housekeeping genes and lacks 
TATA boxes and CAAT boxes,  which is consistent with the fact that the GR is ubiquitously 
expressed (Breslin et al., 2001). There are four Sp-1 sites upstream to the exon 1B 
transcriptional start site. Transcriptional regulation through GC-rich regions is complicated, 
as several factors other than Sp-1 can recognise this sequence (Berg, 1992). Tissue-specific 















share a common promoter with transcript 1A3, yet they have a broader expression pattern 
(Breslin et al., 2001).  
Computer analysis has suggested that there is a half-GRE present in the 1C promoter region, 
and that this sequence can bind GRβ. However deletion studies did not completely abolish 
Dex responsiveness. Finally a site resembling the nuclear factor-κB (NF-κB) site was found on 
the 1C promoter region, with preliminary studies showing NF-κB can bind to this site (Breslin 
et al., 2001). 
 
Figure 1.14 (A-B): Generation of multiple hGR isoforms form a single gene. (A) Genomic structure 
of the hGR gene. (B) The generation of multiple hGR transcripts as a result of alternative RNA splicing 
(Zhou and Cidlowski, 2005). 
Alternative splicing of the hGR  gene in exon 9 generates two highly homologous receptor 















and 94 kDa in molecular weight, respectively (Figure 1.15) (Zhou et al., 2005; Cidlowski,  et 
al. 1990; Oakely,  et al. 1996).  
These two isoforms have identical N-terminal domains, and differential C-terminal domains 
(Figure 1.15) (Lu and Cidlowski, 2005). hGRα resides in the cytoplasm and represents the 
classical GR that functions as a ligand-dependent transcription factor. hGRβ exerts a 
dominant negative effect on the transcriptional activity of hGRα, and shows cell specific 
differences in transcriptional activity compared to hGRα in response to Dex (Oakley et al., 
1999; Kino et al., 2009). 
 
Figure 1.15: Primary structure comparison between the glucocorticoid receptor isoforms α and β. 
LBD (Ligand binding domain); DBD (DNA binding domain); HR (hinge region); and AF (transcriptional 
activation domains 1 and 2) are shown.  Illustration shows comparison between GRα and β GR 
isoforms. The amino acid positions for each domain are indicated under primary structure. The 
positions of additional sub-domains are indicated for the GRα isoform. Illustration not to scale 
















1.7.2  GR-mediated signalling 
In the absence of ligand hGRα resides in the cytoplasm in a hetero-oligomeric complex 
containing heat shock proteins (HSP) 90, 70 and 50, immunophilins, as well as other proteins 
(Pratt et al., 1993). HSP 90 exposes the ligand domain and mediates ligand binding, while 
retaining cytoplasmic location through masking the nuclear localisation sequence (Figure 
1.14) (Terry et al., 2007). Immunophilin proteins are thought to be involved in GR nucleo-
cytoplasmic shuttling, as a study has shown immunophilins FKBP51 and FKBP52 interact 
with the hGRα to mediate cytoplasmic or nuclear localisation, respectively (Davies et al., 
2002; Davies et al., 2005; Echeverria et al., 2009). 
Upon ligand-induced activation, GRα undergoes a conformational change that results in 
dissociation from the multi-HSP protein complex and translocates to the nucleus (Pratt et 
al., 1993). To initiate transactivation, the GRα homodimer binds to an inverted hexametric 
palindromic DNA sequence, and interacts with receptor co-activators and chromatin 
remodelling complexes as described in Section 3.2. Some GC-responsive genes containing 
simple-acting GREs include the serine/threonine protein kinase, tyrosine hydroxylase and 
tyrosine aminotransferase (TAT) genes (Schoneveld et al., 2004; Schmid et al., 1987). 
Alternatively ligand bound GRα can modulate gene expression independent of GRE binding, 
through GR monomer and NF-κB, AP-1 or STAT protein-protein interactions (Kassel and 
Herrlich. 2007). The effects of glucocorticoids on the immune system are mediated by the 
transrepressive effects on pro-inflammatory transcription factors AP-1 and NFκB. GRα 
inhibits AP-1 and NF-κB mediated transcription through interacting with, and blocking 
subsequent transcription initiation complex formation (Jonat et al., 1990; Mukaida et al., 
1994). In addition to transrepression, GR protein-protein interactions can also lead to a 
synergistic induction of promoter activity, as seen with the interaction of GR and Stat-5 on 
the β-casein promoter (Stocklin et al., 1996). 
Post-translational modifications have been shown to affect GR signalling (Avenant, et al 
2010; Nicolaides et al., 2010). The hGRα has several phosphorylation sites including serines 
at positions 113, 141, 203, 211, 226 and 404, located in the AF-1 sub-domain. 















transcriptional activity, sub-cellular trafficking, target promoter specificity, duration of GR 
mediated signalling, and GR stability (Ismaili and Garabedian. 2004). However, 
phosphorylation at Ser 203, 211 and 226 does not affect angonist-induced hGR degradation, 
but has been shown to regulate GR-mediated transactivation through co-factor recruitment 
(Avenant et al., 2010) 
The GR is also modulated through acetylation, which occurs after ligand-binding and prior to 
nuclear translocation (Ito et al., 2006). A known acetylation site of the GR is the leucine rich 
region in the hinge domain (amino acids 492-465, sequence KKTK), which is analogous to 
the acetylation sites found in other SRs. Mutations at K494 and 495 on the hGR that 
prevented acetylation reduced the sensitivity to Dex suppression of interleukin 1beta-
induced granulocyte/macrophage colony-stimulating factor production, however, did not 
affect the repression of NF-κB genes (Ito et al., 2006). An additional study has shown that 
the circadian rhythm-generating transcription factors CLOCK and BMALI repress GR-induced 
transcriptional activity by acetylating several lysine residues located in the hinge region. This 
post-translational modification attenuates GR binding to GREs, and its ability to 
glucocorticoid-responsive gene expression (Nader et al., 2009). 
1.7.3  Regulation of GR mRNA expression by hormones 
GR mRNA expression is regulated by glucocorticoids. However, no full consensus GRE, TATA-
box or CAAT-box can be found in the promoter region or in the first untranslated exon of 
the hGRα gene (Zong et al., 1990). A study has shown that cells which contain endogenous 
GR protein undergo down-regulation in GR protein GC-binding capabilities and GR mRNA 
expression (Burnstein et al., 1990). This study suggests that GR mRNA and protein are down-
regulated in responses to GCs (Burnstein et al., 1990). 
In most cells tested to date, GR mRNA and protein are down-regulated by glucocorticoids, 
and has been extensively proven in several cell lines including the HeLa cell line (Burnstein 
et al., 1990; De Silva et al., 1993; Freeman et al., 2004). A representation of this model is 
shown in the HPA signalling axis (Figure 1.3). An exeption to the suppressive role of 















treatment results in the up-regulation of GR mRNA expression to aid in subsequent 
apoptosis (Breslin et al., 2001; Burnstein et al., 1990; Ramdas et al., 1999). 
 
1.8   Extra-nuclear signalling by steroid receptors 
The first evidence for rapid steroid signalling at the plasma membrane was published in 
1967, showing that an E2 binding protein at the plasma membrane of cells induced a rapid 
stimulation of cAMP production and Ca2+ flux in the uterus of rodents (Szego and Davis, 
1967). In various cells and tissue types a large variety of cytoplasmic signalling pathways 
have since been reported to be activated in response to steroid treatment. Depending on 
the steroid hormone and tissue-specific response, it appears that different receptors and 
mechanisms are involved in mediating the rapid actions of steroids. In the literature, four 
such mechanisms have been proposed to mediate these rapid effects of steroid hormones 
(Edwards, 2004). 
The first mechanism involves novel membrane receptors that are unrelated to conventional 
SRs, yet have been shown to mediate the specific non-genomic actions of hormones. The 
first protein/receptor that fulfils the requirements of a novel membrane receptor for P4 is 
mPR (Thomas et al., 2007). This receptor was cloned and characterised as a GPCR involved 
in mediating P4-induced oocte maturation in seat trout (Zhu et al., 2003) (Refer to 5.1). 
The second mechanism suggests that classical SRs interact with or are modified by signalling 
responses at the plasma membrane through GPCR crosstalk. Support for this is seen in the 
case of ER signalling in CHO cells. The E2 induced rapid stimulation of adenyl cyclase activity 
and inositol phosphate (IP3) formation was associated with the involvement of ERα and the 
activation of GαS & Gαq proteins (Razandi et al., 1999). Additionally, rapid phosphorylation of 
the unliganded PR and GR was shown to be mediated by the GnRHR in the LβT2 cell line, to 
regulate downstream target gene expression (An et al., 2009; Kotitschke et al., 2009). 
The third mechanism suggests that sub-cellular location of SRs is important in modulating 















the key for mediating the rapid effects of steroid hormones. Several truncated SRs have 
been identified that are linked to the rapid actions of hormones. Post-translational 
modifications of these isoforms have been shown to promote cell membrane association (Li 
et al., 2003). These truncated SR isoforms have been involved in mediating many rapid 
signalling responses in a hormone-dependent manner, including the activation of MAPK 
pathways in the Neo-cortex (Toran-Allerand et al., 2002; Marquez and Pietas, 2001), 
activation of PKC and Src in oesteoblasts (Longo et al., 2004), and the induction of Ca2+ 
fluxes in ovarian granulosa cells (Peluso et al., 2002; Peluso et al., 2003). It is thought that 
truncated SRs, through altered folding properties, are better substrates for lipid 
modifications and differential cell compartmentalization compared to full length SRs.  
The fourth and final mechanism suggests a subpopulation of conventional SRs associate 
with signalling complexes in the cytoplasm or the plasma membrane to induce the non-
genomic actions of steroid hormones. Several studies have shown that SR plasma 
membrane localisation is facilitated by the association of scaffolding proteins that 
translocate the protein-SR complex to the cell membrane. These scaffolding proteins 
include caveolin-1, Shc and insulin-like growth factor 1 (IGF1). Caveolin-1 is a major 
structural protein of caveolae (present in plasma membrane micro domains), and has been 
shown to physically interact with the ER in endothelial cells (Razandi et al., 2002), and 
promote ER translocation to the plasma membrane (Razandi et al., 2002). Another adaptor 
protein Shc, complexes with the ER to promote plasma membrane translocation, where it 
associates with IGF1 receptor in an E2 dependent manner in MCF-7 breast cancer cells (Song 
et al., 2004). 
One of the better characterised signalling actions of steroids is the rapid activation of the 
Src/ras/raf/MAP kinase (Erk) pathway. Through co-immunoprecipertation and pull down 
assays, it has been shown that the ER and PR interact with Src in a ligand-dependent maner 
(Song et al., 2002; Wong et al., 2002; Edwards et al., 2002; Migliaccio et al., 1998). Src is a 
key component in the coupling of extracellular signals with a variety of intracellular 
signalling transduction pathways, with SR-mediated Src/MAPK activation involved in 
multiple cell functions including proliferation, differentiation and apoptosis (Martin, 2001; 















ER and PR interact with Src though a 120 kDa adaptor protein termed modulator of 
nongenominc action of estrogen Receptor (MNAR). The N-terminal domain of MNAR 
contains multiple LxxLL motifs that interact with the AF-2 domain of the ER (Heery et al., 
1997) and a short polyproline sequence (PPPLPPR) of the PR (Figure 1.12) 
(Boonyaratanakornkit et al., 2001). Three PxxP motifs on MNAR have been shown to 
interact with the SH3 domain of Src (Barletta et al., 2004). These protein-protein 
interactions are responsible for stabilizing the Scr/ER or PR complex. Thus, the LxxLL motifs 
of MNAR may also interact with other SRs including the AR, GR and PR, in a ligand-
dependent manner (Barletta et al., 2004; Wong et al., 2002). However, this mechanism has 
















1.9 Integration of nuclear and extra-nuclear signalling pathways of 
steroid receptors to regulate gene expression 
It has become increasingly more evident that conventional SRs are multi-functional proteins, 
capable of acting in the nucleus as ligand-dependent transcription factors and outside the 
nucleus to activate non-genomic signalling pathways. There is a body of knowledge 
regarding the conventional ligand-dependent mechanisms of SR-medaited gene regulation 
(Avenant, 2009; Weigel and Moore, 2007) (Figure 1.16 - pathway 1). This pathway shows SR-
mediated gene regulation via ligand-dependent HRE binding and/or tethering mechanisms 
(refer to Section 1.4.2).  
The section above highlights the role SRs have in initiating extra-nuclear signalling pathways. 
SRs regulate extra-nuclear signalling cascades through interacting with scafolding proteins 
and signalling complexes at the cell membrane (Song et al., 2002; Wong et al., 2002; 
Edwards et al., 2002). Alternately the extra-nuclear effects of steroids can be mediated by 
putative mSRs to initiate extra-nuclear signalling cascades (Figure 1.16 – 2).  
Many extra-nuclear signalling pathways converge to activate nuclear transcription factors 
through post-translational modifications. This suggests that SR-mediated extra-nuclear 
signalling may ultimately affect gene expression patterns within the cell. Therefore to the 
knowledge of the author, the rapid steroid-induced activation of cell signalling events can 
influence the outcome of steroid-mediated gene expression through several hypothesised 
















Figure 1.16: Intergration of nuclear transcription and extranuclear signalling by conventional SRs 
and GPCRs. All numbered pathways are relavent to this current sIn the classical nuclear transcription 
pathway (1); steroid hormones activate steroid receptors (SR) by inducing conformational changes 
to promote nuclear translocation, dimerization, and direcet or indirect binding to promoters of 
target genes. Activated SR bound to target promoter DNA can regulate (positively or negatively) 
target gene transcription via HRE or tethering mediated mechanisms. A subpopulation of steroid 
receptors can associate with cytoplasmic or cell membrane signalling molecules including the 
tyrosine kinase Src in a hormone-dependent manner. This interaction leads to an activation of Src 
and the downstream MAPK signalling cascades (not numbered on figure). In addition to this, novel 
membrane receptors (mSR), unrelated to conventional receptors, have heen shown to activate 
MAPK signalling (2). Therefore steroid-induced activation of MAPK may influence gene transcription 
by 2 hypothesised mechanisms. The first hypothesis is genes that lack HREs can be regulated in 
response to steroid hormones (3). The second hypothesis is that HRE-regulated genes can be 
influenced bytranscription factors (TF), whose activities are regulated by MAPK signalling (4). Two 















crosstalk signalling (5). The first hypothesis is that GPCR ligands can ligand-independently activate 
SRs to regulate SR- and GnRHR-target gene expression via SR/GPCR crosstalk (6).The second 
hypothesis is that GPCR ligands can induce the expression of HRE regulated genes through ligand-
independent activation of SRs via by SR/GPCR crosstalk (7). (mSR – membrane steroid receptor; HRE 
– hormone response element; TF – transcription factor; SR – steroid receptor; P – phosphorylation; 
GPCR – G-protein coupled receptor) [figure adapted from Edwards, (2006), Schoneveld et al., 
(2004) and Kotitschke et al., (2009)]. 
 
The first potential hypothesised mechanism suggests target genes that lack conventional 
HREs, may be regulated in response to steroids (Figure 1.16 – pathway 3). This may be 
mediated by the liganded SR interacting with a signalling complex at the cell membrane (not 
shown on Figure 1.16) or via putative mSR signalling (Figure 1.16 – 2), to activate MAPK 
signalling and subsequent transcription factors (TFs) (Figure 1.16 – pathway 3). This was 
shown to be the case in the MCF-7 breast cancer cells, where E2-induced c-fos mRNA 
expression is mediated by a serum response element (SRE) in the proximal promoter, and 
not an ERE. Furthermore c-fos mRNA expression was mediated by an ER-dependent 
activation of the Src/Ras/MAPK pathway to activate the Elk1 transcription factor (which can 
bind to and transactivate an SRE) (Duan et al., 2001); or the Src-RAS/PI3K pathway to 
activate the serum response factor (SRF) (which can bind to and transactivate an SRE) (Duan 
et al., 2002). This study helps supports the hypothesis that steroid-induced MAPK signalling 
can regulate target gene promoters that lack HREs, further expanding the gene “network” of 
steroid hormones. 
The second mechanism proposes that complex promoters of SR target genes contain 
additional binding sites for other transcription factors, suggesting a required cooperative 
interaction between transcription factors and SRs. This cooperation may occur through 
post-translational modifications of transcription factors, mediated by protein kinase 
cascades (which are activated by SRs) (Figure 1.16 – pathway 4). This hypothesis is 
supported by a study from Watters et al., (2001) who show liganded ER directly interacts 
with EREs in the promoter region of the prolactin gene to positively influence gene 















MAPK pathway (Walters et al., 2001). This suggests that E2 induction requires cooperative 
interactions between the ER (bound to EREs) and other transcription factors modulated by 
MAPK signalling to enhance gene expression (Vasudevan et al., 2001). Furthermore the 
effects of GR binding to a GRE in the proliferin gene can either result in transactivation or 
transrepression, depending on the composition of the AP-1 proteins, c-jun and c-fos, on an 
adjacent AP-1 site (Miner and Yamamoto, 1992; Pearce et al., 1998). These studies confirm 
the hypothesis that target HRE-regulated promoters can be influenced by other 
transcription factors, whose activities are regulated through MAPK signalling (Figure 1.16 – 
pathway 4). 
This integration of nuclear and extra-nuclear signalling mediated by SRs, is what makes 
crosstalk signalling between endocrine signalling axes achievable. Therefore, these 
hypothesised mechanisms outlined above, give some insight into how target mRNA levels 
may be regulated in response to hormones treatments. It must be noted that the 
involvement of signalling complexes at the cell membrane (including as Src) in mediating 
steroid-induced responses will not be assessed in this study. Instead emphasis will be laid on 
















1.9.1 Integration of nuclear and extra-nuclear signalling between 
GnRHR and other SRs in pituitary gonadotropes 
In the past, the mechanisms of action of a particular SR have usually been studied in 
isolation. It is becoming increasing clear that endocrine signalling is not one-dimensional. 
However different signalling pathways must crosstalk in order to fine tune and integrate the 
cell’s responses to multiple and simultaneous signals from the environment. Steroids 
orchestrate a broad and complex array of signalling cascades beyond the classical genomic 
role of SR-dependent gene transcription. Considering that all SRs act via similar mechanisms, 
insights into the function of one is likely to be relevant to the group of SRs as a whole. 
Recent studies are beginning to reveal crosstalk mechanisms between the SRs and GnRHRs 
that mediate a number of HPG signalling events at the level of gonadotropes (An et al., 
2009; Kotitschke et al., 2009; Chen et al., 2009) (Figure 1.16 – 5). These studies were 
performed in the LβT2 cell line, and represent important findings with regards to the ligand-
independent activation of SRs mediating gonadotrope cell responses.  
The study performed by An et al., (2009) revealed a crosstalk mechanism between the PR 
and GnRHR (Figure 1.16 – pathway 6). Here they demonstrated that GnRH treatments 
induce PR phosphorylation to increase its interaction with the co-activator nuclear co-
activator 3 (NCoA3). This enhances PR recruitment to the PRE-region of the fshβ promoter 
through co-factor interaction. An et al., further shows PR-B is phosphorylated at Ser-249 in 
response to GnRH by PKC, promoting interaction with the co-activator NCOA3. It is this co-
factor recruitment that results in the rapid and positive effect GnRH has on fshβ expression 
in the LβT2 cell line (An et al., 2009). 
A study performed by Kotitschke et al., (2009) revealed a crosstalk mechanism between the 
GR and GnRHR. The study showed that Dex and GnRH act synergistically to regulate GnRHR 
expression in LβT2 cells in a GR-dependent manner (Figure 1.16 – pathway 6). Kotitschke et 
al., showed that Dex treatment resulted in the Dex-mediated activation of the GR (Figure 
1.16 – pathway 1), while GnRH treatment resulted both the activation of c-Jun/c-fos 
transcription factors, and the ligand-independent activation of the GR through site specific 















independent effects of GnRH on the GR were replicated on a TAT-GRE-Luc reporter in LβT2 
cells (Figure 1.16 – pathway 7) (Kotitschke et al., 2009).  
A study performed by Chen et al., (2009) revealed that GnRHR and ERα crosstalk to 
transcriptionally regulate the fosB gene in the LβT2 cell line. The data suggests that GnRH-
mediated phosphorylation of ERα results in the rapid association with the co-factor PCAF. 
This increases the co-recruitment of the ERα to an ERE within the endogenous fosβ 
promoter region in LβT2 cells, in turn activating fosβ expression (Figure 1.16 – pathway 6). 
The authors also demonstrated that this mechanism activates other genes in the LβT2 cell 
line, including the fshβ sub-unit gene (Chen et al., 2009). 
Taken together these studies show signalling pathways mediating the actions of GnRH and 
steroid hormones are dependent on SRs, and converge to regulate gene expression in 
gonadotrope cells. Furthermore, nuclear and extra-nuclear signalling is likely to reveal 
further insight into the mechanisms underscoring important biological functions, including 
the neurological, immune, stress, and reproductive signalling axes. Finally, putative 
mechanisms for signalling crosstalk between hormone receptors will give a new perspective 
on possible drug targets, and generate a better understanding of the endocrine signalling 


















MATERIALS AND METHODS 
2.1  Compounds and antibodies 
Dex, P4, E2, GnRH and the P4 agonist, R5020, were purchased from Sigma-Aldrich, South 
Africa. Polycolonal antibodies for the mammalian GR (H-300, sc-8992), PR-B (C-20, sc-539), 
ERα (MC-20, sc-542) and the HA-tag (Y-11, sc-805), as well as the monoclonal antibodies for 
the mPRα (Y-14, sc-50113), the human PR-B (B-30)(sc-811) and PR(A+B) (AB-52) (sc-810), 
were obtained from Santa Cruz Biotechnology, USA. Polycolonal antibodies for Flotilin-1 
(#610820) were obtained from BD Biosciences, USA. Polyclonal antibodies for p44/42 MAP 
Kinase (ERK1 and ERK2) (#9102) were obtained from Cell Signalling, South Africa. The 
monoclonal antibody for β-Tubilin (T4026) was obtained from Sigma-Aldrich, South Africa. 
The secondary anti-rabbit HRP conjugate (sc-2313), anti-mouse HRP conjugate (sc-2005) and 
anti-goat HRP conjugate (sc-2350) antibodies were purchased from Sigma-Aldrich, South 
Africa. Refer to section 2.11 for dilutions used for each specific primary antibody, as well as 
the corresponding secondary antibody and dilution thereof. 
2.2  Incubation with test compounds 
Dex, P4, and R5020 were diluted in 100% EtOH to a final concentration of 100 µM. E2 was 
diluted in 100% EtOH to a final concentration of 100 nM. GnRH was purchased as a 
lyophilized salt and dissolved in H2O to a final concentration of 100 µM. All test compounds 
















2.3  Plasmids 
Wild type HA-tagged human GR (pCMV-HA-human GR) expression vector was obtained from 
Prof. M.J. Garabedian at NYU Department of Microbiology, New York. The pTAT-GRE-E1b-luc 
plasmid was a gift from Dr G. Jenster at Erasmus University of Rotterdam, Netherlands and 
the pCMV-ß-galactosidase plasmid was a gift from Dr. G. Haegeman (University of Gent, 
Belgium). The pMT-PR-B was gift from Prof. S. Okret (Karolinka Institute, Sweden). The 
expression plasmid pSG5-hERα was a gift from F. Gannon (EMBL, Germany) and the 
ERE.vit2-luc was a kind gift from K. Korach (National Institute of Environmental Health 
Science, USA). The human mPRα expression plasmids (pcDNA3.1/hmPRα, 
pcDNA3.1/V5/hmPRα and pHA/hmPRα) were kindly given from Dr. B. Gellersen 
(Endokrinologikum Hamburg, Germany). Plasmid maps were generated for mPRα constructs 
through DNA sequence analysis (Figure 12.1, Figure 12.2 and Figure 12.3). 
2.4 Cell culture 
LβT2 mouse pituitary gonadotrope cells were kindly provided by Dr. P. Mellon from the 
University of California, San Diego, USA. COS-7 monkey kidney fibroblast cells were 
purchased from American Type Culture Collection (ATCC, USA). Both cell lines were 
maintained in high glucose Dulbeccos’s Modified Eagles Medium (DMEM, Sigma-Aldrich, 
South Africa) supplemented with 10% fetal calf serum (FCS) (Delta Bioproducts, South 
Africa), 50 µg/ml penicillin and 50 U/ml streptomycin (Gibco-BRL Life Technologies, UK), 
unless stated otherwise. All cultures were maintained in 75 cm2 culture flasks (Greiner Bio-
one International, Austria) at 37°C, in an atmosphere of 90% humidity and 5% CO2. LßT2 
cells and COS-7 cells were passaged with 0.25% trypsin / 0.1% EDTA in calcium- and 
magnesium-free PBS (Highveld Biologicals, South Africa) once or twice a week, respectively. 
LßT2 cells were very sensitive to over-trypsinising, and were therefore not incubated in the 
trypsin solution for longer than 3 minutes. All cell lines were regularly tested for 
mycoplasma infection by means of Hoechst staining (Freshney, 1987), with only 
mycoplasma-negative cells used. 
End1/E6E7 (endocervical cells immortalised with the human papillomavirus 16/E6E7) cells 















America. The End1 cells were gown in StemlineTM Keratinocyte Medium II (KSF) (Sigma-
Aldrich, South Africa) supplemented with CaCl2 (final concentration 0.4 nM), 100 U/µl 
penicillin and 100 µg/µl streptomycin (Gibco-BRL Life Technologies, UK), as were the bovine 
pituitary extract (BPE) StemlineTM Keratinocyte Growth Supplement, Sigma-Aldrich, South 
Africa). Passaging and maintenance of the Endo-cervical cell line was performed by Nicky 
Verhoog. (Verhoog, 2010) 
2.5  Plasmid transformation and preparation 
The plasmids were transformed into Escherichia coli DH5α cells by heat shock 
transformations according to Sambrook et al. (Sambrook et al., 1989). Briefly, 100 µl 
competent cells were mixed with 10 ng of DNA. The mixture was placed on ice for 30 min, 
followed by 2 min incubation at 42°C and 2 min incubation on ice. Immediately after 
transformation, cells were mixed with 900 µl SOC medium [2% (w/v) tryptone, 0.5% (w/v) 
yeast extract, 0.05% (w/v) NaCl, 2.5 mM KCl, 10 mM MgCl2 and 20 mM glucose] (Sambrook 
et al., 1989) and incubated (1 hour, 37°C while shaking at 200 rpm). Cells were subsequently 
plated out on LB agar plates [1% (w/v) tryptone, 0.5% yeast extract, 1% NaCl and 1.5% agar 
containing 50 µg ampicillin] (Sigma-Aldrich, South Africa) and allowed to grow overnight at 
37°C (Sambrook et al., 1989). The following day, colonies were picked and grown in 50 ml LB 
medium [1% (w/v) tryptone, 0.5% yeast extract and 1% NaCl, containing 50 µg/ml ampicillin] 
for at least 8 hours at 37°C while shaking. For glycerol stocks 500 µl 80% (w/v) glycerol was 
mixed with 500 µl of the cell suspension and stored at -80°C. For plasmid preparations, LB 
medium containing 50 µg/ml ampicillin was inoculated and allowed to grow overnight at 
37°C while shaking. The next day the plasmid DNA was purified with the GeneEluteTM 
Plasmid Midiprep Kit from Sigma (Sigma-Aldrich, South Africa), according to the 
manufacturer’s protocol. The integrity and purity of the plasmids were tested by restriction 
















2.6  Transient transfections and reporter assays 
LßT2 cells were plated in 12-well culture plates (Greiner Bio-one, International,  Austria) at a 
density of 1 X 105 cells per well in 1 ml DMEM supplemented with 10% FCS and antibiotics 
as described elsewhere. Twenty-four hours after plating, the medium was replaced with 
phenol red-free Dulbecco’s Modified Eagles Medium (D1145) (Sigma-Aldrich, South Africa) 
supplemented with 10% charcoal-striped FCS serum (#306) (Highveld Biological, South 
Africa) and antibiotics (as describedin Section 2.4). Cells were transfected with 250 ng pTAT-
GRE-E1b-luc or 300 ng ERE.vit2-luc promoter-reporter constructs. In order to correct for 
transfection efficiency, 25 ng pCMV-ß-galactosidase was co-transfected. All transfections 
were performed according to the FuGENETM 6 (Roche Applied Science, South Africa) product 
protocol, at a ratio of 1μg DNA: 2 μl FuGENETM 6. At least 24 h after transfection, the 
medium was replaced with phenol red-free Dulbecco’s Modified Eagles Medium (D1145) 
(Sigma-Aldrich, South Africa), serum-free medium containing antibiotics (described in 
Section 2.4). Incubations were performed with test compounds as indicated in appropriate 
figure legends. For reporter assays, cells were harvested in 50 μl reporter lysis buffer 
(Promega Corp., USA) per well. The luciferase assays (Luciferase Assay System, Promega, 
USA) and β-galactosidase assays (Galacto-Star, Tropix Inc, USA) were carried out with 10 μL 
cell extract in white 96-well plates in a Modulus microplate reader (Turner Biosystems, 
USA). Luciferase values were normalised to corresponding β-galactosidase values and 
expressed relative to vehicle control values. 
2.7  Isolation of total RNA 
LβT2 cells were plated in 12-well culture plates (Greiner Bio-one, International, Austria) at a 
density of 4,5 X 105 cells per well in 1 ml DMEM medium supplemented with 10% FCS and 
antibiotics (as described Section 2.4). Twenty-four hours after plating, the medium was 
replaced with Phenol red-free Dulbecco’s Modified Eagles Medium (D1145) (Sigma-Aldrich, 
South Africa) supplemented with 10% charcoal stripped serum and antibiotics (as described 
in Section 2.4). If indicated, a concentration of 0.2 nM E2 was added to each sample as 
shown in appropriacte figure legends. Seventy-two hours after plating, the medium was 















South Africa), serum-free media, containing antibiotics (described in Section 2.4) and 
incubated with 100 nM test compound for 8 hours, as indicated in the figure legends. Total 
RNA was isolated with Trizol reagent (Sigma-Aldrich, South Africa) according to the 
manufacturer’s protocol. Briefly, 400 μl Trizol reagent was added per well and incubated at 
RT for 5 min. Thereafter cell lysates were transferred into microcentrifuge tubes and 
centrifuged for 10 min at 12 000 g (4°C). The supernatant was transferred into new 
microcentrifuge tubes, 80 μl chloroform was added to each sample and vortexed for 15 sec. 
Thereafter the samples were centrifuged for 15 min at 14 000g (4°C). The top aqueous 
phase (125 µl) containing the RNA was transferred into new microcentrifuge tubes and 200 
µl of isopropanol was added. Subsequently, the samples were incubated at RT for 10 min 
followed by centrifugation for 10 min at 14 000 g to pellet the RNA (4°C). The RNA 
precipitates were washed twice with 400 μl 70% EtOH and centrifuged for 5 min at 14 000 g 
(4°C). The RNA was allowed to air dry for 5 min and re-suspended in 15 μl DEPC-treated-
water (Addendum F). The RNA was then incubated at 55°C for 5 min, where after the 
samples were stored at -20°C. 
To confirm the integrity of the isolated RNA, denaturing formaldehyde agarose gel 
electrophoresis was performed (Sambrook et al., 1989). Sample loading buffer (15 μl, 
Addendum F) was added to 0,5 μg of each RNA sample, incubated at 65°C for 10 min to 
denature secondary structures and cooled on ice. The samples were analyzed by gel 
electrophoresis on 1% formaldehyde agarose gels in RNA electrophoresis buffer (Addendum 
F) at 65 V for approximately 1.5 h (Sambrook et al., 1989). 
2.8  cDNA synthesis 
Total RNA was reverse-transcribed using the Transcriptor First Strand cDNA Kit (Roche 
Applied Science, South Africa) according to the manufacturer’s protocol for cDNA synthesis 
using anchored oligo (dT) priming. Each RNA sample (≈1 μg) was mixed with 0.5 μl oligo(dT) 
pimers (final concentration 2,5 μM) and DEPC-treated water to make up a final volume of 
6.5 μl. The mixture was incubated for 10 min at 65°C. Samples were put on ice and allowed 
to cool down. Subsequently, 2 μl Transcriptor Reverse Transcriptase Reaction Buffer, 0.25 μl 















and 0,25 μl Transcriptor Reverse Transcriptase (5 units) were added to each sample, mixed 
carefully and incubated at 50°C for 1 hour. To stop the Transcriptor Reverse Transcriptase 
samples were incubated for 5 min at 85°C. Thereafter samples were used for PCR or stored 
at -80°C. 
2.9  Conventional PCR 
Conventional PCR was performed using GoTaq buffer and GoTaq Flexi DNA polymerase 
(Promega Corp., USA). Each reaction contained the following: 
 
5x GoTaq Buffer   1x 
10 mM dNTP’s    0.2 mM of each dNTP final  
Sense and anti-sense primers  See Table 2.1 
25 mM MgCl2    1.5 mM 
5 U/µl Go Taq Flexi Polymerase  1.25 U 
Input/Template DNA   1 µl 
PCR H2O    Make up to final volume of 25 µl 
 
The PCR protocol was as follows: Initial denaturing 95°C for 2 mins followed by 35 cycles of 
denaturing 95°C for 30 sec, annealing for 45 sec, extending 72°C for 45 sec, followed by a final 
extension 72°C for 5 min. Table 2.1 shows the gene-specific primers used for conventional PCR. Refer 
to Addendum B for Primer design. 
Table 2.1: Sequences, concentration, annealing temperatures and product sizes of gene-specific 
primers used in conventional PCR.  

























































After conventional PCR, the amplified DNA was analysed on a 1.5% agarose gel by means of 
gel electrophoresis and visualised with ethidium bromide. 
2.10 Quantitative real-time PCR 
It must be noted that all gene-specific primer pairs used in conventional and quantitative 
real-time PCR experiments were chosen with intron spanning properties; with the exception 
of the PR-B and and-(A+B) primer pairs (Addendum B). This was determined using the NCBI 
database BLAST searches (data not shown). Intron-spanning primers were used to control 
for any genomic contamination that may have carried through during the preparation of 
RNA samples.  
The authors’ reproducibility in the use of quantitative real time PCR was first assessed as 
described in Addendum C. 
Quantitative real-time PCR was performed using SensiMixTM dT kit (Quantace, UK) and the 
Corbett real-time PCR machine and reaction tubes according to the manufacture’s protocols 
















Sensi-MixdT     12.5 μl  
50x SYBR®Green I solution   0.5 μl 
Sense and anti-sense primers   (see table 2.2 for final concentration of primers) 
cDNA Template    1 μl  
PCR-grade H2O    Make up a total volume of 25 μl.  
The PCR protocol was as follows: 95°C for 10 min followed by 40 cycles of 95°C denaturation 
for 10 sec, (see Table 2.2 for annealing temperatures) annealing for 10 sec, 72°C extension 
for 10 sec and a final 72°C for 7 min (refer to Addendum B for primer design). 
Melting curve analysis and gel electrophoresis was performed to confirm the generated 
product in each sample. Relative gene transcript levels were calculated using the Pfaffl 
equation below, normalised to GAPDH transcript levels. 
Relative expression =  [ET] 
ΔCt (control-sample) 
   [ER]
ΔCt (control-sample) 
Where [ET] is the primer efficiency of target gene and [ER] is the primer efficiency of 
reference gene. 
Table 2.2: Sequences, concentrations, annealing temperatures and product sizes for gene-primers 
used in quantitative real-time PCR. 



















































Refer to Addendum B for primer design. 
Table 2.3: Primer Efficiency for primer pairs used in real-time PCR. 
Primer pair Primer Efficiency 
ER 113% (E=2) 
PR 75% (E=1.75) 
GR 130% (E=2) 
GnRHR 95% (E=1.95) 
GAPDH 95% (E=1.95) 
Primer efficiency was calculated for the ER, PR and GR primer pairs; (Addendum C). Primer Efficiency 
for GAPDH and GnRHR primers were previously determined (Kotitchke, 2009) 
2.11 Western blot analysis 
For over-expression (positive controls), COS-7 cells were plated in 6-well culture plates 
(Greiner Bio-one, International,  Austria) at a density of 2 X 105 cells per well in 2 ml DMEM 
supplemented with 10% FCS and antibiotics as describedin Section 2.4. Twenty for hours 
after plating, medium was replaced with fresh media and cells were transfected with 1 µg 
pCMV-HA-hGR, pMT-PR-B and pSG5-hERα expression vectors. All transfections in the COS-7 
cell line were performed using the DEAE Dextran transfection protocol adapted from 
Ausubel, (1999). Briefly, transfection media was prepared (2.5% FCS DMEM containing 0.1 
mM chloroquinediphosphate, 1 µg/ml expression construct and 0.1 mg/ml DEAE Dextran) 
and 500 µl  was added to each well and incubated for 1 hour at 37°C. Transfection medium 
was aspired and replaced with 1 ml warmed (37°) 10% (v/v) DMSO/PBS and incubated for 3 
min. Thereafter the cells were gently washed with PBS, and full DMEM was replaced. 
LβT2 cells were plated in 12-well culture plates (Greiner Bio-one, International, Austria) at a 















antibiotics (as describedin Section 2.4). Twenty-four hours after plating, medium was 
replaced with Phenol red-free Dulbecco’s Modified Eagles Medium (D1145) (Sigma-Aldrich, 
South Africa) supplemented with 10% charcoal stripped serum and antibiotics (as described 
in Section 2.4). If indicated, a concentration of 0.2 nM E2 was added to each sample as 
shown in the appropriate figure legends. Forty-eight hours after E2 priming, the medium 
was replaced with phenol red free Dulbecco’s Modified Eagles Medium (D1145) (Sigma-
Aldrich, South Africa), serum-free media, containing antibiotics (as described in Section 2.4) 
and 100 nM test compounds for 8 hours, as indicated in the figure legends. Thereafter the 
cells were washed twice with cold PBS and harvested in 50 μl 1x SDS sample buffer buffer 
[5x SDS sample buffer: 100 mM Tris-HCL pH 6.8, 5% (w/v) SDS, 20% (v/v) glycerol, 2% ß-
mercaptoethanol and 0.1% (w/v) bromophenolblue] (adapted from Karteris et al., 2006) and 
incubated at 95°C for 10 min. Protein samples were separated by SDS-PAGE at 120 V in 25 
mM Tris-HCL, 250 mM glycine and 0,1 % SDS, pH 8,4 (Sambrook et al., 1989) using a BioRad 
Mini ProteanR II electrophoresis cell. Proteins were electro-blotted onto HybondTM 
ECLTM(AEC Amersham Biosciences, South Africa) nitrocellulose membrane for 1 h at 180 mA 
(Sambrook et al., 1989) using a BioRad Mini Trans-BlotTM cell in transfer buffer [25 mM Tris, 
200 mM glycine, 10% (v/v) methanol]. Membranes were blocked in 5% blocking solution 
(5% (w/v) milk powder) in Tris buffered saline (50 mM Tris, 150 mM NaCl) (TBS) containing 
0.1% (v/v) Tween (TBS-Tween) for 1 h at RT and subsequently incubated with primary 
antibody (see Table 2.4 for specific dilutions) in blocking solution at 4°C overnight. The 
following day the membranes were incubated with secondary HRP conjugate antibodies 
(see Table 2.4 for specific dilutions) for 1 h at RT in 5% milk powder (w/v) in TBS-Tween. 
After antibody incubation, the membranes were washed for 15 min and 2x 5 min in TBS-
Tween at RT. Thereafter the blots were kept in TBS. For consecutive detection steps, the 
membranes were stripped in stripping buffer [100 mM ß-mercaptoethanol, 2% (w/v) SDS, 
62.5 mM Tris-Cl, pH 6.7] for 30 min at 65°C (Sambrook et al., 1989), washed 2x 10 min with 
TBS-Tween and blocked for 1 h in 5% blocking solution before repeating antibody 
















Table 2.4: Dilutions of primary and secondary used in Western blot analysis 
Antibody Dilution Secondary Dilution 
Erα (polycolonal) 1:1000 (4°C-O/N) Rabbit 1:10000 (RT-1h) 
PR-B (polycolonal) 1:1000 (4°C-O/N) Rabbit 1:10000 (RT-1h) 
hPR-B (monoclonal) 1:500 (4°C-O/N) Mouse 1:5000 (RT-1h) 
hPR (A+B) (monoclonal) 1:000 (4°C-O/N) Mouse 1:5000 (RT-1h) 
GRα (polycolonal) 1:4000 (4°C-O/N) Rabbit 1:10000 (RT-1h) 
mPRα (monoclonal) 1:2000 (4°C-O/N) Goat 1:7500 (RT-1h) 
ERK1/2 (polycolonal) 1:1000 (4°C-O/N) Rabbit 1:10000 (RT-1h) 
Flotilin-1 (polycolonal) 1:4000 (4°C-O/N) Mouse 1:5000 (RT-1h) 
HA (polycolonal) 1:1000 (4°C-O/N) Rabbit 1:10000 (RT-1h) 
Β-Tubilin 1:1000 (4°C-O/N) Mouse 1:5000 (RT-1h) 
 
2.12 Immuno-blotting and quantification of Westerns 
Immuno-blotting and ECL visualization were performed with Amersham HyperfilmTM MP 
high performance autoradiography film. Autoradiograms were photographed using the 
Kodak Electrophoresis Documentation and Analysis System (EDAS) 290. Autoradiograms 
signal intensities were quantified using AlphaEaseFCTM Software (AlphaInnotech, USA). 
2.13 mPRα protein extraction optimization 
2.13.1 HEPES lysis protocol 
The HEPES lysis protocol was adapted from Krietsch, (2006). 
Endo-cervical cells were plated in 6-well culture plates (Greiner Bio-one, International, 
Austria) at a density of 2 X 105 cells per well in KSF culture medium supplemented with 10% 
bovine pituitary extract and antibiotics, as described in Section 2.4. LβT2 cells were plated 
on 6-well culture plates (Greiner Bio-one, International, Austria) at a density of 5 X 105 cells 
per well in DMEM culture medium supplemented with 10% FCS and antibiotics, as described 
in Section 2.4. At 75% confluency, the cells were washed twice with PBS, thereafter the cells 















µM EGTA, 50 µl NaCl, 5% (w/v) glycerol, 1% (w/v) Nonidet P-40, 1 tablet Complete Mini 
Protease Inhibitor Cocktail per 10 ml (Roche Applied Science, South Africa)].  Appropriate 
volume of 5x SDS Sample application buffer (a modification of the methods of Karteris et al., 
2006) [5x SDS sample buffer: 100 mM Tris-HCL pH 6.8, 5% (w/v) SDS, 20% (v/v) glycerol, 2% 
ß-mercaptoethanol and 0.1% (w/v) bromophenolblue] was added for a final 1x 
concentration. Protein samples were analysed using western blot techniques as described 
above. 
2.13.2 CREBS lysis protocol 
End-1 cells were plated in 6-well culture plates (Greiner Bio-one, International, Austria) at a 
density of 2 X 105 cells per well in KSF culture medium supplemented with 10% bovine 
pituitary extract and antibiotics, as described elsewhere. LβT2 cells were plated on 6-well 
culture plates (Greiner Bio-one, International, Austria) at a density of 5 X 105 cells per well in 
DMEM culture medium supplemented with 10% FCS and antibiotics as described elsewhere. 
At 75% confluency, the cells were washed twice with PBS, scraped and harvested in 100 µl 
of CREBS Lysis buffer [20 mM Tris-HCL, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) 
Triton X-100, 0.1% (w/v) Sodium Pyroph sphate, 1 µM β-glycerolphosphate, 1 tablet 
Complete Mini Protease Inhibitor Cocktail per 10 ml (Roche Applied Science, South Africa)].  
An appropriate volume of 5x SDS sample application buffer [using a modification f the 
methods of Karteris et al., (2006)], [5x SDS sample buffer: 100 Mm Tris-HCL Ph 6.8, 5% (w/v) 
SDS, 20% (v/v) glycerol, 2% ß-mercaptoethanol and 0.1% (w/v) bromophenolblue] was 
added for a final 1x concentration, with protein samples analysed using Western blotting 
techniques as described above. 
2.14 Statistical analysis 
Results were statistically analysed and plotted with GraphPad PRISMTM (version 5) software 
from GraphPad Software Inc. All real-time and quantified protein expression data was 
statistically analysed using non-parametric two-way ANOVAs, with a Bonferroni post-test 
(comparing all values to control column). Reporter assays used to investigate basal SR-
transactivation (Figures 3.3, 4.3 and 5.3) were statistically analyzed using two tailed t-tests. 















were statistically analysed using non-parametric two-way ANOVAs, with Dunnette post-test. 
Where statistical significance was obtained relative to a single control, statistical significance 
is denoted by *, ** or ***, to indicate P<0.05, P<0.01 or P<0.001, respectively. All statistical 
calculations are represented in Addendum E 

















RESULTS AND DISCUSSION 
3. The effects of Dex, P4, E2 and GnRH regulating GnRHR mRNA 
expression in LβT2 cells 
 
3.1.  Synergistic effects of Dex and GnRH on GRE-mediated 
transactivation 
Glucocorticoids have been shown to increase GnRHR mRNA expression, with the ligand-
dependent activation of the GR inducing endogenous GnRHR mRNA expression in LβT2 cells 
(von Boetticher, 2008; Kotitschke et al., 2009). In addition to GCs, GnRH has also been 
shown to increase GnRHR expression. Previous studies from the Hapgood lab have shown 
that continuous treatment with 100 nM GnRH not only increases the expression of a 
transiently transfected mouse GnRHR reporter-promoter construct by 2.5 fold (Sadie, 2006), 
but also up-regulates endogenous LβT2 GnRHR mRNA expression (Kotitschke et al., 2009; 
Sadie, 2006). In the physiological context of GnRH secretion, studies performed by 
Bedecarrats et al., (2003) have shown that pulsatile stimulation of GnRH (1 pulse every 30 
min) for 10 hours resulted in a 2-fold increase in GnRHR promoter activity and a 2-fold 
increase in GnRHR numbers on the cell surface of LβT2 cells (Bedecarrats and Kaiser, 2003).  
It was recently shown that combined treatment with both Dex and GnRH regulate GnRHR 
gene expression in LβT2 cells through a mechanism involving GnRHR and GR-mediated 
signalling (Kotitschke et al., 2009). Dex treatment alone resulted in the ligand-mediated 
activation of the GR, and GnRH treatment alone resulted in the ligand-independent 
activation of the GR and the activation of AP-1 transcription factors c-Jun and c-Fos. The 
study further showed that combined treatment withDex and GnRH acted synergistically to 
regulate GnRHR expression through mechanisms dependent on both the GR and the GnRHR. 















to GnRH treatments were seen on a TAT-GRE-luc reporter plasmid, however, the 
mechanism of transactivation on a TAT-GRE differs from that of the endogenous promoter 
region of the GnRHR gene. The GnRHR promoter does not contain any full GREs, but is 
regulated by a number of different cis-elements, including an AP-1 site (Figure 1.8) 
(Kotitschke et al., 2009).   
In addition to Dex and GnRH, P4 treatment has also been shown to regulate LHβ and FSHβ 
mRNA expression in LβT2 cells (Thackray et al., 2009; An et al., 2009). The suppressive 
action of P4 on LHβ mRNA expression is mediated by the recruitment of liganded PR to the 
endogenous LHβ promoter region in LβT2 cells (Thackray et al., 2009). It was further shown 
that LHβ suppression does not require direct binding of the PR to the promoter, and thus PR 
is likely to be recruited to the promoter via interaction with other transcription factors 
(Thackray et al., 2009). It was further established that PR and GnRHR crosstalk signalling up-
regulates PRE-luc reporter expression in αT1-3 cells (An et al., 2006) and FSHβ mRNA 
expression in LβT2 cells (An et al., 2009). In both cases, GnRH treatment increased mRNA 
expression of target genes via the ligand-independent activation of the PR (An et al., 2006; 
Thackray et al., 2006). An et al., (2009) showed direct binding of the PR to a PRE in the FSHβ 
promoter, mediated by an increase in steroid receptor co-activator NCOA3 interaction in 
response to GnRH in LβT2 cells (Thackray et al., 2006), and in αT3-1 cells (An et al., 2006). 
Therefore P4 treatments were included into this study to assess the potential for PR and 
GnRHR crosstalk in mediating GnRHR mRNA expression.  
Before investigating novel crosstalk pathways, the effects of Dex and GnRH on GR-mediated 
GRE-luc reporter plasmid transactivation were first confirmed in the LβT2 cell line. LβT2 cells 
transiently transfected with a TAT-GRE-luc reporter-promoter plasmid, were treated with 
saturating concentrations (100 nM) of Dex, P4, GnRH and combinations thereof, for 8 hours. 













































































Figure 3.1: Dex and GnRH, but not P4, treatments synergistically up-regulate TAT-GRE-luc 
expression. LβT2 cells were seeded into a 24-well plate in DMEM supplemented with 10% serum. 
After a 24 hour incubation period, the medium was replaced with phenol red-free media, 
supplemented with 10% charcoal stripped serum and incubated for 24 hours. Thereafter the cells 
were transiently tranfected with 250 ng GRE-Luc reporter plasmid and 25 ng β-galactosidase 
expression vectors and incubated for 48 hours. After the incubation period, the medium was 
replaced with phenol red-free, serum-free media and the cells were the stimulated for 8 hours with 
vehicle (EtOH) or 100 nM of the various hormones and combinations thereof, as indicated in the 
figure. The cells were harvested, and luciferase and β-galactosidase assays, as well as a Bradford 
assay were performed. The data were normalised for transfection efficiency and cell number by 
expressing luciferase (luc) activity relative to β-galactosidase activity and total protein. The results 
represent the average of three independent experiments, performed in triplicate and presented as 
















difference when compared to vehicle control, defined by a non-parametric one-way ANOVA, with a 
Dunnette post test.  
 
The result shows that GR agonist Dex increases GRE-mediated transcription by about 4 fold 
relative to control (Figure 3.1). Although no statistical significance was observed, this is still 
consistent with the role of Dex, activating the GR in a ligand-dependent manner to drive 
GRE-promoter expression (Kotitschke et al., 2009; Sadie, 2006; von Boetticher, 2008). P4 
exhibits no transcriptional effects on GRE-mediated transcription, while GnRH treatment 
appears to increase transcriptional activity by 1.5 fold when compared to vehicle. Upon Dex 
and GnRH co-incubation, a significant and synergistic increase of roughly 16 fold, relative to 
control, is seen on GRE-mediated transcription, while P4 and GnRH appeared to have no 
effect on the transcriptional activity on the GRE-reporter promoter plasmid. The result of 
Dex plus GnRH is consistent with a previous study showing crosstalk between GR and 
GnRHR signalling pathways (Kotitschke et al., 2009). However the lack of a significant 
response from GnRH treatment alone does not coincide with the finding of Kotitschke et al., 
(2009), as it was previously reported that GnRH is able to significantly induce GRE-mediated 
transcription. Nevertheless the 16 fold increase seen with Dex and GnRH co-treatment 
(Figure 3.1) indicates that the current LβT2 cells are responding to Dex plus GnRH according 
to the literature, and that novel signalling pathways can be further investigated. 
From Figure 3.1 it appears that 100 nM P4 treatments do not activate the GR (Figure 3.1). 
However, it is known that P4 is not a PR specific agonist, and has been shown to be a partial 
agonist for the GR (Ronacher et al., 2009). Considering the relative binding affinities (RBA) of 
both P4 and Dex for the GR (with a Kd of 270 nM and 14 nM, respectively) (Ronacher et al., 
2009), concentrations of 100 nM of P4 were used to ensure PR-specific activation. The 100 
nM P4 treatments should not saturate the GR, and all results with 100 nM P4 treatments 
should represent PR-mediated signalling and not GR-mediated signalling. Previous reports 
have shown that P4 regulates LHβ mRNA expression through mechanisms dependent on the 
PR directly binding to a PRE in the LHβ promoter in the LβT2 cell line (Thackray et al.,  2009). 
In addition, crosstalk signalling between the PR and GnRHR has been shown to regulate 















αT3-1 cells (An et al., 2006), via GnRHR mediating the ligand-independent activation of the 
PR. No studies in the literature have shown the combined effects of P4 plus GnRH co-
treatment on GRE/PRE-mediated transcription, or on GnRHR mRNA expression. It is known 
that no consensus PRE/GRE is present on the GnRHR promoter (Kotitschke et al., 2009). 
Additional cis-elements in the GnRHR promoter may mediate novel effects of P4 and GnRH 
on GnRHR mRNA expression. Therefore the effects of P4, GnRH and combinations thereof 
were tested on endogenous GnRHR gene expression.  
3.2 Dex and GnRH regulate endogenous GnRHR mRNA expression in 
LβT2 cells 
Having shown that Dex plus GnRH synergistically activate transcription of a GRE-reporter 
promoter, the synergistic effect of Dex plus GnRH on endogenous GnRHR mRNA expression 
was next investigated in LβT2 cells, to confirm previous results from the Hapgood laboratory 
(Kotitschke et al., 2009). 
SR and GnRHR crosstalk mechanisms have been shown to regulate LβT2 responses (An, et al 
2009; Chen et al., 2009). For example, a PR and GnRHR crosstalk mechanism mediated by 
GnRH treatment, results in the rapid phosphorylation of the PR. This induces PR co-factor 
recruitment with NCOA3 to mediate PR binding to the Fshβ promoter, in turn up-regulating 
endogenous expression of the FSHβ mRNA in LβT2 cells (An, et al 2009). Another crosstalk 
mechanism between the ER and GnRHR shows the rapid phosphorylation of the ERα in 
response GnRH, mediates the ER to associate with the co-factor p300/CREB association 
factor (PCAF), in turn increasing the transcriptional activity on the endogenous fosB gene in 
LβT2 cells (Chen et al., 2009). 
In order to determine whether E2 or P4, alone or in combination with GnRH, regulate 
GnRHR mRNA expression, as well as to confirm previous results by others for Dex and GnRH, 
experiments were designed to assess the effect of the test compounds on endogenous LβT2 
GnRHR mRNA expression. Previous studies in the literature have used 0.2 nM E2 priming to 
assess effects of E2 on PR-mediated transcription in the LβT2 cell line (Turgeon and Waring, 
2006; An et al., 2009). Therefore keeping in line with the current literature, LβT2 cells were 















responses. Thereafter the cells were treated for 8 hours with vehicle or test compounds, 
Dex, P4, GnRH and combinations thereof, at saturating concentrations (100 nM). After 
ligand incubation, samples were harvested and RNA was extracted (Figure 9.6), followed by 
subsequent cDNA conversion. Quantitative real-time PCR with GnRHR-specific primers was 
performed to assess the transcriptional effects of hormones in regulating endogenous 

















Figure 3.2: Endogenous GnRHR xpression is regulated in a ligand-dependent manner.  LβT2 cells 
were plated into 12-well plates in DMEM supplemented with 10% serum. After a 24 hour incubation 
period, the cells were treated with or without 0.2 nM E2 in phenol red-free medium supplemented 
with 10% charcoal stripped serum. After 48 hours, the cells were treated with 100 nM vehicle (EtOH) 
or the appropriate ligands and combinations thereof, in phenol red-free, serum-free media. The cells 
were stimulated for 8 hours prior to harvesting and subsequent RNA extractions. cDNA was 
generated for all mRNA sample sets, and was further analysed using GnRHR-specific primers and 
quantitative real-time PCR (Rotogene machine; Rotogene-6000). Endogenous GnRHR expression 
(Figure 11.5.1) was normalised to endogenous GAPDH expression (Figure 11.6.1), and is represented 
as fold induction relative to vehicle (EtOH). The graph shows pooled results for several independent 
experiments (n=4 for all samples without E2, n=3 for all E2 containing samples, and n=1 for +E2 P4 
sample). Stars represent a significant (P < 0.01 = **) difference when compared to untreated control 
















From Figure 3.2 it appears that endogenous GnRHR expression is regulated in a ligand-
selective manner. In the absence of E2 priming, stimulation with Dex appears to result in a 4 
fold increase in relative GnRHR expression, while stimulation with GnRH shows a 3 fold 
increase in relative GnRHR expression. Upon Dex and GnRH co-treatment, GnRHR mRNA 
levels significantly increased to 9.5 fold when compared to vehicle. Although the magnitude 
of the Dex plus GnRH response varied between individual experiments (due to the high 
sensitivity of gonadotrope cells to their environment and biological variation) the same 
trend was always observed. After much statistically analysis, it would appear that the large 
and varied response observed for the Dex plus GnRH response reduces the statistical 
significance of other responses seen. However, the Dex plus GnRH response still appears to 
be greater than the sum of the individual Dex and GnRH responses. These results are 
consistent with previous reports in the literature which showed a synergistic effect of Dex 
and GnRH on LβT2 GnRHR expression (Kotitschke et al., 2009).  
Stimulation with P4 in the absence of E2 priming did not significantly change endogenous 
GnRHR expression (Figure 3.2). Although P4 plus GnRH co-treatment in the absence of E2 
priming resulted in a roughly 2 fold increase in GnRHR expression, this increase may be 
accounted for by the action of GnRH treatment alone. The effects of P4 plus GnRH on 
endogenous GnRHR expression have not been shown in the literature previously. This result 
suggests that PR and GnRHR crosstalk is not involved in regulating endogenous GnRHR 
mRNA expression in LβT2 cells. 
The effects of E2 priming alone had no significant effect on basal GnRHR expression, when 
comparing the two vehicle samples (Figure 3.2). Considering the E2 primed cells, stimulation 
with Dex appeared to increase relative GnRHR mRNA expression to about 6 fold, as 
compared to the 4 fold response in the absence of E2. However the presence of E2 
appeared to have no effect on the GnRH response (Figure 3.2). Interestingly, the synergistic 
effect of Dex and GnRH co-treatment in the absence of E2 appeared to be lost in the 
presence of E2. Although the Dex plus GnRH response was still the largest across the E2 
primed sample set, this approximate 8 fold increase was no longer additive or of synergistic 















does not persist when Dex is co-incubated with GnRH. This result may suggest that E2 
priming is able to modulate the transcriptional activity of Dex signalling on GnRHR mRNA 
expression. However, the statistical significance of this result (with only three data sets 
being collected), should be confirmed with further repeat experiments. 
Stimulation of the E2 primed cells with P4 alone appeared to increase GnRHR expression by 
about 2 fold relative to vehicle (Figure 3.2). However this result is only from one 
experimental repeat and needs to be confirmed through additional repeats. Co-stimulation 
with P4 and GnRH resulted in roughly a 3 fold increase relative to vehicle. However, as in the 
case of the un-primed cells, this increase in expression may be accounted for by the effect 
of GnRH treatment alone on LβT2 signalling. This result supports the previous finding in 
Figure 3.2 that PR and GnRHR crosstalk pathways do not affect GnRHR expression in the 
absence or presence of E2 priming. 
Taken together, these results show the existence of GR and GnRHR crosstalk pathways 
regulating GnRHR expression in LβT2 cells (Kotitschke et al., 2009). A novel and interesting 
finding suggests that E2 is able to affect the Dex response. P4 and P4 plus GnRH treatments, 
in the absence and presence of E2, revealed no significant changes in GnRHR expression. 
This result was unexpected as crosstalk mechanisms between PR/ER and GnRHR have 
previously been shown to regulate LβT2 gene targets including FSHβ and fosB mRNA 
expression in LβT2 cells (An et al., 2009; Chen et al., 2009). However the potential that other 
target genes may be affected by these treatments through receptor crosstalk mechanisms is 
still plausible. 
In conclusion, these results are in agreement with the literature. The increase in GnRHR 
expression with Dex and GnRH treatments alone shown above (Figure 3.2) is in agreement 
with previously published results in the literature regarding endogenous LβT2 GnRHR 
regulation. Statistical significance could not be established in the current study, most likely 
due to the large number of conditions. A published mechanism explaining how GnRHR 
mRNA expression is transcriptionally regulated by GnRH in LβT2 cells suggests the 
involvement of the GR. Dex induces the ligand-dependent activation of the GR resulting in 
GR-mediated transcription. In the presence of GnRH, GnRHR induces the site-specific 















(Kotitschke et al., 2009). Upon Dex and GnRH co-stimulation, these mechanisms act 
synergistically to increase the transcriptional activity on the GnRHR promoter.  
On the other hand, the effect of E2 priming on GR-mediated signalling is not as well 
established in the literature. From Figure 3.2 it appears that E2 may be able to modulate the 
effect of Dex treatments on GnRHR mRNA expression. This suggests a number of 
mechanistic possibilities. However, with the current experimental data, a precise 
mechanism cannot be established. What can be said is that crosstalk must exist between 
the ER and GR for such response to occur. Further experiments are required to assess 
statistical significance, and determine the possible involvement of the ER in mediating this 
response. 
In order to further understand the responses seen from Figure 3.2, an assessment of the 
overall effect these ligand treatments may have on SR expression levels would be required. 
Therefore the effect of Dex, P4, GnRH, E2 and combinations treatments thereof were tested 
on the relative expression levels of the SRs (ER, PR and GR) in LβT2 cells, to get a more 
detailed picture on the effects various ligand treatments have on LβT2 physiology. This 

















RESULTS AND DISCUSSION 
4. Regulation of ERα expression and function in LβT2 responses 
As shown earlier, E2 priming treatments appear to affect the Dex response regulating 
GnRHR mRNA expression (Figure 3.2), indicating potential crosstalk between the ER and the 
GR. Although E2 had no effect on the GnRH-mediated increase of GnRHR expression in LβT2 
cells (Figure 3.2), ER and GnRHR crosstalk pathways have been shown to regulate fosβ 
expression in LβT2 cells, through the rapid GnRH-induced phosphorylation of ERα (Chen et 
al., 2009). In addition, PR-B was shown to recruit a repressor complex to a half-PRE site in 
the ERα gene promoter in MCF-7 human breast cancer cells (Amicis et al., 2009). Therefore 
the question of whether Dex, P4, GnRH, E2 and combinations thereof affect ERα mRNA or 
protein expression levels in LβT2 cells was next examined. 
4.1 Characterisation of endogenous ERα mRNA and protein 
expression in LβT2 cells 
Before examining the effect of hormone treatments on ERα mRNA and protein expression, 
untreated LβT2 cells were first used to characterise ERα mRNA levels under basal 
conditions. LβT2 cells were cultivated under basal conditions, and harvested. Subsequent 
RNA extractions and cDNA conversions were performed. Thereafter, conventional PCR with 

















Figure 4.1: Endogenous ERα mRNA is basally expressed in LβT2 cells. LβT2 cells were seeded into 6-
well plates in DMEM supplemented with 10% serum, and were left to grow to 70% confluency under 
basal conditions. Thereafter the cells were harvested and RNA extractions were performed, followed 
by a reverse transcriptase reaction to generate LβT2 cDNA. Signals were amplified using 
conventional PCR with ERα-specific primer pairs. PCR products were generated over 35 PCR cycles 
and separated on a 2% agarose gel using electrophoreses, and visualised with ethidium bromide 
staining. The arrow marks the position of ERα amplicon at 235bp. NTC defines the no template 
control.  
 
From Figure 4.1 it is evident that ERα mRNA is expressed under basal conditions in LβT2 
cells. This is in agreement with the current literature regarding the presence of ERα mRNA 
(Schreihofer et al., 2000) and ER function in mediating LβT2 responses (Chen et al., 2009).  
Having shown the presence of ERα mRNA in LβT2s cells, it was next determined whether 
LβT2 cells have detectable levels of ERα protein. In order to determine this, crude cell 















using western blotting techniques and a specific anti-ERα antibody. COS-7 cells over-
expressing hERα were harvested and investigated alongside the LβT2 lysates on the western 
blot, to serve as a positive control in assessing ERα protein levels in LβT2 cells. 
 
 
Figure 4.2: Endogenous ERα protein levels were not detected by Western blotting. COS-7 cells 
were seeded into 6-well plates in DMEM supplemented with 10% serum. After a 24 hour incubation, 
the cells were either transiently transfected with 1 µg of pSG5-hERα expression vector (positive COS-
7 control) (+), or left to grow under basal conditions (negative COS-7 control) (-). LβT2 cells were 
seeded into a 6-well plate in DMEM supplemented with 10% serum, and left to grow under basal 
conditions. After all cells had reached 70% confluency (at least 24 hours after transfection), the COS-
7 cells and untreated LβT2 cells were harvested in 50 µl SDS sample application buffer. Equal 
volumes (10 µl) of all lysates were separated on 8% SDS polyacrylamide gel, transferred to a 
nitrocellulose membrane and probed with anti-ERα-specific and anti-ERK1/2-specific (Loading 
control) primary polyclonal antibodies. Anti-rabbit-HRP secondary antibodies were used for 
detection of both ERα and ERK1/2 primary antibodies. The signals were visualised with Amersham 
Chemiluminescence. ERK1/2 proteins observed 42 kDa & 44 kDa, respectively. Arrows indicate 
observed difference in molecular weight between LβT2 and COS-7 ERK 2 proteins.  
 
Although ERα protein could not be detected in LβT2 cells at the 66 kDa marker, a signal 
could also not be detected for the positive control (COS-7 cells over-expressing pSG5-hERα 
plasmid) (Figure 4.2), indicating 2 possible outcomes. The first and more likely is that the 

















compromised.  The second possibility is that the ERα expression plasmid did not over-
express in the COS-7 positive control and that LβT2 cells have low amounts of ERα protein 
that are undetectable using Western blotting. Therefore ERα protein levels could not be 
detected for further assessment of the response to Dex, P4, GnRH, E2 and combination 
treatments. 
An additional observation is the difference in ERK 2 migration through the polyacrylamide 
gel between LβT2 and COS-7 lysates (Figure 4.2). The top band (representing ERK 2 protein) 
was shown to be at a slightly higher position in mice LβT2 cells (≈45 kDa), when compared 
to monkey COS-7 cells (≈44 kDa). This may be due to tissue-specific and species-specific 
differences.  A similar observation was made for ERK1/2 levels, in all subsequent western 
blots, when characterising SR protein levels. 
Having been unsuccessful in detecting ERα protein by means of western blotting, a different 
strategy was implemented to assess functional ERα protein expression. ERα transactivation 
was investigated using an ERE-luc reporter assay in the LβT2 cell line. Therefore LβT2 cells 
were transiently transfected with an ERE-luc reporter plasmid, and treated with ER agonist 

















Figure 4.3: Endogenous ERα shows no functional activity on an ERE-luc in LβT2 cells. LβT2 cells 
were seeded into a 24-well plate in DMEM supplemented with 10% serum.  After a 24 hour 
incubation period, the medium was replaced with phenol red-free media, supplemented with 10% 
charcoal stripped serum and incubated further for 24 hours. Thereafter the cells were transiently 
transfected with 300 ng ERE-Luc reporter plasmid and 25 ng β-galactosidase expression vector and 
incubated for an additional 48 hours. After the incubation period, the medium was replaced with 
phenol red-free, serum-free media and the cells were the stimulated for 8 hours with vehicle (EtOH) 
or 100 nM ER-specific agonist E2. After the cells were harvested, luciferase and β-galactosidase 
assays, as well as a Braford assay, were performed. The data was normalised for transfection 
efficiency and cell number by expressing luciferase (luc) activity relative to β-galactosidase activity 
and total protein. The graph shows pooled results from two independent experiments, each 
performed in triplicate, which is presented as fold induction relative to vehicle (EtOH) control. 
 
Figure 4.3 illustrates that on treatment with saturating concentrations (100 nM) of ER 
agonist (E2), no ER-mediated transactivation was seen in the LβT2 cell line. This result 
suggests LβT2 cells lack functional ER protein, which is in contrast with previous findings in 
the literature showing the presence of functional ERα protein in LβT2 cells (Chen et al., 
2009; Schreihofer et al., 2000). It is possible that LβT2 cells may have functional ER, 















transfections resulting in a false negative result. For example, transfection of the ERE-luc 
reporter plasmid into the LβT2 cells may have been unsucsessful.  
4.2  ERα mRNA levels are regulated by GnRH in a ligand-dependent 
manner in LβT2 cells 
While no functional ERα protein was observed by western blot and functional reporter assay 
(Figures 4.2 and 4.3), endogenous mRNA was detected (Figure 4.1). Technique sensitivity 
may have accounted for the lack of detection as western blotting and reporter promoter 
techniques failed to allow detection of functional ER protein. For this reason real-time PCR 
was used to assess the transcriptional regulation of LβT2 ERα mRNA levels in response to 
ligand treatments. 
LβT2 cells were either pre-treated with 0.2 nM E2 or left untreated for 48 hours, followed by 
an 8 hour treatment with saturating concentrations (100 nM) of Dex, P4, GnRH and 
combinations thereof. Thereafter cells were harvested and RNA was extracted (Figure 9.6), 
followed by subsequent cDNA conversion. Quantitative real-time PCR with ERα-specific 
primers were performed to assess the transcriptional effects of hormones in regulating 
















Figure 4.4: GnRH and P4, but not Dex and E2 treatment suppresses endogenous ERα mRNA 
expression levels in LβT2 cells. LβT2 cells were plated into 12-well plates in DMEM supplemented 
with 10% serum. After a 24 hours incubation period, the cells were treated with 0.2 nM E2 in phenol 
red-free media supplemented with 10% charcoal stripped serum or left untreated. After 48 hours, 
the cells were treated with 100 nM vehicle (EtOH) or the appropriate ligands or combinations 
thereof in phenol red-free, serum-free media. The cells were stimulated for 8 hours prior to 
harvesting and subsequent RNA extractions. cDNA was generated for all mRNA sample sets and was 
further analysed using ERα-specific primers and quantitative real-time PCR (Rotogene machine; 
Rotogene-6000). Endogenous ERα mRNA expression (Figure 11.7.1) was normalised to endogenous 
GAPDH mRNA expression (Figure 11.6.1), and was represented as fold induction relative to vehicle 
(EtOH). The graph shows pooled results for several independent experiments (n=4 for all samples 















significant (P < 0.05 = *; P < 0.01 = **; P < 0.001 = ***) difference when compared to untreated 
control (-E2 EtOH), defined by a non-parametric, two-way ANOVA with a Bonferroni post test. 
 
From Figure 4.4 it is apparent that endogenous ERα mRNA expression is regulated in a 
ligand-specific manner. Dex treatments revealed no significant changes in ERα expression, 
while stimulation with P4 reduced relative ERα mRNA levels to 0.55 fold expression. The 
suppressive effect of P4 on ERα mRNA expression is consistent with the literature showing 
P4 has suppressive effects on ER expression and function in breast cancer cells (Graham and 
Clarke, 1997). However, it has not been previously investigated in LβT2 cells. Treatment with 
GnRH also showed a significant suppressive effect on ERα gene transcription, decreasing 
ERα mRNA levels to 0.25 fold relative to vehicle.  
Co-treatments with GnRH plus Dex or with GnRH plus P4 resulted in a similar suppressive 
effect as observed for GnRH treatment alone, where both co-incubations resulted in ERα 
mRNA levels decreasing significantly to 0.25 fold relative to vehicle (Figure 4.4). The 
suppressive effects of Dex plus GnRH co-treatment can be accounted for through GnRH 
treatment alone, as no differences are seen between the GnRH plus Dex and GnRH 
treatments. Although it appears that P4 alone, and GnRH alone both significantly represses 
ERα mRNA expression, co-incubation with both P4 and GnRH show no additive repressive 
properties, suggesting two possibilities. One possibility is that GnRH and P4 signalling are 
not functionally integrated in regulating ERα mRNA expression. The other is that both GnRH 
and P4 alone maximally inhibit ERα mRNA expression to the extent that additional 
treatment no longer has a repressive effect, as the expression of ERα cannot be suppressed 
beyond maximum. Further experiments using lower concentrations of GnRH (i.e. 1 nM) 
during GnRH and P4 co-treatment should discriminate between the two possibilities. 
It appears that E2 priming alone has no significant effect on ERα mRNA expression in LβT2 
cells (1.1 fold), as compared to unprimed E2 vehicle (Figure 4.4). This result was unexpected 
since it was previous shown that E2 has a suppressive effect on ERα mRNA and protein 
expression in primary rat pituitary cells (Schreihofer et al., 2000). However, this may be 















Perhaps an effect would be seen if LβT2 cells were treated with E2 at a saturating 
concentration of 100 nM E2 (as used by Schreihofer et al., (2000). The IC50 for the ERα 
binding to E2 has been determined experimentally to be 0.9 nM (Blair et al., 2000). 
Therefore a concentration of 0.2 nM E2 should not result in an ERα-specific response. 
Furthermore treatment with, E2 and P4 had no significant effect on the receptor GnRHR 
mRNA expression (Figure 3.2). Therefore it appears that the repressive effects of E2 and P4 
in LβT2 cells are gene-specific, repressing ERα and LHβ (Schreihofer et al., 2000; Thackray et 
al., 2009), but not GnRHR levels. 
Stimulation of E2 primed cells with Dex shows an apparent, although not significant, 
increase in ERα mRNA expression of 1.4 fold relative to vehicle, as compared to the un-
primed Dex treatment (0.8 fold) (Figure 4.4). This is the second time that E2 has affected the 
outcome of a Dex response in this study, the first seen in the GnRHR mRNA expression 
result (Figure 3.2). This apparent change in ERα mRNA expression may be a result of several 
possibilities. One possibility suggests that E2 may increase GR levels, in turn increasing Dex 
responsiveness on ERα mRNA transcription. Another possibility suggests that liganded ER 
may directly interact with the GR, in turn increasing the transcriptional activity of the GR 
through the formation of a GR/ER complex on the ERα promoter (Cvoro et al., 2011). A final 
possibility may suggest E2 (via the ER) may indirectly affect the phosphorylation status of 
the GR through a possible change in kinase or phosphatase activity (Zhang et al., 2009). 
Taken together this result suggests that low dosages of E2 may influence the transcriptional 
outcome of Dex treatments on GR-regulated genes, suggesting potential crosstalk between 
the ER and the GR in LβT2 responses. Further experiments will be needed to establish 
whether this increase is statistically significant, and to determine the molecular mechanism 
governing the effect of E2 priming influencing Dex-induced GR transcriptional regulation. 
The effects of P4 on E2 primed LβT2 cells still show a reduction in relative ERα mRNA 
expression (0.65 fold) when compared to the un-primed sample set (0.55 fold) (Figure 4.4). 
However, it should be noted that this result is from one experiment and thus additional 
repeat experiments are required to determine whether this response is reproducible. From 
the single P4 (+E2) treatment, it nevertheless appears that E2 priming has no effect on the 















Stimulation with GnRH on +E2 primed LβT2 cells significantly reduced ERα mRNA levels to 
0.25 fold relative to vehicle, similar to the effects of GnRH treatment on un-primed LβT2 
cells (Figure 4.4). Therefore it appears that E2 priming has no effect on the GnRH-mediated 
down regulation of endogenous ERα mRNA expression in LβT2 cells. Similarly, the effects of 
GnRH co-treatment with Dex or P4 on E2 primed LβT2 cells show no differences when 
compared to the unprimed samples set (Figure 4.4). Both hormone combination treatments 
reduce ERα mRNA levels to 0.3 fold relative to vehicle, and are most likely due to the 
suppressive effects of GnRH treatment alone in regulating endogenous ERα mRNA 
expression in LβT2 cells. To the author’s knowledge, no previous studies in the literature 
have shown the effects of E2 priming on Dex and GnRH signalling in LβT2 responses.  
In conclusion, GnRH treatments had the most significant effect in regulating endogenous 
ERα mRNA expression in LβT2 cells. Treatment with GnRH alone resulted in a significant 25-
30% reduction in relative mRNA expression levels (Figure 4.4), with E2 priming having no 
effect. To the author’s knowledge, little is known about the precise mechanism of GnRH-
induced ERα mRNA suppression in LβT2 cells. It is possible that a transcription factor may be 
phosphoryated and activated to regulate ERα mRNA expression in response to GnRHR-
mediated signalling. Interestingly, previous studies have shown the presence of an AP-1 site 
(Tang et al., 1997), a half-PRE/GRE site (Amicis et al., 2009), and a palindomic binding site 
for ERF-1 (McPherson et al., 1997), however, no full ERE has been found in the promoter 
region of the ERα gene. However, the precise mechanism of action cannot be predicted with 
the current data, yet this will most likely involve these cis-elements in the ER promoter 
region. 
P4 also has a suppressive effect on ERα expression, reducing levels to about 45 % relative to 
vehicle in LβT2 cells. The anti-estrogenic action of P4 has been previously established in 
MCF-7 breast cancer cells, with liganded PR recruiting specific repressor complexes to a half-
PRE/GRE site in the ERα gene promoter region (Amicis et al., 2009). P4-mediated inhibition 
of ERα mRNA expression has also been shown in a number of other reproductive tissues 
including breast cells (Read et al., 1989; Alexander et al., 1990), and the uterus (Master et 
al., 1974; Hsueh et al., 1975), yet has not been shown in gonadotrope cells. Futhermore the 















suggesting that the GnRH and P4 signalling pathways do not crosstalk in regulating ERα 
mRNA expression at the level of the pituitary. 
Finally E2 priming appeared to modulate the Dex response regulating ERα mRNA expression. 
Stimulation of E2 primed LβT2 cells with Dex appeared to show an increase in ERα mRNA 
levels, compared to Dex treatment alone. Although this result is not statistically significant, 
it appears that low doses of E2 may influence the transcriptional outcome of GR-mediated 
signalling. This further supports the idea that E2 priming is able to modulate the Dex 
responses as seen in GnRHR mRNA expression (Figure 3.2). No studies regarding the effects 
of E2 and Dex co-incubations on ERα and GnRHR mRNA expression have been found in the 
literature, indicating a novel result that should be considered for further research.  
4.3   The effects of GnRH priming on ERE-luc reporter expression  
No functional ERα protein could be detected and no increase in ERE-reporter activity was 
seen in response to E2 in LβT2 cells (Figures 4.2 and 4.3). Therefore the question was asked, 
does GnRH modulate ER activity via an ERE in the absence and presence of E2. 
LβT2 cells transiently transfected with ERE-luc reporter plasmid were either pre-treated 
with GnRH or left untreated for 24 hours prior to 8 hour stimulation with an ER-specific 





















(100nM GnRH pre-treat) EtOH 
2.232 0.754 
(100nM GnRH pre-treat) E2 
1.962 0.128 
Figure 4.5: GnRH pre-treatment increases basal transcriptional activity on an ERE-Luc in LβT2 cells. 
LβT2 cells were seeded into a 24-well plate in DMEM supplemented with 10% serum.  After a 24 
hour incubation period, the medium was replaced with phenol red-free media, supplemented with 
10% charcoal stripped serum and incubated further for 24 hours. Thereafter 300 ng ERE-Luc reporter 
plasmid and 25 ng β-galalactosidase expression vector was transiently transfected and the cells were 
incubated with or without 100 nM GnRH for an additional 24 hours. After the incubation period, 
medium was replaced with phenol red-free, serum-free media and the cells were the stimulated for 
8 hours with vehicle (EtOH) or 100 nM ER specific agonist E2. After harvesting the cells, luciferase, β-
galactosidase and a Brafords assay was performed. The data was normalised for transfection 
efficiency and cell number by expressing luciferase (luc) activity relative to β-galactosidase activity 















performed in triplicate, which is presented as fold induction relative to vehicle (EtOH) control. Stars 
represent a significant (P < 0.01 = **) defined by a non-parametric, two-way ANOVA with a 
Bonferroni post test. 
 
Considering ER agonist treatment alone, a small, but statistically insignificant, decrease in 
ER-mediated transactivation was observed (Figure 4.5). This result suggests a lack of ER-
mediated activity in the current LβT2 cell line. It contradicts conventional models of ER 
activity, where E2 ligand-dependently activates the ER to drive ERE-mediated transcription 
(Edwards, 2005), which has been shown to regulate a number of LβT2 responses 
(Schreihofer et al., 2000; Chen et al., 2009). This result was previously discussed in Figure 
4.3. 
Nevertheless, the overall effect of a 24 hour GnRH pre-treatment on ERE-reporter activity 
revealed a significant increase in basal activity of roughly 2 fold relative to vehicle (Figure 
4.5). The fact that the ERE-luc reporter is responsive to GnRH treatments indicates a 
functional ERE-luc reporter plasmid. This increase in basal transcriptional activity may be 
due to a general increase in basal transcription-factor recruitment to the ERE-luc reporter 
mediated by the GnRHR signalling pathway. GnRH pre-treated samples subjected to 
saturating concentration (100 nM) of ER specific agonist (E2) treatment show no significance 
difference compared to its internal control (100 nM GnRH pre-treat EtOH). 
In conclusion, GnRH pre-treatment induced an increase in basal promoter activity (Figure 
4.5) in the absence of E2 in these cells. Whether this response is mediated by endogenous 
ER, via the ERE site in the reporter gene, still need to be determined. Given the 
undetectable response to E2, it is possible that the cells contain a mutated version of the ER 
that is unable to respond to E2, but can be activated by GnRHR, to increase transcription via 
binding to the ERE. This mechanism is possible, since Chen et al., (2009) showed that GnRH 
treatment mediates the site-specific phosphoylation of ERα protein to increase co-activator 
recruitment with the p300/CBP-associated factor (PCAF). These effects of GnRH on 
endogenous LβT2 fosB mRNA expression are dependent on the ER, and mediated by an ERE 















response observed is independent of the ER, and may be mediated by GnRH activating 
component(s) of the basal transcription machinery present on the ERE-reporter construct. 
Future experiments using a mutated ERE within this construct should discriminate between 

















RESULTS AND DISCUSSION 
5. Regulation of PR-B expression and function in LβT2 responses 
As mentioned in Chapter 3, P4 treatment has been shown to have suppressive effects on 
GnRH signalling (Thackray.et al.  2009), suggesting hormone treatments may influence PR 
and GnRHR signalling to regulate LβT2 gene expression. A recent study has shown the 
existence of such a PR and GnRHR crosstalk mechanism regulating Fshβ mRNA expression in 
LβT2 cells (An et al., 2009). This mechanism involves the rapid phosphorylation of the PR in 
response to GnRH treatment, in turn activating unliganded PR to recruit transcriptional co-
factors to modulate FSHβ expression.  
Therefore crosstalk between the GR/PR/ER and the GnRHR, in mediating the regulation of 
LβT2 target genes, including GnRHR, FSHβ and fosβ mRNA expression, respectively 
(Kotitschke et al., 2009; An et al., 2009; Chen et al., 2009), highlight the potential existence 
of such a mechanism for regulating target LβT2 PR gene expression. 
Having shown that both P4 and GnRH appear to effect ERα mRNA expression (Figure 4.4), 
while GR and GnRHR crosstalk was shown to mediate GnRHR mRNA expression (Figure 3.2), 
the role of these signalling pathways on PR expression was next examined. The effects of E2 
on PR-B mRNA expression were also assessed using 0.2 nM E2 priming. With regards to the 
literature, E2 priming has been shown to regulate PR mRNA expression in primary mice and 
















5.1  Characterisation of endogenous PR-B in LβT2 cells 
Before examining the role of hormone signalling on PR expression, untreated LβT2 cells 
were used to characterise PR-A and PR-B mRNA levels under basal conditions. LβT2 cells 
were cultivated under basal conditions, and harvested. Subsequent RNA extractions and 
cDNA conversions were performed to generate basal LβT2 cDNA. Thereafter conventional 
PCR using PR-B-specific and PR-(A+B)-specific primers was used to assess basal PR 
expression in LβT2 cells. The PR-B primers were designed to anneal and amplify a 121 bp 
amplicon from the unique 5’ end of the PR-B mRNA transcript, while the PR-(A+B) primers 
were designed to anneal and amplify a 121 bp amplicon from the shared 3’ end of the PR-A 
and PR-B mRNA transcripts (Addendum A, Figure 9.7) (Turgeon et al., 2006). 
 
Figure 5.1: Endogenous PR mRNA is basally expressed in LβT2 cells. LβT2 cells were seeded into 6-
well plates in DMEM supplemented with 10% serum, and were left to grow to 70% confluency under 
basal conditions. Thereafter the cells were harvested and RNA extractions were performed, followed 
by a reverse transcriptase reaction to generate basal LβT2 cDNA. Signals were amplified using 
conventional PCR with PR (A+B)- and PR-B-specific primer pairs. PCR products were generated over 















bromide staining. The arrow indicates the presence of PR (A+B) aplicon at 121bp and PR-B aplicon at 
121bp. NTC defines the no template control. 
 
From Figure 5.1 it appears that the mRNA for both PR isoforms is expressed under basal 
conditions, which is in agreement with current literature regarding endogenous LβT2 PR 
mRNA expression (Turgeon and Waring, 2006). PR-B is the more “transcriptionaly active” 
isoform (Graham and Clarke, 1997). Therefore this study will focus on the ligand-mediated 
transcriptional effects on PR-B mRNA expression. Specific detection of PR-B mRNA 
expression is possible via PR-B-specific primers directed against the 5’ end of the PR 
transcript, as this is absent in the PR-A isoform. 
Having shown the presence of PR-B mRNA in LβT2s cells, it was next determined whether 
the LβT2 cells express detectable levels of PR-B protein. In order to determine this, crude 
cell lysates were generated from cultivated LβT2 cells, and subjected to Western blotting 
and probed with specific PR-B- and ERK1/2(loading control)-antibodies. Lysates from COS-7 
cells over-expressing hPR-B were harvested and run alongside LβT2 lysates on the western 
blot to serve as a positive control in assessing PR-B protein levels in LβT2 cells. 
 
Figure 5.2: Endogenous PR-B protein is not detectable in LβT2 cells by western blotting. COS-7 cells 
were seeded into 6-well plates in DMEM supplemented with 10% serum. After a 24 hour incubation, 
the cells were either transiently transfected with 1 µg of pMT-hPR-B expression vector (positive COS-















seeded into a 6-well plate in DMEM supplemented with 10% serum, and left to grow under basal 
conditions. After all cells had reached a 70% confluency (at least 24 hours after transfection), the 
COS-7 cells and untreated LβT2 cells were harvested in 50 µl SDS sample application buffer. Equal 
volumes (10 µl) of all lysates were separated on 8% SDS polyacrylamide gel, transferred to a 
nitrocellulose membrane and probed with PR-B-specific and ERK1/2-specific (Loading control) 
primary polyclonal antibodies. Anti-rabbit-HRP secondary antibodies were used for detection of both 
PR-B and ER1/2 primary antibodies. Signals were visualised with Amersham Chemiluminescence. 
Arrows indicate PR-B protein at 116 kDa. ERK1 and 2 proteins are seen at 42 kDa & 44 kDa, 
respectively. 
 
Although PR-B protein was not detected in LβT2 cell lysates, a signal was detected for the 
positive control (COS-7 cell lysate over-expressing pMT-hPRβ plasmid) (Figure 5.2), 
suggesting that the PR-B antibody is effective in detecting PR-B protein. Because PR-B mRNA 
is detectable under basal conditions in LβT2 cells (Figure 5.1), suggests that PR-B protein is 
either not expressed or expressed at levels too low for detection using western blotting 
techniques.  
Therefore, a potentially more sensitive reporter-promoter assay was used to assess 
functional PR protein using the PR-specific agonist, R5020. LβT2 cells were transiently 
transfected with a TAT-GRE-luc reporter plasmid, and treated with PR agonist (R5020) at 
saturating concentrations (100 nM) for 8 hours to assess PR-mediated transactivation in 

















Figure 5.3: Functional reporter assay did not detect endogenous PR-mediated transactivation in 
LβT2 cells. LβT2 cells were seeded into a 24-well plate in DMEM supplemented with 10% serum.  
After a 24 hour incubation period, the medium was replaced with phenol red-free media, 
supplemented with 10% charcoal stripped serum and incubated further for 24 hours. Thereafter 250 
ng TAT-GRE-Luc reporter plasmid and 25 ng β-galactosidase expression vector were transiently 
transfected into the cells, which were then incubated for an additional 48 hours. After the 
incubation period, the medium were replaced with phenol red-free, serum-free media and the cells 
were stimulated for 8 hours with vehicle (EtOH) or 100 nM PR-specific agonist, R5020. The cells were 
harvested, with luciferase and β-galactosidase assays, as well as Braford assays, were performed. 
The data was normalised for transfection efficiency and cell number by expressing luciferase (luc) 
activity relative to β-galactosidase activity and total protein. The graph shows pooled results from 
two independent experiments performed in triplicate, which is presented as fold induction relative 
to vehicle (EtOH) control. 
 
Figure 5.3 shows that upon R5020 treatment, a small but not significant increase in PRE-
reporter activity is seen (1.4 fold relative to vehicle). This result may suggest that low 
amounts of PR protein are expressed in LβT2 cells. However, more experiments are required 
to establish whether functional PR is expressed at high enough levels to elicit a significant 
PR-mediated response. Previous studies have shown the presence and a role for the PR in 
mediating LβT2 responses (Thackray et al., 2006; Thackray et al., 2009; An et al., 2009). Yet 















exogenously expressed PR protein (Thackray et al., 2009), suggesting that there are only low 
levels of PR present in this cell model. 
5.2 The effect of hormone and combination treatments thereof on 
PR-B mRNA levels  
Although no statistical significant levels of functional PR protein could be detected (Figures 
5.2 and 5.3), PR-B mRNA is expressed in the LβT2 cell line (Figure 5.1). Additionally, as 
mentioned above, there is evidence for crosstalk between GnRHR and PR/ER/GR signalling 
pathways (An et al., 2009; Chen et al., 2009; Kotitschke et al., 2009). In order to determine 
whether these pathways regulate PR-B mRNA expression, experiments were designed to 
assess the effect of the test compounds on endogenous LβT2 PR-B mRNA expression.  
LβT2 cells were primed for 48 hours with or without 0.2 nM E2 to assess the effect of E2 
priming on PR-mediated signalling. Thereafter the cells wer  treated for 8 hours with vehicle 
or test compounds; Dex, P4 GnRH and combinations thereof at saturating concentrations 
(100 nM). After ligand incubations, samples were harvested and RNA was extracted (Figure 
9.6), followed by subsequent cDNA conversions. Quantitative real-time PCR with PR-B-
specific primers was used to assess the transcriptional effects of hormones in regulating 















Figure 5.4: PRβ mRNA expression appears to be up-regulated in response to GnRH, but not by Dex, 
P4 or E2 treatments in LβT2 cells. LβT2 cells were plated into 12-well plates in DMEM supplemented 
with 10% serum. After a 24 hour incubation period, the cells were treated with or without 0.2 nM E2 
in Phenol red-free media supplemented with 10% charcoal stripped serum. After 48 hours, the cells 
were treated with 100 nM vehicle (EtOH) or with the appropriate ligands and combinations thereof 
in phenol red-free, serum-free media. The cells were stimulated for 8 hours prior to harvesting and 
subsequent RNA extractions. cDNA was generated for all mRNA sample sets and was further 
analysed using PR-B-specific primers and quantitative real-time PCR (rotogene machine; Rotogene-
6000). Endogenous PR-B expression (Figure 11.8.1) was normalised to endogenous GAPDH 
expression (Figure 11.6.1), and was represented as fold induction relative to vehicle (EtOH). The 
graph shows pooled results for several independent experiments (n=4 for all samples without E2, 















= *) difference when compared to untreated control (-E2 EtOH), defined by a non-parametric, two-
way ANOVA with a Bonferroni post test. 
 
Figure 5.4 suggests that PR-B mRNA expression is regulated in a ligand-selective manner.  
Treatment with Dex or P4 showed no significant effects on mRNA levels (0.9 fold relative to 
vehicle). Current literature suggests a suppressive role for P4 in regulating PR-B expression 
in primary pituitary tissue (Graham and Clarke, 1997), yet this is in contrast with the current 
data (Figure 5.4). However, it must be noted that primary pituitary cells are composed of a 
number of different cell types, which may explain the differences in responses seen. No 
literature was found regarding the effects of P4 on endogenous PR mRNA expression in the 
LβT2 cell line. Interestingly GnRH treatment did significantly up-regulate endogenous PR-B 
mRNA expression (2 fold increase relative to vehicle).  
 Co-treatment with GnRH plus Dex on PR-B mRNA expression appeared to elicit a similar 
increase (2 fold increase) as seen with GnRH treatment alone, while co-treatment with 
GnRH plus P4 appeared to increase relative PR-B mRNA expression in LβT2 cells by 1.5 fold 
(Figure 5.4). These effects may be accounted for through the actions of GnRH treatment 
alone, as single treatments with Dex or P4 had no apparent effect on PR-B mRNA 
expression. However, it is possible that P4 is able to represses the GnRH response slightly 
when administered together, although further experiments are required to establish 
whether this result is significant. These combination treatments do not reveal any additive 
or synergistic signalling properties by these hormones in regulating endogenous PR-B mRNA 
expression in LβT2 cells, suggesting that potential crosstalk pathways between the GnRHR 
and the GR or PR may not regulate PR-B mRNA expression. It appears that GnRH treatment 
is the only treatment that significantly increases endogenous LβT2 PR-B mRNA expression 
(Figure 5.4).  
E2 priming for 48 hours with 0.2 nM E2 resulted in no significant variation on endogenous 
PR-B mRNA expression in LβT2 cells (1.1 fold) as compared to un-primed vehicle (Figure 5.4). 
This result is consistent with the literature showing that E2 priming has no effect on PR 















in up-regulating PR mRNA levels in primary mouse and rat pituitary cells (Turgeon and 
Waring, 2006). Therefore, in general it may be considered that primary cells respond 
differently to immortalised LβT2 cell lines. Stimulation with Dex or P4 on +E2 primed LβT2 
cells show no significant differences when compared to the –E2 primed data set (0.9 and 0.8 
fold relative to vehicle respectively) (Figure 5.4). However the +E2 P4 treatment is 
representative of one biological repeat, and therefore cannot be statistically analysed. 
Therefore further repeats are required to determine the ligand-induced effects of P4 on E2 
primed LβT2 cells.  
Treatment with GnRH on E2 primed LβT2 cells appeared to increase relative PR-B mRNA 
expression (1.5 fold relative to vehicle). However, this appears to be a reduced response 
when compared to GnRH treatment on the un-primed LβT2 cells (2 fold relative increase) 
(Figure 5.4). It may be that E2 treatment dampens the GnRH response yet the experiment 
only represents a small data set, and further experiments are required to determine if this 
change in PR-B mRNA expression is significant. 
Co-incubation with GnRH plus Dex on E2 primed LβT2 cells resulted in no significant 
differences compared to vehicle (1.1 fold), unlike the apparent 2-fold increase obtained with 
Dex plus GnRH treatments on un-primed samples. Taken together with the results for GnRH 
in the presence and absence of E2 priming strengthens the hypothesis that E2 priming may 
modulate ligand-dependent responses. Co-treatment with GnRH and P4 appeared to 
increase relative fold expression by 1.9 fold (Figure 5.4), which is a slightly higher response 
when compared to the un-primed E2 sample set.  
Taken together, no effects were seen on LβT2 PR-B mRNA expression with E2 treatment 
alone, which is in agreement with current LβT2 literature (Turgeon and Waring, 2006). GnRH 
was the only hormonal treatment resulting in a significant increase in PR-B expression. 
Consistent with this, Dex/P4 plus GnRH co-incubations showed no additive or synergistic 
properties, suggesting that treatment with GnRH alone is responsible for the induction of 
endogenous PR-B mRNA expression in LβT2 cells. The result of hormone combination 
treatments on endogenous LβT2 PR-B mRNA expression suggests that there is no crosstalk 
signalling between PR/GR and GnRHR to regulate PR-B mRNA expression in LβT2 cells. 















GnRH plus Dex responses suggest possible crosstalk between the ER and GnRHR in 
regulating or modulating ERα mRNA expression. 
5.3 Endogenous PR-B protein levels are not detected in response to 
GnRH treatment 
Although no detectable PR protein was seen under basal conditions (Figure 5.2), GnRH 
appeared to up-regulate endogenous PR-B mRNA expression (Figure 5.4). Although basal PR 
protein could not be detected, it may be detectable after GnRH treatments. Thus PR-B 
protein levels may be influenced in responses to ligand treatments. To assess PR protein 
levels in response to ligand treatments and combinations thereof, LβT2 cells were primed 
for 48 hours with or without 0.2 nM E2. Thereafter the cells were treated for 8 hours with 
vehicle or test compounds: Dex, P4, GnRH and combinations thereof, at saturating 
concentrations (100 nM). After ligand incubations, samples were harvested, and resolved 
using western blotting techniques, and probed with a specific antibody raised against PR-B 
protein to assess PR-B protein levels in response to ligand treatments. 
 
 
Figure 5.5: PR-B protein is not detectable under all conditions in LβT2 cells by Western blotting. 
LβT2 cells were plated into 12-well plates in DMEM supplemented with 10% serum. After a 24 hour 
incubation, the cells were treated with or without 0.2 nM E2 in phenol red-free media supplemented 
with 10% charcoal stripped serum. After 48hours, the cells were treated with 100 nM of the 
appropriate ligands and combination thereof in phenol red-free, serum-free media. The cells were 















µl) LβT2 whole cell lysates were separated on a 8% SDS denaturing polyacrylamide gel, transferred 
to a nitrocellulose membrane and probed with PR-B-specific and Flotilin-1-specific (Loading control) 
primary polyclonal antibodies. Anti-rabbit-HRP secondary antibodies were used for detection of PR-B 
primary antibody, while anti-mouse-HRP secondary antibodies were used for detection of Fotilin-1 
primary antibody. Signals were visualised with Amersham Chemiluminescence. PR-B and Flotilin-1 
proteins were observed at 116 kDa and 48 kDa, respectively. 
 
Similar to the results obtained in Figure 5.2, no detectable levels of PR-B could be seen 
under basal conditions, and remain undetectable under all ligand conditions (Figure 5.5). 
Furthermore, treatment with GnRH had no effect on detectable PR protein levels. Priming 
with E2 was also not sufficient to up-regulate PR protein, which is consistent with a previous 
LβT2 study regarding the effects of E2 priming on PR expression and translation (Turgeon 
and Waring, 2006). However, 8 hour ligand treatments may have resulted in insufficient 
time to allow for protein translation, even though the up-regulation of mRNA levels could 
already be detected after 8 hours (Figure 5.4). Therefore, additional samples should be 
collected at later time points, after hormone treatments, to confirm any delayed protein 
translation. 
Taken together, no detectable levels of PR-B protein could be seen in un-stimulated or 
stimulated LβT2 cells by western blotting (Figure 5.5). 
5.4 Endoge ous PR protein cannot be up-regulated to induce PR-
mediated transcription in LβT2 cells 
As shown previously, GnRH appeared to induce the up-regulation of PR-B mRNA (Figure 
5.4), yet no detectable levels of PR protein were seen under the same conditions using 
Western blotting techniques (Figure 5.5). Eight hour incubation periods may have resulted 
in insufficient time to allow for sufficient protein translation, to the extent that protein 
would not be detectable by means of western blot analysis. Therefore a different approach 















In a previous study it was shown that GnRH mediates the rapid phosphorylation of PR, 
inducing the ligand-independent activation in LβT2 cells (An et al., 2009). The PR-B mRNA 
expression data suggests that GnRH also up-regulates PR mRNA levels (Figure 5.4). 
Therefore attempts were made to assess the role of GnRH on PR activity on a PRE in the 
absence and presence of PR agonist (R5020) in LβT2 cells.  
Assuming GnRH increases PR-B mRNA expression and hence protein expression, an increase 
in PRE-reporter activity would be expected with R5020 under GnRH pre-treatment. 
However, if GnRH also activates the PR in a ligand-independent manner, as An et al., 
suggested, then GnRH would also increase basal PRE-reporter activity. 
 Additionally, the effects of 0.2 nM E2 priming revealed no significant changes in PR mRNA 
and protein levels (Figure 5.4 and Figure 5.5). This is consistent with current literature 
regarding LβT2 cells (Turgeon and Waring, 2006), but inconsistent with results obtained 
from primary mouse and rat pituitary cells, where it was shown that E2 priming over 3 days 
results in an increase in endogenous PR mRNA expression (Turgeon, and Waring, 2006).   
Thus a TAT-GRE reporter-promoter assay was used to assess the transcriptional activity of 
PR protein in the absence and presence of agonist, in response to GnRH or E2 pre-
treatments. A GRE reporter was used because the PR is able to act via a GRE, as the 
consensus sequence of a GRE is identical to that of a PRE. Therefore LβT2 cells transiently 
transfected with 250 ng TAT-GRE-luc reporter plasmid were pre-treated with and without 
GnRH or E2 for 24 hours prior to 8 hour stimulation with PR-specific agonist R5020 at 

















Treatment (A) Mean Std. Dev. Treatment (B) Mean Std. Dev. 
 EtOH 1.000 0.190 EtOH 1.000 0.112 
R 5020 0.791 0.185 R 5020 0.976 0.170 
(GnRH pre-treat) EtOH 1.201 0.297 (E2 pre-treat) EtOH 1.708 0.345 
(GnRH pre-treat) R5020 1.340 0.304 (E2 pre-treat) R5020 1.550 0.243 
Figure 5.6 (A-B): No PR-mediated transactivation seen on a PRE after GnRH (A) and E2 (B) pre-
treatments in LβT2 cells. LβT2 cells were seeded into a 24-well plate in DMEM supplemented with 
10% serum.  After a 24 hour incubation period, the medium was replaced with phenol red-free 
media, supplemented with 10% charcoal stripped serum and incubated further for 24 hours. 
Thereafter 250 ng ERE-Luc reporter plasmid and 25 ng β-galactosidase expression vector were 
transiently transfected into the cells and were incubated with or without 100 nM GnRH (A) or 0.2 
nM E2 (B) for an additional 24 hours. Thereafter, the medium was replaced with phenol red-free, 
serum-free media and the cells were the stimulated for 8 hours with vehicle (EtOH) or 100 nM PR-
specific agonist, R5020. The cells were harvested, and luciferase, β-galactosidase and Brafords assays 
were performed. The data was normalised for transfection efficiency and cell number by expressing 
luciferase (luc) activity relative to β-galactosidase activity and total protein. The graph shows pooled 
results from three independent experiments, each performed in triplicate, which is presented as fold 
induction relative to vehicle (EtOH) control. Stars represent a significant (P < 0.001 = ***) defined by 

















Figure 5.6A shows the effects of GnRH pre-treatment on PRE/GRE-transcription in LβT2 
cells. Upon 8 hour R5020 treatment alone it appears that a slight reduction in relative 
activity is seen on PRE-activity. This result suggests no functional PR protein is present in 
LβT2 cells under basal conditions, which is consistent with previous results obtained in this 
study (Figure 5.2 and Figure 5.5). Pre-treatments with GnRH alone significantly increased 
basal PRE-reporter activity to 1.2 fold relative to vehicle. On addition of 8 hour PR agonist 
(R5020) treatments, it appears that a slight increase in PRE-reporter activity is seen, relative 
to its internal control (GnRH pre-treatment plus EtOH), which may be due to GnRH up-
regulating PR-B expression. However, this result is not statistically significant. Whether this 
increase in basal reporter activity is mediated by endogenous PR is unknown. Given the 
undetectable response to R5020, it is possible that the cells contain a mutated version of 
the PR that is unable to respond to P4 or R5020, but can be activated by GnRH, to increase 
transcription via binding to the PRE. This mechanism is possible, since An et al., (2009) 
showed GnRH treatment mediates the site-specific phosphorylation of the PR protein to 
increase endogenous LβT2 fshβ mRNA expression (An et al., 2009). On the other hand it is 
possible that the response observed in the current study is independent of the PR, and may 
either be mediated by GnRH activating some component(s) of basal transcription machinery 
present on the PRE, or GnRH ligand-independently activating the GR to drive GRE-reporter 
activity (Kotitschke et al., 2009). 
Considering the effects of E2 pre-treatment (Figure 5.6B), PR agonist (R5020) treatment 
alone revealed no difference compared to vehicle, which is consistent with the result that 
little to no functional PR is present in LβT2 cells (Figure 5.3). However the effect of 24 hour 
0.2 nM E2 treatment showed a significant increase in basal transcriptional activity (1.7 fold 
relative to vehicle). However, PR agonist treatments on E2 primed LβT2s showed no 
apparent increase in PRE-mediated transcription (1.5 fold relative to vehicle). This result is 
consistent with PR-B expression data observed in  the study (Figure 5.4), showing that E2 
treatment does not up-regulate PR-B mRNA expression, as well as other studies in the LβT2 
cell line (Turgeon and Waring, 2006), but inconsistent with data observed in primary 















Taken together, attempts to up-regulate functional PR protein and PRE-reporter activity in 
LβT2 cells though ligand pre-treatments was unsuccessful, suggesting that LβT2 cells have 
very low levels of functional classical PR-B. 
5.5  mPRα does not mediate the effects of P4 in LβT2 cells 
Recent studies have shown the presence of a novel mPR in mediating non-genomic P4 
signalling in various tissue types (Zhu et al., 2003). The present study has shown that in the 
LβT2 cell line grown in our laboratory, PR protein is undetectable by western blotting (Figure 
5.2 and Figure 5.5). Endogenous PR-B mRNA expression is not significantly affected by 
treatments with Dex, P4, and E2 (Figure 5.4) and functional PR-B activity is not detectable 
on a PRE-luc reporter promoter assay (Figure 5.3). Nevertheless both GnRHR (Figure 3.2) 
and ERα (Figure 4.4) mRNA levels are regulated by P4 treatment, suggesting the presence of 
a functional PR. Thus it is possible that P4 signalling may be mediated through receptors 
besides the classical PR in LβT2 cells.  
In light of this theory, an attempt was made to assess the presence of mPRα mRNA 
expression in the LβT2 cell line. LβT2 cells were cultivated under basal conditions, and cDNA 
samples were generated. mPRα mRNA was amplified using conventional PCR and a mPRα-
primer pair (Addendum B, Table 10.1). cDNA from human endo-cervical cells (End-1) was 
used as a positive control as previous work from the Hapgood lab has shown mPRα mRNA 
expression in this cell line (Jaravaza, 2009). Note that these End-1 cells were found, by 
conventional PCR, to express mPRα and GR, but not PR (A+B) mRNA (Addendum A, Figure 



















Figure 5.7: mPR mRNA is not expressed under basal conditions in LβT2 cells. LβT2 cells were 
seeded into 6-well plates in DMEM supplemented with 10% serum, and were left to grow to 70% 
confluency under basal conditions. End1/E6E7 (End-1) cells were seeded into 12-well plates in KSF 
media,. Thereafter both cell lines were left to grow to 70% confluency under basal conditions. 
Thereafter End-1 and LβT2 cells were harvested and RNA extractions were performed, followed by a 
reverse transcriptase reaction to generate basal cDNA samples. Signals were amplified using 
conventional PCR with mPRα-specific primer pairs. An mPRα expression vector (pcDNA3.1/mPRα) 
was used as a positive control (+), and 1 µl dH2O was used as the input for the no template control (-
). PCR products were generated over 30 cycles, separated on a 2% agarose gel using electrophoresis, 
and visualised using ethidium bromide staining. Arrow indicates mPRα amplicon at 214 bp. 
 
Figure 5.7 indicates that LβT2 cells do not express endogenous mPRα mRNA, suggesting that 
the effects of P4 on LβT2 cell responses are not mediated by mPRα. A positive signal at 241 
bp is seen for the endo-cervical cell line (End-1) (Figure 5.7). Although human mPRα primers 
were used in the PCR reaction (Figure 5.7) on mouse LβT2 samples, NCBI mRNA sequence 
blast did show that the human mPRα primer pair used can anneal to mouse mPRα mRNA 
transcript (data not shown).  
Taken together, the results show End-1 cells lack PR-A and PR-B mRNA and protein 






















End-1 cell line. This suggests that mPRα may play an important role in mediating the effects 
of P4, as these cells have been shown to respond to P4 (Zhu et al., 2003; Cai et al., 2005; 
Karteris et al., 2006) and progestins (Verhoog, 2010). 
For a side study, mPRα exogenous expression and mPRα protein detection was optimised in 
light of the hypothesis that mPRα may play an important role in P4-mediated signalling in 
the End-1 cell line. Therefore several mPRα expression vectors were acquired (Krietsch et 
al., 2006), to serve as a positive control in the investigation of mPRα protein levels in the 
End-1 cell line. mPRα expression vectors were subsequently cloned and sequenced, so that 
detailed plasmid maps could be constructed for future reference (Addendum D, Figures 
12.1, 12.2 and 12.3). To optimize exogenous mPRα expression, End-1 cells were transfected 
with tagged mPRα-HA or untagged mPRα expression constructs and left to grow under basal 
conditions. Thereafter End-1 cell lysates were harvested (using multiple harvesting 
protocols, outline in methods Section 2.13) and probed for mPRα protein using Western 
blot techniques and anti-HA- (Addendum A, Figure 9.4) or anti-human/mouse mPRα-specific 
primary antibodies (Addendum A, Figure 9.5). A summary of exogenous mPRα protein 
expression is shown in Addendum A, Table 9.1. An 80 kDa mPRα dimer or a 40 kDa mPRα 
monomer (Krietsch et al., 2006) were not detected using DEAE or Fugene transfection 
protocols. Transfection controls were incorporated for all experiments (pCMV-HA-human 
GR) and yielded positive protein expression under all conditions, indicating transfection 
conditions used were appropriate. This result may suggest improper protein folding and/or 
membrane localisation of the mPRα protein in the End-1 cell line. To address this 
hypothesis, mPRα over-expression was attemped in the LβT2 cell line, on the account of its 
endogenous GPCR (GnRHR) expression (Navratil et al., 2009). Exogenous mPRα protein 
expression appeared unsuccessful under all transfection conditions (Addendum A, Figure 
9.4). It was concluded that the mPRα expression vectors must be the root of the problem, as 
a result of no differences between mock (-mPRα) and transiently transfected (+mPRα) End-1 
and LβT2 cells (Addendum A, Figure 9.4).Therefore any attempt to characterise End-1 cells 
for endogenous mPRα protein expression proved unsuccessful as no over-expressed mPRα 















On a separate issue, it should be noted that a number of non-specifics bands were seen 
when using the anti-mPRα anti body (Addendum A, Figure 9.5). However this is most likely 
due to a high exposure of western blot development in assessing mPRα protein levels.  
In conclusion, LβT2 cells show no detectable levels of functionally active PR protein using 
Western blotting (Figure 5.2), and no detectable levels of endogenous mPRα mRNA 
expression using conventional PCR (Figure 5.7). This result suggests that the mPRα is not 

















RESULTS AND DISCUSSION 
6. Regulation of GRα expression and function in LβT2 responses 
As mentioned earlier, LβT2 genes have been shown to be regulated by the GR via GR ligand-
dependent and GR ligand-independent mechanisms (Kotitschke et al., 2009), with previous 
results showing crosstalk between the GR and GnRHR signalling pathways. 
 It is apparent that GnRH signalling effects ERα (Figure 4.4) and PR-B (Figure 5.4) mRNA 
expression in LβT2 cells, and that GR and GnRHR crosstalk regulates GnRHR mRNA 
expression in LβT2 cells (Figure 3.2). In addition, a novel and interesting effect of E2 priming 
appeared to modulate Dex-mediated responses on GnRHR (Figure 3.2), and possibly also 
ERα mRNA expression (Figure 4.4). Therefore the effects of Dex, P4, E2, GnRH and 
combinations thereof on GR expression was investigated in LβT2 cells.  
6.1   Characterisation of endogenous GRα in LβT2 cells 
Before assessing a role for hormone signalling in regulating GRα mRNA expression, 
untreated LβT2 cells were first used to characterise endogenous GRα mRNA levels under 
basal conditions. LβT2 cells were cultivated under basal conditions, and harvested. 
Subsequent RNA extractions and cDNA conversions were performed to generate LβT2 
cDNA. Thereafter conventional PCR with intron spanning GRα-specific primers was used to 
















Figure 6.1: Endogenous GRα mRNA is basally expressed in LβT2 cells. LβT2 cells were seeded into 6-
well plates in DMEM supplemented with 10% serum, and were left to grow to 70% confluency under 
basal conditions. Thereafter the cells were harvested and RNA extractions were performed, followed 
by a reverse transcriptase reaction to generate basal LβT2 cDNA. Signals were amplified using 
conventional PCR with GRα-specific primer pairs. PCR products were generated over 35 PCR cycles 
and separated on a 2% agarose gel using electrophoreses, and visualised with ethidium bromide 
staining.  Arrow indicates GRα amplicon at 299 bp. NTC defines the no template control. 
 
From Figure 6.1 it is clear that GRα mRNA is expressed under basal conditions in LβT2 cells, 
in agreement with the current literature showing endogenous LβT2 GRα expression 
(Kotitschke et al., 2009; Nicolaides et al., 2010). Having shown the presence of GRα mRNA in 
LβT2s cells, it was next determined whether LβT2 cells express detectable levels of GRα 
protein. Crude cell lysates were generated from cultivated LβT2 cells and GR protein levels 
were investigated using western blotting with specific anti-GRα antibodies. COS-7 cells over-
expressing hGRα-HA were harvested and the extracts electrophoresed alongside LβT2 
















Figure 6.2: Endogenous GRα protein is expressed under basal conditions in LβT2 cells. COS-7 cells 
were seeded into 6-well plates in DMEM supplemented with 10 % serum. After a 24 hour incubation, 
the cells were either transiently transfected with 1 µg of pGMV-HA-hGR expression vector (Positive 
control) (+) or left to grown under basal conditions (negative control) (-). LβT2 cells were seeded into 
a 6-well plate in DMEM supplemented with 10% serum, and left to grow under basal conditions. 
After all cells had reached a 70% confluency (at least 24 hours after transfection), the COS-7 cells 
and untreated LβT2 cells were harvested in 50 µl SDS sample application buffer. Equal volumes (10 
µl) of all lysates were separated on 8% SDS polyacrylamide gel, transferred to a nitrocellulose 
membrane and probed with GRα-specific or ERK1/2-specific (Loading control) primary polyclonal 
antibodies. Anti-rabbit-HRP secondary antibodies were used for detection of both GRα and ER1/2 
primary antibodies. Signals were visualised with Amersham Chemiluminescence. The top arrows 
indicate the GRα protein observed at 95 kDa, with the second arrow indicates a non-specific band 
(N/S) at 94 kDa. ERK1/2 proteins are seen at 42 kDa and 44 kDa, respectively. 
 
From Figure 6.2 it is evident that GRα protein is present under basal conditions in LβT2 cells, 
in agreement with the current literature showing expression of GRα protein in LβT2 cells 
(Kotitschke et al., 2009). It must be noted that a non-specific band was seen in the COS-7 
positive and negative control cell lysates. This non-specific band (as indicated by the arrow 
in Figure 6.2) was seen to run at a slightly lower molecular weight compared to the over-
expressed GRα protein signal, and is most like endogenous COS-7 GRα protein. These 
GRα 
Endogenous  















differences in protein migration through the SDS polyacrylamide gel may be a result of cell-
specific differences between COS-7 and LβT2 cells 
Taken together, Figures 6.1 and 6.2 illustrate that GRα mRNA is basally expressed and 
translated into GR protein. To test whether this GR protein is functionally active in LβT2 cells 
and will drive GRE promoter-reporter transactivation upon agonist treatment, LβT2 cells 
were transiently transfected with a TAT-GRE-luc reporter plasmid, and treated with GR 
agonist (Dex) at saturating concentrations (100 nM) for 8 hours.  
 
Figure 6.3: Functional reporter assay shows endogenous GRE-mediated transcription in LβT2 cells. 
LβT2 cells were seeded into a 24-well plate in DMEM supplemented with 10% serum.  After a 24 
hour incubation period, the medium was replaced with phenol red-free media, supplemented with 
10% charcoal stripped serum and incubated further for 24 hours. Thereafter 250 ng TAT-GRE-Luc 
reporter plasmid and 25 ng β-galactosidase expression vector were transiently transfected into the 
cells, which were then incubated for an additional 48 hours. Thereafter, the medium was replaced 
with phenol red-free, serum-free media and the cells were the stimulated for 8 hours with vehicle 
(EtOH) or 100 nM GR-specific agonist, Dex. Thereafter, the cells were harvested, and luciferase, β-
galactosidase and Brafords assays were performed. The data was normalised for transfection 
efficiency and cell number by expressing luciferase (luc) activity relative to β-galactosidase activity 
and total protein. This graphs shows pooled results from two independent experiments, each 















represent a significant (P < 0.001 = ***) difference when compared to untreated control, defined by 
a two-tailed T-test 
 
Figure 6.3 shows a 6 fold increase in relative TAT-GRE-reporter-activity in response to 100 
nM GR agonist (Dex) treatment. This is consistent with the genomic roles of Dex in 
activating the GR to drive GRE-promoter expression (Nicolaides et al., 2010).  
6.2 GRα mRNA expression is ligand-dependently regulated in 
response to hormone treatments in LβT2 cells 
As the GRα is endogenously expressed in LβT2 cells (Figures 15 and 16), there is a potential 
for the GRα gene to be transcriptionally regulated in response to ligand treatments. 
Additionally, as mentioned earlier, recent evidence has shown that crosstalk mechanisms 
occur between the GRα and other receptors (Kotitschke et al., 2009; Chen et al., 2009; An et 
al., 2009). Therefore to determine whether these crosstalk pathways (ER/PR/GR and 
GnRHR) feedback to regulate GRα mRNA expression, experiments were designed to assess 
the effect of appropriate test compounds (Dex, P4, GnRH and combinations thereof) on 
endogenous LβT2 GRα mRNA expression.  
LβT2 cells were pre-treated with or without 0.2 nM E2 for 48 hours, as well as an 8 hour 
treatment at saturating concentrations (100 nM) of Dex, P4, GnRH and combinations 
thereof. Thereafter cells were harvested and RNA was extracted (Figure 9.6), followed by 
subsequent cDNA conversion. Quantitative real-time PCR with GRα-specific primers were 
used to assess the transcriptional effects of Dex, P4, GnRH, E2 and combinations thereof in 
















Figure 6.4: GR mRNA expression is significantly suppressed in a ligand-dependent manner in LβT2 
cells. LβT2 cells were plated into 12-well plates in DMEM supplemented with 10% serum. After a 24 
hour incubation, the cells were treated with or without 0.2 nM E2 in phenol red-free media 
supplemented with 10% charcoal stripped serum. After 48 hours, the cells were treated with 100 nM 
appropriate ligand and combination thereof in phenol red-free, serum-free media. The cells were 
stimulated for 8 hours prior to harvesting and subsequent RNA extractions. cDNA was generated for 
all mRNA sample sets, and was further analysed with GRα-specific primers and quantitative real-time 
PCR (Rotogene machine; Rotogene-6000). Endogenous GRα mRNA expression (Figure 11.9.1) was 
normalised to endogenous GAPDH expression (Figure 11.6.1), and was represented as fold induction 
relative to vehicle (EtOH). The graph shows pooled results for several independent experiments (n=4 
for all samples without E2, n=3 for all E2 containing samples, and n=1 for +E2 P4 sample). Stars 
represent a significant (P < 0.05 = * P < 0.01 = **) difference when compared to untreated control (-
















From Figure 6.4, Dex treatment significantly down-regulated GRα mRNA expression to 0.5 
fold relative to vehicle, which is consistent with the current literature showing that GCs 
down-regulate GRα mRNA expression in most target cell lines (Burnstein et al., 1990; De 
Silva et al., 1993; Freeman et al., 2004). Additionally a study has shown a correlation 
between Dex treatments and an increase in GR turn-over (Avenant et al., 2010). Therefore 
this result supports the hypothesis that GCs reduce relative levels of GR mRNA and protein 
expression as a result of a feedback mechanism in response to GR-mediated signalling. 
Treatment with P4 resulted in a similar significant repressive trend on LβT2 GRα mRNA 
expression, reducing mRNA levels to 0.55 fold relative to vehicle (-E2 EtOH). Because neither 
PR (A+ B) nor mPRα protein was previously detected in the LβT2 cell line, this raises the 
question of how the effects of P4 are mediated. This result suggests the possibility that the 
GR may be responsible for the P4-mediated down-regulation of GRα mRNA expression via 
the partial agonist properties of P4 towards the GR (Ronacher et al., 2009). 
Stimulation with GnRH resulted in a similar significant repressive trend as compared to Dex 
treatment (0.5 fold relative to vehicle). This result suggests a number of possibilities. One 
explanation is that GnRH is acting via the unliganded GR, as suggested by Kotitschke et al., 
Therefore the ligand-independent activation of the GR by GnRH may regulate endogenous 
GRα mRNA expression through cis-elements in the GR gene promoter, possibly to serve as a 
signalling feedback mechanism in LβT2 cells. Another explanation could suggest that GnRH 
acting via GnRHR is able to regulate the GR-promoter activity via kinase signalling cascades 
involved in GnRHR signalling (PKA, PKC or MAPK) to regulate downstream transcription 
factors like AP-1 (Kotitschke et al., 2009). A final explanation may involve a combination of 
the two mechanisms. Yet a precise mechanism cannot be established with the current data 
available, and further experiments are required to assess these hypothesised mechanisms. 
Co-stimulation with Dex plus GnRH further reduced GRα mRNA levels to 0.3 relative fold 
induction, compared to the 0.5 fold reduction with Dex or GnRH treatment alone. This novel 
finding reveals that the repressive properties of Dex and GnRH signalling may act in concert 
to repress GRα expression (Figure 6.4). This result may be representative of two separate 















possible that the effects of Dex are mediated through the ligand-dependent activation of 
the GR, while the effects of GnRH may be a result of GnRHR-mediated signalling. However, 
further experiments would be required to assess the statistical significance of this result, 
and elucidate a mechanism responsible for mediating this response.  
Co-stimulation with P4 plus GnRH elicited a similar response as compared to GnRH 
treatment alone, reducing GRα mRNA levels to 0.45 fold relative to vehicle (Figure 6.4). 
However no additive properties were observed with P4 plus GnRH treatment. This result 
appears to be different to the effects of Dex plus GnRH treatment, suggesting that the 
effects of P4 are not mediated by the GR. 
Taken together, the un-primed  results in Figure 6.4 show a potential for Dex and GnRH 
signalling pathways to be functionally integrated in regulating LβT2 GRα mRNA expression, 
however further experiments are required to assess this hypothesis. What can be said is 
that Dex and GnRH feedback signalling must exist to modulate GRα mRNA expression in 
LβT2 cells. 
Priming with 0.2 nM E2 for 48 hours resulted in no significant change in basal GRα mRNA 
expression in LβT2 cells (0.9 fold relative to vehicle) (Figure 6.4). Stimulation with Dex on E2 
primed LβT2 cells appeared to show a novel abolishment of Dex-induced repression of GRα 
mRNA expression when compared to un-primed Dex treatment, with mRNA levels 
remaining unchanged at 0.9 fold relative to E2 primed vehicle (+E2 EtOH) (Figure 6.4). This 
result suggests a switch from a repressive role for Dex signalling in regulating GRα mRNA, to 
no effect on the addition of 48 hour E2 priming. This result appears to support ER and GR 
crosstalk (Figures 3.2 and 4.4), suggesting that prolonged low doses of E2 may influence the 
expression of GR regulated genes in response to GCs. This response to E2 may occur 
indirectly through ER-mediated changes in GR phosphorylation at Ser-211, as seen with the 
E2-induced up-regulation of protein phophatase 5 (PP5) expression in MCF-7 cells (Zhang et 
al., 2009).  
Treatment with P4 on E2 primed LβT2 cells resulted in a similar trend to that obtained with 
P4 alone, i.e. repression of GRα mRNA levels to 0.6 fold relative to vehicle (Figure 6.4). 















required to determine the significance of E2 priming on P4 responses in LβT2 cells. However 
it appears that low doses of E2 treatment do not affect the repressive effect of P4 regulating 
GRα mRNA expression. This result argues against the hypothesis that P4 signalling acts via 
the GR, as the effects of E2 priming were only influential in abolishing Dex-induced 
repression and not P4-induced repression. This suggests that Dex and P4 signalling is 
mediated by two different receptor pathways to regulate GRα mRNA levels. 
Treatments with GnRH on E2 primed LβT2 cells appeared to have a similar repressive trend 
in regulating GRα mRNA expression when compared to the un-primed sample set (Figure 
6.4), with relative GRα mRNA levels dropping to 0.5 fold expression compared to vehicle 
(Figure 6.4). Thus E2 priming does not affect GnRH-mediated signalling in regulating LβT2 
GRα mRNA expression. Co-stimulation with Dex plus GnRH on E2 primed LβT2 cells reduced 
GRα mRNA levels to 0.45 fold relative to vehicle (Figure 6.4). Although repression is still 
observed upon Dex plus GnRH co-treatment, the combined repressive effects of Dex and 
GnRH appear to be reduced when compared to the un-primed Dex plus GnRH sample set. 
This suggests that the response may be representative of GnRH action alone, as E2 priming 
was able to reduce Dex-mediated repression (Figure 6.4). Further experiments are required 
to establish whether this change in Dex-response between E2 primed and un-primed LβT2 
cells is statistically significant. Stimulation with P4 plus GnRH co-treatment reduced GRα 
mRNA levels to 0.7 fold in relative expression (Figure 6.4). Once again this suggests that P4 
does not act via the GR and that E2 priming does not influence P4 or GnRH-mediated 
regulation of GRα mRNA expression in LβT2 cells.  
In conclusion, Figure 6.4 shows that endogenous LβT2 GRα mRNA is transcriptionally 
repressed in a ligand-dependent manner, upon Dex, P4 and GnRH treatments alone, but not 
with E2 priming alone. The finding that GR mRNA repression in the presence of Dex plus 
GnRH appears to be greater than that observed with each ligand alone, could suggest Dex-
mediated and GnRH-mediated signalling are acting simultaneously. This would suggest GR 
and GnRHR crosstalk regulates GR levels. Additionally the novel result of E2 priming 
appearing to abolish Dex-mediated repression of GRα mRNA, may suggest GR and ER 
crosstalk may regulate GR levels. However, E2 priming did not appear to affect P4-mediated 















involving (GR-specific) Dex treatments seemed to be the only responses affected by E2 
priming (Figures 3.2 and 4.4), while no effects were seen on GnRH or P4 signalling. The 
implications of this result suggest ER and GR signalling pathways may crosstalk in order to 
finely balance endocrine activity in the body. This further suggests that low doses of E2 may 
modulate GR-mediated activity, yet additional experiments are required to assess the 
involvement of the GR and ER in this response. 
6.3 GRα protein levels are ligand-dependently regulated in response 
to hormone treatments in LβT2 cells. 
As shown earlier, functional GR protein is present under basal conditions (Figure 6.2 and 
Figure 6.3). This study has shown GR mRNA levels are regulated in response to ligand 
treatments (Figure 6.4), suggesting ligand-dependent mechanisms regulate GR-mediated 
responses. Therefore the rationale was to determine whether observed changes in GRα 
mRNA levels mimicked the changes in protein levels. To measure varying GR protein levels, 
LβT2 cells were primed for 48 hours with or without 0.2 nM E2. Thereafter the cells were 
treated for 8 hours with vehicle or test compounds, Dex, P4 GnRH and combinations thereof 
at saturating concentrations (100 nM). Thereafter, samples were harvested, and resolved 
using western blotting, and probed with a specific antibody raised against GRα protein to 

















Figure 6.5 (A-B): Effects of Dex & GnRH, but not P4 and E2, on GR protein levels correlate with GR 
mRNA levels. LβT2 cells were plated into 12-well plates in DMEM supplemented with 10% serum. 
After a 24 hour incubation period, the cells were treated with or without 0.2 nM E2 in phenol red-
free media supplemented with 10 % charcoal stripped serum. After 48 hours, the cells were treated 
with 100 nM of the appropriate ligand and combination thereof in phenol red-free, serum-free 
media. The cells were stimulated for 8 hours prior to harvesting in 50 µl SDS sample application 
buffer. Equal volumes (10 µl) of LβT2 whole cell lysates were separated on a 8% SDS denaturing 
polyacrylamide gel transferred to a nitrocellulose membrane and probed with anti-GRα-specific and 

















antibodies were used for detection of GRα and anti-mouse-HRP secondary antibodies were used for 
detection of flotilin-1 primary antibodies. Signals were visualised using Amersham 
Chemiluminescence. GRα and flotilin-1 proteins are observed at 95 kDa and 48 kDa (A). GRα signals 
were developed on radioautographs and scanned. Signal intensities were quantified using AlphaEase 
FCTM Software (Alpha Innotech Corperation). Loading was normalised through flotilin-1 protein levels 
and represented as relative GR protein, relative to vehicle treated EtOH. The blot in A is a single 
representative of a GRα immune-blot, while the graph shows pooled results for several independent 
western blots (n=4 for all samples without E2, n=3 for all E2 containing samples, and n=1 for +E2 P4 
sample). 
 
Figure 6.5A is a representation of an immuno-blot showing varying GRα protein levels in 
response to multiple ligand conditions. No significant differences in total GR levels are seen 
(Figure 6.5B), unlike the results obtained for GR mRNA levels (Figure 6.4). The responses 
observed on relative GRα protein levels appear small and insignificant. Error in 
quantification and normalisation may have resulted in no significant changes GRα protein 
expression. The rate of GR turn-over in response to hormone treatments, may account for 
this apparent discrepancy in GRα protein levels (Avenant et al., 2010). 
 Treatment with Dex appeared to reduce GR protein levels to 75% relative to vehicle, while 
P4 and GnRH treatments alone show no effect on regulating GR protein levels (Figure 6.5B). 
Dex and GnRH co-treatment appears to reduce GRα protein levels (70% relative to vehicle) 
(Figure 6.5B). This result corresponds to the suppressive combinational effects of Dex and 
GnRH co-treatment on GRα mRNA levels (Figure 6.4). 
An apparent repressive trend is seen when comparing the effects of Dex and Dex plus GnRH 
conditions on total GRα protein levels (Figure 6.5B) with GRα mRNA levels (Figure 6.4). Not 
all ligand-dependent trends correlated with the GRα mRNA expression, as no effects were 
seen on GRα protein levels with P4 treatment, and no abolishment of Dex-mediated 
















The effects 0.2 nM E2 on GRα protein levels yielded a range of insignificant responses which 
appear to be highly variable when compared to the un-primed sample set (Figure 6.5B). This 
may be a result of biological and technical variation between experimental repeat 
experiments. E2 priming alone showed no effect on GRα protein levels, while E2 priming 
and Dex treatment appeared to reduce GRα protein levels to 70% relative to vehicle (Figure 
6.5B). P4 treatment on E2 primed LβT2 cells result in no effect on GR protein levels, with 
GRα levels remaining unchanged compared to vehicle (Figure 6.5B). GnRH treatments on E2 
primed LβT2 cells appeared to show a reduction in GRα protein levels to about 80% relative 
to vehicle.  
Co-treatments with Dex and GnRH on E2 primed LβT2 cells appear to show the largest 
reduction in GRα protein levels (about 60% relative to vehicle) (Figure 6.5B), in correlation 
with GRα mRNA expression levels (Figure 6.4). Finally the effects of P4 and GnRH co-
treatments appear to show a highly varied response, with GRα protein levels dropping to 
60% relative to vehicle (Figure 6.5B). 
Taken together, E2 priming appears to increase the variability of GRα protein levels in 
response to ligand treatment (Figure 6.5B). This suggests that the quantitative analysis of GR 
protein through western blotting and subsequent computer scanning is not the most 
sensitive technique. This may explain discrepancies observed between GR mRNA and 
protein levels in response to ligand treatments. However, the trend in varying GR protein 
levels in relation to ligand treatments (Figure 6.5B) appears to correlate with the observed 
trend in GRα mRNA expression with regards to Dex and Dex plus GnRH treatments (Figure 
6.4). Dex treatments suppress GRα mRNA and protein levels, in a ligand-dependent manner, 
with the combined effects of Dex plus GnRH being seen on Dex plus GnRH treatments, 
highlighting potential GR and GnRHR crosstalk regulating GR protein levels. 
Therefore the down-regulation of GRα mRNA and protein levels in response to Dex and 
GnRH treatments may serve as feedback signalling mechanisms, to regulate GR-mediated 
signalling (Kotitschke et al., 2009) To further confirm this, additional data sets are needed to 
be investigated using a more sensitive and accurate method of quantifying GRα protein 
levels (such as using digital imaging software opposed to using x-ray film for image 















GnRH signalling on GnRHR expression relative to functional GR protein levels in LβT2 cells. 
This feedback signalling may have influential downstream effects of GR-mediated 


















A central aim of this study was to assess the effect of GnRHR and SR signalling on 
endogenous hormone receptor mRNA levels in the LβT2 cell line. Receptors of interest 
included the GnRHR, and the ER, PR and GR steroid receptors. Basal steroid receptor 
expression and activity were characterised. The effect of hormone treatments on relative 
GnRHR and steroid receptor mRNA expression was examined using quantitative real-time 
PCR. Results presented in this study show significant ligand-dependent regulation of 
endogenous LβT2 GnRHR and steroid receptor mRNA expression. These results do not 
establish a precise mechanism of repression. But, they do establish a basis for further 
experimental assessment on the specific responses observed. 
7.1  ER, PR and GR characterisation in the LβT2 cell line  
Table 7.1: Characterisation of steroid receptors in the LβT2 cell line. Table summarizes results on 
basal mRNA expression, basal protein expression and agonist-mediated activity of target steroid 
receptors (ER, PR and GR) in the LβT2 cell line.  
Steroid Receptor Observed Results Relevant 
Figures 
ERα 
ERα mRNA is detected with conventional PCR Figure 4.1 
No ERα protein detected with Western blotting  Figure 4.2 
No ER-mediated activity on ERE-luc reporter Figure 4.3 
PR-B 
PR-B mRNA is detected with conventional PCR Figure 5.1 
No PR-B protein detected with Western blotting  Figures 5.2 & 5.4 
No PR-B-mediated activity on PRE-luc reporter Figure 5.3 
GRα 
GRα mRNA is detected with conventional PCR Figure 6.1 
GRα protein detected with Western blotting  Figures 6.2 & 6.4 
GR-mediated activity on GRE-luc reporter Figure 6.3 
In this study it was shown that ERα mRNA is basally expressed in the LβT2 cell line (Figure 
4.1), but assessment of ERα protein levels proved inconclusive. The ERα-specific primary 
antibody used appeared to be unsuccessful in detecting of ERα protein (Figure 4.2), as was 
shown from antibody optimization for the ERα primary antibody (data not shown). 
Furthermore ERE-luc reporter promoter assays showed no change in ER-mediated activity 















GnRH treatments (Figure 3.5), suggesting a response independent of the ER. ER isoforms 
were not assessed in this study, leaving the possibility that a truncated or even mutated ER 
isoform may be present in the LβT2 cell line. A previous study has shown the presence of 
functionally active ERα protein in the LβT2 cell line (Shupnik et al., 2000; Chen et al., 2009), 
yet the current study was unsuccessful in detecting any ER protein and activity. Therefore in 
conclusion, ERα mRNA is basally expressed in the LβT2 cell line (Figure 4.1), and is ligand-
dependently regulated in response to hormone treatments (Figure 3.4). This suggests the 
ERα is likely to have some functional purpose in LβT2 responses (Chen et al., 2009).  
This study has shown that PR-B mRNA is basally expressed in the LβT2 cell line (Figure 5.1). 
However, no PR-B protein could be detected using Western blotting techniques (Figures 5.2 
and 5.4). This result was further confirmed, as PR (A+B) primary antibody was shown to be 
specific for the PR protein during PR (A+B) antibody optimization in the LβT2 and Cos-7 cell 
lines, however this data is not shown. The results of the reporter assay show no significant 
levels of agonist (P4 and R5020) activated PR-B protein (Figures 5.3 and 5.6). Interestingly, 
P4 treatments did significantly affect ERα mRNA expression (Figure 4.4) and GRα mRNA 
expression (Figure 6.4), suggesting the presence of a progesterone receptor mediating the 
transcriptional effects of P4 on target gene-expression in the LβT2 cell line. 
One weakness of this study was in the failure to detect ERα and PR-(A+B) protein, despite 
the detection of their respective RNAs by conventional and real time PCR. Interestingly, new 
studies are beginning to reveal a complex relationship between SRs and endogenous 
miRNAs. miRNAs are an abundant class of small nonprotein-coding RNAs that mostly 
function as negative regulators of protein-coding gene expression in multiple tumor cell 
lines (Cochrane et al.,2010). Several miRNAs have been shown to directly target and repress 
the translation of ERα. These include miR-206, miR-222, miR-22, miR-18a, miR-19b, miR-20b 
and miR145 (Cochrane et al., 2010; Mallot et al., 2009; Kondo et al., 2008; Xiong et al., 2010; 
Zhao et al., 2010). Overexpression of these miRNAs has been shown to decrease ERα 
protein and suppress ERα-mediated signalling (Cochrane et al., 2010). Futhermore, two 
miRNAs, the production of which was inhibited by estrogen, have been shown to target PR 
and reduce PR mRNA and protein levels (Maillot et al., 2009). Whether this relationship 















detection in the LβT2 cell line still needs to be determined. This could be assessed through 
the use of real time PCR, using LβT2 RNA samples and stem-loop RT primers specific for the 
miRNAs in question (Vreugdenhil et al., 2009; Maillot et al., 2009). With regards to the GR, it 
was shown that GR protein is present and functionally active in the LβT2 cell line. Results 
show basal GRα mRNA expression (Figure 6.1) and basal GRα protein expression (Figure 
6.2). Results further show functional GR-mediated transcription in response to GR agonist 
(Dex) treatment on a GRE-reporter plasmid (Figure 6.3), consistent with the literature 
(McGillivray et al., 2007; Kotitschke et al., 2009). Furthermore GR protein levels appear to 
be regulated in response to ligand treatments, suggesting that the GR is likely to have a 
functional purpose in mediating LβT2 responses (Figure 6.4). Taken together, these results 
show functionally active GRα in the LβT2 cell line. 
 
7.2  Summary of the effects hormones have on SR mRNA expression 
Table 7.2: Summary of mRNA expression results. In this study a number of ligand-dependent 
responses were seen affecting hormone receptor mRNA expression in LβT2 cells. The main results 
obtained from this study have been summarized in the table below. 
Target of 
Interest 




Appears to increase in response to Dex 
Appears to increase in response to GnRH 
Significant increase in response to Dex + GnRH 
E2 priming appears to increase the Dex response 
E2 priming appears to eliminate Dex additive effect 
Figure 3.2 
ER mRNA levels Significant decrease in response to GnRH 
Significant decrease in response to P4 
E2 priming appears to increase Dex response 
E2 priming appears to reduce Dex repressive response 
Figure 4.4 
PR mRNA levels Significant increase in response to GnRH 
No effect in response to Dex, P4 and E2 treatment alone 
E2 priming appears to have no effect on PR mRNA expression 
Figure 5.4 
GR mRNA levels Significant decrease in response to Dex 
Significant decrease in response to P4 
Significant decrease in response to GnRH 
Significant decrease in response to Dex + GnRH 
E2 appears to inhibit Dex response 
















A success of this study revealed that the GnRHR gene and SRs genes (ER, PR and GR) are 
significantly regulated in the LβT2 cell line, showing reproducible ligand-dependent trends in 
response to hormone treatments. This suggests that promoter regions of these target genes 
are transcriptionally regulated via hormone-responsive cis-elements. The GnRHR-gene 
promoter has been extensively characterised (Sadie, 2006), showing multiple factors 
recognizing specific cis-elements within the GnRHR promoter (Figure 1.8). SR-gene 
promoters have been sequenced (Breslin et al., 2001; Kos et al., 2001; Kastner et al., 1990), 
and show multiple promoters and transcriptional start sites. SR-gene promoters contain GC-
rich regions and generally lack TATA or CAAT boxes (Breslin et al., 2001; Kastner et al., 
1990), making interpreting mechanisms for transcrpitional regulation complicated. The 
author feels there is a lack of studies addressing the characterisation of cis-elements and 
molecular mechanisms mediating ligand-dependent SR-gene promoter regulation. For this 
reason, more research is required in this field. 
Interestingly P4 treatments were seen to significantly down-regulate ERα (Figure 4.4) and 
GRα mRNA expression (Figure 6.4). How these effects of P4 are being mediated to regulate 
target LβT2 gene expression is unclear, given the lack of detectable functional PR protein. P4 
has been shown to be a partial agonist for the GR, having a relative binding affinity (RBA) of 
274 nM for P4 binding to the GR; established in COS-1 cells by competitive binding assays 
using radio-labelled GR agonist, Dex, and transiently expressed recombinant GR protein 
(Ronacher et al., 2009). The RBA for Dex binding to the GR was also calculated to be 14 nM 
(Ronacher et al., 2009). Therefore one can estimate that the concentrations of P4 used in 
this study (100 nM) will not be high enough to saturate the GR, yet may have some partial 
effect on GR activity (Kontula et al., 1983; Koubovec et al., 2005).  
However a role for the GR in mediating the effects of P4 is not supported by the results 
showing significant differences between Dex and P4 treatments on ERα mRNA expression 
(Figure 4.4). ERα mRNA expression is significantly down-regulated in response to P4 
treatment, yet is not regulated in response to Dex treatment (Figure 4.4). Therefore GR 
















Another possibile mechanism by which P4 may elicit these responses is thought to be via a 
putative mPR. However, the results in this study suggest that mouse mPRα mRNA is not 
expressed in the LβT2 cell line (Figure 5.7). The presence of mPRα protein could not be 
determined due to problems in recombinant mPRα protein expression and mPRα protein 
detection using Western techniques (Addendum A, Table 9.1). The effects of P4 may be 
mediated by mPRβ or mPRγ, the expression of which was not examined in the current LβT2 
study. However, this is unlikely as others have shown that mPRβ and mPRγ mRNA are not 
expressed in the pituitary of humans (Zhu et al., 2003).  
A number of studies assessing the role of PR have been performed in the LβT2 cell line and 
have shown the presence of transcriptionally active PR-B protein (Thackray et al., 2009; An 
et al., 2009; Sleiter et al., 2009). However, these studies also used transiently transfected PR 
protein to confirm a role for PR signalling. The current author queries the need to over-
express PR protein, and the physiological significance of doing PR studies in a cell line which 
appears to exhibit little to no functional PR protein (Figure 5.1), when others have shown 
endogenous PR in both primary rat and mice models (Turgeon and Waring, 2000; Turgeon 
and Waring, 2006). This further highlights the importance of doing research in primary cell 
lines, as it may be possible for immortalised cell lines to change their properties over time 
under laboratory conditions. Taken together, P4 treatments did elicit a significant response 
on both ER and GR mRNA expression (Figures 4.4 and 6.4), supporting the concept that a 
functional PR protein is most likely present at low levels in the current LβT2 cell line.  
Interestingly GnRH treatments were seen to affect the transcriptional expression of all 
steroid receptors examined in this study (Figures 4.4, 5.4 and 6.4), highlighting the 
importance of GnRH signalling feedback in regulating gonadotrope steroid receptor levels. 
To the knowledge of the author, these are the first studies showing the effects of GnRH on 
endogenous SR mRNA expression in LβT2 cells. 
Mechanisms explaining how GnRH is able to regulate target receptor expression are still 
unknown, and require further experimental assessment. Two possible mechanisms could 
account for the observed regulation of target steroid receptor gene expression: The first 
may be via GnRH activating a wide variety of signalling proteins indirectly involved in gene 















target transcription factors (including c-Jun and c-Fos) to regulate cis-elements in target SR 
promoter regions. A site resembling an NF-κB in the GRα 1C promoter region (Figure 1.14) 
(Breslin et al., 2001), and an AP-1 site found in the ERα promoter (Tang et al., 1997) may be 
potential promoter targets for transcriptional regulation in response to GnRHR signalling 
(Kotitsche et al., 2009; von Boetticher, 2008; Marinissen and Gutkind, 2001). 
The effect of GnRH in modulating SR activity through ligand-independent mechanisms has 
been reported in a number of published studies. GnRH has been shown to ligand-
independently activate the GR (Kotitschke et al., 2009), ER (Chen et al., 2009) and PR (An et 
al., 2009) in LβT2 cell line. These studies show ligand-independent phosphorylation of SRs at 
key amino acid residues in response to GnRH treatment. Therefore a second mechanism 
may be via GnRHR activating SRs, in the absence of steroids, to regulate promoter activity. 
Potential targets for SR-mediated regulation include a half-GRE site in the GRα 1C promoter 
region (Berslin et al., 2001), a half-ERE in the PR-A promoter (Kastner et al., 1990) and, a 
half-PRE site in the ERα promoter (Amicis et al., 2009). 
One final explanation could involve a combination of GnRH-induced ligand-independent SR 
activation, and conventional GnRH-mediated signalling. Although one can hypothesise a 
mechanism based on the current literature, further experimental information on the ligand-
dependent regulation of endogenous SR promoter expression would help in assessing the 
observed transcriptional effects GnRH has on target SR genes 
Combination treatments of hormones were seen to significantly modulate mRNA receptor 
expression in LβT2 cells. Specifically, Dex and GnRH co-treatments were seen to act 
additively too significantly up-regulate GnRHR mRNA expression. As explained earlier, this 
result confirms a mechanism previously suggested (Kotitschke et al., 2009). Dex plus GnRH 
treatments also significantly down-regulate GRα mRNA expression more so when compare 
to individual treatments alone (Figure 6.4). Dex-mediated ligand-dependent activation of 
the GR, and GnRH-mediated ligand-independent activation of the GR, may mediate the 
transcriptional effects seen the GRα mRNA expression. Therefore two separate signalling 
pathways may be activated in response to Dex and GnRH alone, yet both pathways may 
converge on the GRα promoter to potentiate the observed Dex + GnRH repression on GRα 















site (Figure 1.14) (Breslin et al., 2001), two potential cis-elements that may be involved in 
this response. However, this hypothesis requires further experimental assessment before 
any conclusions can be made. 
An interesting trend was seen with E2 priming appearing to modulate Dex responses 
regulating GnRHR (Figure 3.2), ER (Figure 4.4) and GR (Figure 6.4) mRNA expression levels. 
This response was not apparent for all genes (Figure 5.4), suggesting it is gene-specific. In 
the literature, the effect of 0.2 nM E2 priming has been examined in the context of PR-
mediated signalling, as E2 priming shows a positive influence on PR expression in primary 
rat and mice gonadotropes (Turgeon and Waring, 2006; Turgeon and Waring, 2000). In this 
current study, it appears that E2 may have a broader effect on SR-mediated transcription. 
Low dosages were seen influencing the transcriptional effect Dex treatments may have on 
endogenous SR mRNA levels in the LβT2 cell line. These results suggest that E2 and Dex 
signalling pathways may crosstalk along the HPG and HPA axes (Figure 1.4). Yet molecular 
mechanisms of crosstalk between estrogens and glucocorticoids are poorly understood. 
Interestingly two studies have shown E2 treatment can inhibit glucocorticoid action. The 
first study shows that ligand-bound ERα can block Dex-mediated repression on the IL-8 
promoter in U2Os cells (Cvoro et al., 2011). Here, ERα directly interacts with the GR to 
interfere with the recruitment of nuclear co-activator 2 to the IL-8 promoter (Cvoro et al., 
2011). A second study shows that E2 can indirectly decrease ligand-induced GR 
phosphorylation at Ser-211 in MCF-7 and T47D cells (Zhang et al., 2009). Here, E2 increased 
the expression of protein phosphatase 5 (PP5), a phosphatase involved in 
dephosphorylating the GR at Ser-211, to decrease the transcriptional activity of GR protein 
(Zhang et al., 2009). The question whether this effect of E2 priming is mediated directly by 

























Agonist treatments show no increase in ERE-transcription with and 
without GnRH priming 




Agonist treatments show no increase in PRE-transcription with and 
without GnRH priming 




Agonist treatments show no increase in PRE-transcription with and 
without E2 priming 
E2 priming significantly effects basal PRE-reporter activity 
Figure 5.6 
The aim of the reporter-promoter assays was to assess if E2 or GnRH priming could 
modulate SR (ER and PR) activity on a HRE-reporter plasmid, in the absence and presence of 
agonist. ER-specific agonist treatment (E2) and PR-specific agonist (R5020) showed no 
significant increase in ERE-mediated and PRE-mediated transcription, respectively. Both 
results have been discussed previously in Section 7.1.  
Interestingly, when LβT2 cells were primed with GnRH, a significant increase in basal ERE 
and PRE-reporter activity was observed. Previous studies have highlighted the ligand-
independent effects of GnRH on the ER and the PR in the LβT2 cell line (Chen et al., 2009; An 
et al., 2009). These studies show that ER and PR activation is mediated by GnRH treatments, 
inducing site specific phosphorylation and co-activator interaction to promote endogenous 
fosB and fshβ mRNA expression, respectively, and ERE-or PRE-reporter promoter activity in 
LβT2 cells (Chen et al., 2009; An et al., 2009). Unfortunately the hypothesised GnRH-
mediated ligand-independent SR activation cannot be confirmed from HRE-luc reporter 
results alone. Further experiments are required before any conclusions may be made. A 
more plausible conclusion may suggests GnRH-priming is modulating the activity of RNA 
polymerase II or basal transcription factors involved in HRE-reporter expression, as no 
functional ER or PR protein could be detected in the current LβT2 cell line (Figures 4.2, 4.3, 
5.2, 5.4). 
Furthermore, a significant increase in PRE-reporter activity was seen in response to 0.2 nM 















(Blair et al., 2000). Therefore at a concentration of 0.2 nM E2, only a small fraction of the ER 
would be occupied by E2. This suggests the increase in PRE-reporter activity (in response to 
E2 priming) may not be mediated by liganded ER. However, one can only conclude that 
further experimental data is required to investigate the potential involvement of ER protein 
in this significant response. 
7.4  Statistical analysis of SR mRNA expression data 
An important aspect of all biological research is the statistical significance of the data 
collected during any study in question. In order to gather statistically relevant data, the 
researcher must be unbiased in interpreting his/her results, and appropriate statistical 
analysis should be applied. Therefore quantitative real-time PCR expression data was 
analyzed using a non-parametric two way ANOVA with bonferroni post tests. This ANOVA 
test was chosen to assess the significance of hormone treatments (variable 1) and E2 
priming (variable 2) on endogenous LβT2 GnRHR and SR mRNA levels. Furthermore, 
bonferroni post test were used to assess the significance of individual ligand treatments 
relative to control (-E2 EtOH).  
A limitation of this statistical test occurs when using large number of hormone conditions 
(large sample set). A central aim of this thesis was the broad assessment of hormone-
dependent effects on multiple genes in the LβT2 cell line, with the intent to establish a basis 
for further research. A large number of biological and technical repeats are required to 
obtain statistical significance for small differences on a large sample set. In this study, four 
biological repeats were collected for the un-primed (–E2) sample set, and three biological 
repeats for the E2 primed (+E2) sample set. Ideally more experimental repeats would be 
preferred for a study of this nature. However due to financial and time constraints, repeat 
number (n) was kept to a minimum to allow for the high number of hormone conditions. 
This may imply that some of the smaller insignificant responses observed on target mRNA 
levels may hold more significance if additional repeat experiments are performed. 
For this reason effects of hormone treatments on endogenous LβT2 GnRHR mRNA 
expression did not reveal much statistical significance in responses. However, this statistical 















conditions) and low number of biological repeats (n=3), coupled to possibly small fold 
changes. The large degree of variability for the two ligand conditions (-E2 and +E2, Dex + 
GnRH treatments), further reduces any possibility of getting statistically significant data. 
What can be said is that there is a reproducible ligand-dependent trend regulating GnRHR 
mRNA expression in the LβT2 cell line (Figure 3.2), which appears similar to the results 
previously  seen (Kotitsche et al., 2009; von Boetticher, 2008). Kotitsche et al, (2009) 
showed that GnRHR mRNA expression is synergistically up-regulated in response to Dex plus 
GnRHR co-treatment. It was shown that the transcriptional effects of Dex and GnRH 
treatment are mediated via an AP-1 site on the GnRHR promoter, through a mechanism 
dependent on the GR and the GnRHR (Figure 1.8) (Kotitschke et al., 2009). These results 
further show the potential for HPA and the HPG crosstalk regulating LβT2 gene expression. 
Taken together, the current study supports the finding that Dex, GnRH and co-treatment 
with both ligands, up-regulate GnRHR mRNA expression (Kotitsche et al., 2009). 
In an attempt to reduce the error present in real-time PCR data, one could incorporate a 
more accurate normalisation method of real-time PCR data by geometric averaging of 
multiple internal control genes (Vandesompele et al., 2002). These authors showed that the 
use of a single gene for normalisation may lead to a relatively large error in a significant 
proportion of the samples tested. This normalisation stratagy has been validated, and 
presents the possiblilty of studying the biological relevance of small expression differences 
















7.5  A model to represent receptor mRNA levels relative to 
endogenous GAPDH mRNA expression 
It is becoming clearer that a cell system exists in a constant state of flux, with multiple 
signalling events occurring constantly to maintain cellular homeostasis. This suggests that 
the expression of multiple target genes is regulated simultaneously in response to multiple 
signalling molecules. In the context of this study, varying SR-levels will have a significant 
consequence on down-stream SR-mediated signalling and/or target gene expression. 
Graphically representing total mRNA expression data relative to GAPDH mRNA expression 
will help visualise the “bigger picture”; the effects hormone treatments have on multiple 
receptor mRNA levels in the LβT2 cell line. Therefore, a model that integrated all the relative 
levels of target mRNA expression, was devised to visualise ligand-dependent trends on LβT2 
target gene expression (Figure 7.1). The model assumes that the transcriptional effects of 
hormone treatments on SR mRNA levels have a concomitant effect on protein translation. 
However this is not necessarily the case (Malys and McCarthy, 2011), but is a useful 











































Figure 7.1: A cellular representation of total receptor levels in response to treatments, assuming 
relative protein levels follow relative mRNA levels. Using quantitative real time PCR data, Ct values 
obtained under basal (EtOH) conditions were averaged (n=3) for each gene of interest (GAPDH; 
GnRHR; ER; PR; GR). Total receptor levels were normalised to GAPDH expression under basal 
conditions (EtOH). Ligand-dependent effects were set relative to (EtOH) by applying the receptor 
ratio under basal conditions to the ligand-depend trends (ΔCt) observed for each receptor and each 
condition. Note, this model only represents a projection of relative cellular receptor content from 















receptor mRNA levels is translated through to protein levels. This model serves as a visualising aid, 
to help gain insight into the overall effects hormone treatments have on total receptor expression. 
Firstly, an aspect of this study that has fallen short was in the assessment of SR protein 
levels. GRα protein levels were detected and appear to be regulated in a similar ligand-
dependent trend as GRα mRNA, in response to Dex and GnRH treatments. The question 
whether ERα, PR-B and GnRHR protein levels will follow similar ligand-dependent trends 
cannot be concluded, as ERα and PR-B protein could not be detected using Western blot 
techniques. Furthermore, previous attempts in detecting GnRHR protein levels, in the 
Hapgood lab, have proven unsuccessful due to problems in the immuno-detection of GnRHR 
protein (data not shown). What this model can offer is a possible prediction of ERα, PR-B 
and GnRHR levels under hormone conditions used in this study.  
What is interesting is the interplay of these hormones in regulating multiple receptor mRNA 
levels in the LβT2 cell line. Therefore this model helps to define a complete receptor 
transcriptome for the LβT2 and for the effects of these hormones, both alone and in 
combination.. A recent review has shown a role for multiple and simultaneous hormone 
treatments regulating gonadotrope physiology (Thackray et al., 2010). This review suggests 
that a precise interplay of GnRH, activin and sex hormones is influential in governing 
gonadotropin hormone production. This also highlights the importance of hormones acting 
additively and even synergistically in regulating target gonadotrope genes (Thackray et al., 
2010). Whether these fold changes in receptor levels seen in this study, in response to 
multiple hormone treatments, is enough to result in a physiological effect, is hard to say. 
However, a study has shown that varying GR protein levels do have an influential effect on 
Dex responsiveness (Zhao et al., 2003). Therefore one can hypothesis that these changes in 
receptor levels are influential in LβT2 physiology. Further studies in primary cultures are 
required to assess the effects on gonadotrope physiology.  
An initial observation is the extent to which the GnRHR is regulated. Under all conditions, 
the GnRHR mRNA is never down-regulated. This may suggest that the GnRHR is an 
important receptor for maintaining LβT2 function. Previous studies have shown GnRHR-
mediated signalling regulates a number of important gonadotrope genes, including fshβ (An 















GnRH + Dex conditions the GnRHR mRNA is highly expressed, in excess of any other 
receptor mRNA. This response appears to be synergistic in nature, and further supports the 
possibility that signalling crosstalk may lead to differential mRNA expression (Thackray et al., 
2010). This in not unexpected, as the main function of the pituitary gonadotrope is to 
respond to GnRH, suggesting that GnRHR-mediated signalling will be favoured under the 
combined Dex and GnRH hormone condition.  
Interestingly ERα and GRα mRNA and GRα protein were not up-regulated in response to the 
hormone conditions used in this study. This result suggests negative feedback from the 
gonads and adrenal gland to the pituitary regulates relative SR levels. This feedback has 
been established, with GRα levels down-regulated in response to GCs (Burnstein et al., 
1990) and ER levels down-regulated in response to P4 (Amicis et al., 2009). However, what 
is interesting, is the significant affect GnRH treatment has on reducing both ERα and GRα 
expression levels. 
On the other hand, PR levels do not seem to be affected by Dex P4 and E2 treatments. Only 
GnRH treatments up-regulate PR levels in the LβT2 cell line. As for the effects of E2 priming, 
it appears no significant changes are occurring on mRNA the mRNA levels investigated. The 
only apparent effect is under Dex conditions, where Dex-mediated suppression of GRα is 
lifted in response to E2 priming. Taken together, it is clear that GnRHR, ER, PR and GR 
expression levels are regulated in response to hormone treatments. However, the LβT2 cell 
line may not mimic the effects in primary cells, and therefore need to be confirmed in 
primary cell cultures.  
In conclusion, the most important observation from this study shows the influential role of 
GnRHR-signalling in regulating LβT2 mRNA expression. Not only were most of the significant 
changes in SR mRNA levels in response to GnRH treatment, but GnRHR mRNA levels were 
shown to be highly regulated in response to multiple hormone treatments. These results 
show GnRH-signalling significantly regulates ER, PR and GR mRNA expression in LβT2 cells, a 
















7.6  Final conclusion 
In summary, this current study presents for the first time, an overview of classical SR (ER, PR 
and GR) presence and function in the LβT2 cell line The study shows that GnRHR and SR (ER, 
PR and GR) mRNA levels, and GR protein levels are ligand-dependently regulated in LβT2 
cells. This suggests that target SR promoters are transcriptionally regulated in response to 
multiple hormone treatments. Specifically, several interesting and significant findings were 
established from this study. 
The significant findings in the LβT2 cell line include;  
 GnRH treatment significantly regulates ER, PR and GR mRNA levels 
 GnRH and E2 priming significantly modifies basal HRE-reporter activity 
 GnRHR mRNA levels are significantly up-regulated in response to Dex and GnRH 
 ERα mRNA levels are significantly down-regulated in response to GnRH 
 GRα mRNA levels are significantly down-regulated in response to Dex and GnRH 
 E2 priming appears to dampen the Dex response on ERα and GRα mRNA expression. 
 Combination treatments of GnRH and P4 show no additive effect on ligand-
dependent responses. 
 E2 priming alone has no effect on GnRHR, ERα, PR-(A+B) and GRα basal mRNA levels. 
 E2 priming does not affect P4 and GnRH-mediated responses. 
Although no mechanisms were established for the multiple observed responses, this study 
does serve as a basis for further research into novel HPG and HPA crosstalk mechanisms 
regulating endogenous GnRHR, ER, PR and GR mRNA and protein levels in the LβT2 cell line. 
It is more than likely that SRs are involved in mediating the regulation of some of these 
target genes (Figure 1.9), however many questions remain unanswered. Therefore 
additional experiments will be required to follow up the responses observed in order to 
further interpret and assess mechanisms mediating the observed ligand-induced effects on 


















The results presented in this study show significant changes in GnRHR, ER, PR and GR mRNA 
expression levels in response to multiple hormonal treatments in the LβT2 gonadotrope cell 
line. Many questions remain unanswered, including the presence of functional ER and PR 
protein and the molecular mechanisms that mediate some of the observed responses. For 
this reason additional experimental strategies are required to determine possible 
explanations for the observed responses in this study. 
8.1 Basal ER and PR protein expression in the LβT2 cell line 
No functional ER protein was detected in the LβT2 cell line, contradictory to previous LβT2 
studies (Chen et al., 2009; Shupnik et al., 2000). Although the primary ERα antibody used for 
western blotting proved unsuccessful in detecting ERα protein (Figure 4.2), another ER 
antibody can be ordered to re-assess ER protein levels in this cell line. An additional strategy 
to assess whether functional ER protein is present in the LβT2 cell line would be to 
reproduce the real-time PCR results shown by Chen et al., (2009). If GnRH treatments up-
regulate endogenous fosB mRNA expression, it would suggest that functional ER protein is 
present, as the literature reports that ERα protein mediates the transcriptional effects of 
GnRH on the fosB promoter in a ligand-independent manner (Chen et al., 2009). 
Previous studies have shown a functional role for PR-mediated signalling in the LβT2 cell line 
(An et al., 2009; An et al., 2006). No PR protein could be detected in the LβT2 cell study 
using western blotting techniques in this study, however, the functional PR protein reporter 
assay (Figure 5.3), appeared to show a small increase in PR-mediated transactivation upon 
agonist treatment. Only three replicates were performed, however. Therefore additional 
repeats of the PRE-luc reporter experiment are required to assess the question of whether 
LβT2 cells express low levels of functional PR protein in a statistically relevant manner. 
Interestingly significant changes in ER (Figure 4.4) and GR (Figure 6.4) mRNA expression are 















receptor. A different experimental strategy to address whether LβT2 cells have functional 
PR protein could involve reproducing the real-time PCR results presented by An et al., 
(2009). If it is shown that GnRH treatments can significantly up-regulate endogenous fshβ 
mRNA expression, it would suggest functional PR protein is present in the LβT2 cell line. as 
the literature reports that the PR-B ligand-independently mediates the transcriptional 
effects of GnRH on endogenous fshβ mRNA expression (An et al., 2009). 
Another challange presented by this study was establishing which PR isoform is 
predominantly expressed in the LβT2 cell line. The primers used for amplifying PR mRNA 
expression were not suitable for distinguishing differences between PR-B and PR-A isoforms. 
Therefore PR-B and PR-A-specific primers should be used to investigate firstly if both 
isoforms are present, and secondly at what ratios of PR-B/PR-A mRNA levels exist in the 
LβT2 cell line. 
8.2 Mechanisms for GnRH-mediated regulation of SR levels 
Interestingly GnRH treatment was shown to significantly affect mRNA expression levels of 
the ER, PR and GR in the LβT2 cell line. This may occur via two possible mechanisms. The 
first may be via GnRHR signalling activating intracellular signalling cascades to activate 
various signalling complexes and transcription factors to initiate a transcriptional response. 
A site resembling an NF-κB in the GRα 1C promoter region (Figure 1.14) (Breslin et al., 2001), 
and an AP-1 site found in the ERα promoter (Tang et al., 1997) may be potential promoter 
targets for transcriptional regulation in response to GnRHR signalling. To confirm that the 
effects of GnRH treatments on target SR mRNA expression are mediated by the GnRHR 
signalling pathway; siRNA transfections can be performed to silence basal GnRHR mRNA 
expression and investigate GnRHR-mediated responses.  
The second mechanism may be via GnRHR/SR crosstalk, whereby GnRH mediates SR 
activation via steroid-independent mechanisms (An,et al. 2009; Chen,et al. 2009; Kotitsche et 
al., 2009). Therefore knock down studies using GR-, PR-or ER-specific siRNA tranfections can 
be used to silence GR, PR or ER mRNA expression and determine if the responses to GnRH 
are dependent on unliganded SRs. If SRs are shown to mediate transcriptional responses to 















modifications play an important role in these GnRH-dependent, but steroid-independent 
mechanisms. Previous studies have shown important amino acid residues involved in the 
GnRH-dependent activation of target SRs. Phosphorylation at Ser-118 and Ser-167 have 
been identified to coincide with ER steroid-independent, GnRH-dependent activation (Chen 
et al., 2009). Phosphorylation at Ser-294 has been identified to coincide with PR steroid-
independent GnRH-dependent activation (An et al., 2009); and phosphorylation at Ser-234 
has been identified to coincide with GR steroid-independent GnRH-dependent activation 
(Kotitschke et al., 2009). The question whether these particular serine residues are 
phosphorylated in response to GnRH can be assessed with overexpressed mutant SRs which 
cannot be phosphorylated at target serine residues. 
In both cases, insight into the transcription factors and cis-elements involved in mediating 
this transcriptional regulation of target SR genes would allow for a more thorough 
mechanistic understanding of the responses observed in this study. Therefore it would be 
interesting to utilize co-immuno precipitation  (Co-IP) and chromatin immuno precipitation 
(ChIP) experiments to investigate which transcription factors are recruited to the target 
promoter, and the regions/cis-elements to which they are recruited. 
Finally, significant effects were seen on basal HRE-luc reporter activity in response to GnRH 
priming. Both ERE-luc (Figure 4.5) and PRE-luc (Figure 5.6) expression increased in response 
to GnRH treatments. This may be a result of the ligand-independent activation of the ER or 
PR in response to GnRH. This mechanism is possible, since it has been shown that GnRH 
treatment mediates the site-specific phosphorylation of the ER and PR to increase 
endogenous LβT2 fosB and fshβ mRNA expression respectively (Chen et al., 2009; An et al., 
2009). However, it is also possible that these responses are independent of SRs, and 
mediated by GnRH activating component(s) of basal transcription machinery present on the 

















8.3  Ligand-dependent responses on ERα mRNA expression 
P4 treatment significantly reduced endogenous ERα mRNA expression (Figure 4.4) in the 
LβT2 cell line. This result may demonstrate a direct mechanism for the anti-estrogenic 
effects of P4, as the suppressive effects of P4 on ERα expression have been observed in 
multiple reproductive cell lines (Weigel and deConick, 1993). A half PRE site is present in the 
ERα promoter and is functional in MCF-7 breast cancer cells (Amics et al., 2009). This 
suggests that the effects of P4 may be via the PR binding to this half site. However, since 
functional PR could not be detected in these cells, the question arises whether this response 
is mediated by the PR in the LβT2 cell line. To get a better understanding, Co-IP and ChIP 
experiments can be used to assess which transcription factors may mediate the observed 
response to P4, and with which cis-elements within the ER promoter protein complexes 
interact. 
Another interesting question is whether P4 and GnRH co-treatment act in concert to repress 
ERα mRNA expression. Although a combination of these treatments was shown to repress 
ERα mRNA expression equal to that of GnRH treatment alone (Figure 4.4), it is possible with 
a subtracting concentration of GnRH. P4 c -treatment may act in concert with GnRH to 
suppress ERα mRNA expression. To assess this, an additional experiment can be performed 
using 100 nM, 10 nM and 1 nM GnRH treatments with and without 100 nM P4 treatments. 
This experiment would discriminate whether P4 has any additive properties with GnRH 
signalling. 
Finally, the literature has shown that E2 is able to repress ERα expression in primary 
pituitary cells (Scheihofer et al., 2000). However, in this current study, immortalised LβT2 
cells appeared to show no change in ERα mRNA expression in response to E2 priming (Figure 
4.4). This may be due to the low concentration (0.2 nM) of E2 used in the experiment. This 
difference in response to E2 between primary and immortalised pituitary cell lines shows a 
physiological difference between cell types. However to assess these differences, an 
additional experiment should be performed with LβT2 cells treated with a concentration of 
10 nM E2 for 4 days (as performed by Scheihofer et al., 2009), to assess if the LβT2 cells 















8.4  Ligand-dependent responses on PR (A+B) mRNA expression 
The current study showed little ligand-dependent variation on PR (A+B) mRNA levels. 
However it is possible that small significant changes do occur, which may be significant with 
additional repeat experiments. Designing more efficient PR primers may also improve the 
ability to detect small changes in PR mRNA levels, as the primer efficiency of the PR-A+B 
primer pair was calculated to be 75% (Addendum C, 11.3).  
8.5  Ligand-dependent responses on GRα mRNA expression 
It was shown that relative GR mRNA expression is significantly repressed (50%) in response 
to Dex treatments. An interesting question is whether the GR mediates this response in the 
LβT2 cell line. LβT2 cells transfected with GRα-specific siRNA to knock-down the GR will help 
evaluate the involvement of the GR. Additionally one could utilize a dominant-negative GR 
expression construct, lacking DNA binding and transcriptional capability, to allow further 
assessment of GR involvement in this response to Dex. It has been shown that multiple 
promoters exist in the human GR promoter, with glucocorticoids able to regulate 
endogenous GR gene expression (Breslin et al., 2001). Furthermore a half-GRE site is present 
in the GRα 1C promoter region (Berslin et al., 2001). This suggests the the effects of Dex 
may be via the GR binding to this half site. Therefore, it would be interesting to utilize Co-IP 
and ChIP experiments to investigate whether the GR is recruited to the GR promoter and 
the regions/cis-elements to which it is recruited. 
In the case where Dex and GnRH treatments were seen to act in concert in repressing GRα 
mRNA (Figure 6.4), experiments are needed to assess whether this response is mediated by 
GR and GnRH crosstalk, or whether two separate signalling pathways are activated in 
response to Dex, and GnRH alone, yet converge on the GRα promoter to initiate the 
observed response. For this, GR and GnRHR knock-down studies may be performed using 
siRNA transfections. This would allow the researcher to assess the involvement of each 
receptor in mediating the response to Dex + GnRH treatments, and determine if GR and 















Little information is available in the literature regarding the mechanisms of GRα-gene 
regulation in the LβT2 cell lines. It appears that most of the studies regarding the GRα-
promoter region has been performed over a decade ago (Burnstein et al., 1991; Strahle et 
al., 1992), or performed in immune cell lines (Burnstein et al., 1991; Ramdas et al., 1999). 
Therefore, with the onset of new technologies including Co-IP and Chip experiments, a more 
detailed study on GRα-gene regulation could be performed. 
 8.6  E2 priming influencing Dex-mediated signalling 
An interesting trend was seen with E2 priming appearing to modulate Dex responses in 
regulating GnRHR (Figure 3.2), ER (Figure 4.4) and GR (Figure 6.4) mRNA expression. These 
results suggest that E2 and Dex signalling pathways may crosstalk along the HPG and HPA 
axes (Figure 1.4). Yet molecular mechanisms of crosstalk between estrogens and 
glucocorticoids are poorly understood. Interestingly two studies have shown E2 treatment 
can inhibit glucocorticoid action. The first study shows that ligand-bound ERα can block Dex-
mediated repression on the IL-8 promoter in U2Os cells (Cvoro et al., 2011). Here, ERα 
directly interacts with the GR to interfere with the recruitment of nuclear co-activator 2 to 
the IL-8 promoter (Cvoro et al., 2011). A sec nd study shows that E2 can indirectly decrease 
ligand-induced GR phosphorylation at Ser-211 in MCF-7 and T47D cells (Zhang et al., 2009). 
Here, E2 increases the expression of protein phosphatase 5 (PP5), a phosphatase involved in 
dephosphorylating the GR at Ser-211, to decrease the transcriptional activity of the GR 
protein (Zhang et al., 2009). The question as to whether this effect of E2 priming is mediated 
directly by ER and GR interactions, or indirectly through regulating phosphatase expression 
can be determined using Co-IP experiments. If the ER is found to complex with the liganded 
GR in response to E2 priming, then it is an indication that the ER and GR directly crosstalk to 
regulate GRα mRNA expression. If the ER is not found to complex with the GRα, then it is 
possible that E2 priming may indirectly affect GR activity through phosphorylation, turnover, 
nuclear trafficking or co-factor recruitment. These subsequent questions can be answered 
















8.7   Further statistical analysis for future experimental design 
In order to further investigate interesting responses seen on SR mRNA levels, repeat 
experiments should be performed using only the hormone treatments of interest. This way 
more technical repeats could be collected with every biological repeat, thereby increasing 
the statistical significance of the data collected. Specific hormone responses of interest 
include: 
 The effects of P4 of PRE-mediated transactivation 
 The effects of Dex, GnRH and Dex + GnRH on GRα mRNA expression 
 The effects of E2 priming in modulating Dex-mediated regulation of GnRHR, ERα and 
GRα mRNA levels 
Before additional repeats experiments are to be performed, the researcher must focus on 
designing the experiment around which statistical analysis would be most appropriate for 
analysing the data set. For example, the researcher must take into account the number of 
variables of each experiment (for example, time, treatment or priming), in order to decide 
whether a one-way ANOVA or two-way ANOVA should be applied. Further statistical post-
tests must be considered if the researcher is comparing experimental conditions to control 
(Dunette post-test) or comparing each experimental condition to each other experimental 
condition (Bonferroni post-test). 
Finally, to further reduce experimental error present in a real-time PCR dataset, one could 
perform a more accurate normalisation method by geometric averaging of multiple internal 
control genes (Vandesompele et al., 2002), as mentioned in Section7.4. 
8.8  Physiological relevance of LβT2 cell line studies. 
An ongoing issue in the field of gene regulation is the relevance of results obtained in 
immortalised cell lines, as it may be possible that these cell lines do not respond in the same 
way as primary cells. On the other hand, immortalised cell lines greatly facilitate the 
investigation of cell-specific intracellular signalling. In the case of pituitary function, pituitary 















contain a mixture of cell types. For this reason, it is not always possible to determine 
whether any measured effects are direct or not, as these cultures have a heterogenic cell 
population that may be contributing to the final response measured. To resolve this, 
primary gonadotrope cells can be sorted from a pituitary cell population using flow 
cytometry. This is a technique that will hopefully be adapted by the Hapgood lab in 
assessing ligand-dependent effects on gene regulation in primary gonadotrope cells. This 
will be made possible through collaboration with Dr. Ulrich Boehm at the Institute for 
Neural Signal Transduction, Centre for Molecular Neurobiology, Germany (Wen et al., 2010). 
On the other hand, primary cells cannot be maintained in continuous culture, creating 
practical constraints on experimental design. For this reason, this method can prove 
financially demanding and time consuming in gathering reproducible data. 
However, performing experiments in immortalised cell lines can have its advantages over 
primary cell line work, as long as results are verified in a more physiological system, such as 
transgenic mice. Firstly, target cells can be immortalised at a particular developmental stage 
to represent different chronological differentiation stages of a cell line (Alarid et al., 1996). 
Secondly, immortalised cell lines can be continuously maintained under laboratory 
conditions. For these reasons, immortalised mouse gonadotrope cell lines have been 
previously used to study mechanisms of gene regulation (Hapgood et al., 2005). Yet, the 
author still feels it is in the best interest of all researchers to characterise immortalised cell 
lines used in experiments, and to compare cell-specific properties to primary cell types. 
8.9 Improved experimental design for results presented in this 
current study 
Only one repeat was obtained for the E2 primed P4 treatment for the real-time PCR data 
sets (Figures 3.2, 4.4, 5.4 and 6.4). The combined effects of E2 priming and 100 nM P4 
treatment appeared to up-regulate GnRHR mRNA expression (Figure 3.2), and suppress 
both the ERα (Figure 4.4) and the GRα (Figure 6.4) mRNA expression, with no effects seen of 
PR expression levels. Statistical significance of these treatments where not established due 
to complications during sample collection and preparation. Therefore, additional repeats 















Standards used to calculate GnRHR and GAPDH primer efficiencies were adopted from 
Kotitsche et al., 2009, on the basis that identical protocols and cell lines were used between 
the two studies. However, it would be more appropriate to determine  GnRHR and GAPDH 
primer efficiencies for each experiment in parallell, as primer efficiency can vary between 
each real-time PCR run. Under the assumption that additional data is required for 
publication, primer efficiencies should be determined in parallel with experimental sample 
sets, for each biological repeat. For this, a stock of pooled cDNA (1 or 2 dilutions) can be 
used to determine primer standards for each run, while sample cDNA is simutaniously 
assessed. Unfortunately due to time limits of the MSc, only one standard was performed for 
each primer pair (with the exception of GnRHR and GAPDH) in this study, Furthermore, it 
should be noted that the primer efficiencies for the ERα and GRα were calculated to be 
113% and 130% respectively. High efficiency values indicate target mRNA transcripts are 
being amplified 2.13 and 2.3 times per PCR cycle for the ER and GR, respectively. Primer 
dimers may be one explaintion to the additional DNA amplication during real-time PCR 
cycles. Ideally, primer efficiencies between 80-100% are best for real-time PCR. Therefore to 
correct for inaccurate primer efficiencies, melting temperatures can be adjusted to correct 
for [E] values, or additional cDNA dilutions can be used during the standards to ensure 
accurate [E] value calculations. Finally, one could redesign primers to ensure more accurate 
[E] values. However due to time and finacial constrants, primer efficiencies for ERα and GRα 
were assumed as 2, suggesting 100% efficiency (which is still less efficient compared to 
calculated values). This assumption does not change the outcome of the relative expression 
data.  If a [E] value of 130% was assumed for GRα expression, larger fold values would be 
seen, yet relative ligand dependent trends would remain unchanged. Although this 
approach is not the most ideal way to interpret expression data, it still served as a basis on 
which further experimental assessment can be performed. 
This study showed the effects of agonist and GnRH treatments on endogenous ER- and PR-
mediated HRE-luc reporter activity, but was not performed for GR transactivation due to 
time constraints. Additionally it would have been better to include a positive control (over-
expressed SR) in reporter assay experiments to assess any problems that may have occurred 
during HRE-luc reporter plasmid transfection or ligand stimulation. For example, the results 















change compared to vehicle. This may be a result of problems experienced during transient 
transfection or ligand treatments. Therefore, a positive control for HRE-luc reporter activity 
using exogenous SR protein would assess whether transfection or ligand treatments were 
successful. 
A technique that appeared to show relatively high variability between data sets was the 
quantification of western blots (Figure 6.5). The strategy of measuring band intensity of 
autoradiograms using scanning and AlphaEaseFCTM imaging software was not the most 
reproducible, as many errors were introduced. These errors include the non-linear 
relationship between signal and intensity on the film, and the variation in background. For 
this reason, it is suggested that future western blot developments should use specialised 
imaging hardware (implementing digital camera technology) to increase reproducibility of 



















Figure 9.1: The LβT2 cell line expresses PR, ER, GR and AR mRNA under basal conditions. LβT2 cells 
were seeded into 6-well culture plates in DMEM supplemented with 10% FCS, and were left to grow 
to 70% confluency under basal conditions. Thereafter the cells were harvested and RNA extractions 
were performed, followed by a reverse transcriptase reaction to generate cDNA. Signals were 
amplified using conventional PCR with gene-specific primer pairs. PCR products were generated over 
35 PCR cycles and separated on a 2% agarose gel by electrophoreses, and visualised with ethidium 
bromide staining. Positive signals are seen for PR (A+B) amplicon at 121bp; PR-B amplicon at 121 bp; 



















Figure 9.2: The mPRα and the GR, but not the PR, are endogenously expressed in the End-1 cell 
line. Endocervical cells (End-1were seeded into 6-well culture plates in KSF supplemented with 10% 
BPE, and left to grow to 70% confluency under basal conditions. Thereafter the cells were harvested 
and RNA extractions were performed, followed by a reverse transcriptase reaction to generate 
cDNA. Different biological repeats are annotated cDNA1 and cDNA2. cDNA was amplified using 
conventional PCR with gene-specific primer pairs (Addendum B). PCR products were generated over 
35 PCR cycles, separated on a 2% agarose gel using electrophoreses, and visualised with ethidium 
bromide staining. Gel image shows mPRα and GR mRNA are basally expressed, while no PR mRNA 
can be found in the Endo-cervical cell line. β-actin used as an internal control. Signals are seen for 
the mPRα amplicon at 214 bp, the PR-B amplicon at 196 bp, the GR amplicon at 643 bp and the β-
actin amplicon at 275 bp. Positive controls (+’ive) include the pcDNA3.1/mPRα, pMT-PR-B and 
pCMV-HA-hGR expression constructs. Negitive control (-‘ive) defines the no template control. 
  


















Figure 9.3: PR A + B protein is not detectable by Western blotting in the endo-cervical cell line. 
Endo-cervical cells were seeded into 6-well culture plates in KSF supplemented with 10% BPE and 
antibiotics and were left to grow to 70% confluency under basal conditions. Thereafter the cells 
were harvested in 100 µl 2x SDS sample application buffer. Equal amounts (10 µl) of Endo-cervical 
whole cell lysates were separated on a 8% SDS denaturing polyacrylamide gel, transferred to a 
nitrocellulose membrane and probed with PR-B-specific, PR(A+B)-specific and β-tubilin-specific 
(loading control) primary antibodies. Anti-mouse HRP conjugate secondary antibodies were used for 
detection of protein-specific primary antibodies. Signals were visualised with Amersham 
Chemiluminescence. PR-B and β-Tubilin proteins are observed at 116 kDa and 55 kDa respectively, 
while no signal is seen for PR-A (result not shown) at 81 kDa. Positive controls (+’ive) are COS-7 cells 
lysates transiently transfected with pMT-PR-B expression construct. Negitive control (-‘ive) defines 




















Figure 9.4: Transient expression of the HA-tagged human mPRα construct is not detected in the 
COS-7 cell line. COS-7 cells were seeded into 12-well culture plates in DMEM supplemented with 
10% FCS. Twenty four hours after seeding, the cells were transiently transfected using Fugene or 
DEAE Dextran transfection protocols (Methods), with increasing amounts of  either pHA/hmPRα 
(250 ng, 500 ng and 1 µg) or pCMV-HA-hGR (500 ng and 1 µg) and left to grow to 80% confluency 
under basal conditions. Thereafter the cells were harvested in 50 µl 2x SDS sample application 
buffer. Equal amounts (10 µl) of COS-7 whole cell lysates were separated on an 8% SDS denaturing 
polyacrylamide gel, transferred to a nitrocellulose membrane and probed with anti-HA and anti-
Caveolin-1 (Loading control) primary antibodies. Anti-rabbit HRP conjugate secondary antibodies 
were used for detection of anti-HA primary antibodies, while anti-mouse HRP conjugate secondary 
antibodies were used for detection of anti-Caveolin-1 primary antibodies. Signals were visualised 
using Amersham Chemiluminescence. No expression of HA tagged hmPRα protein is detected at 40 
kDa or 80 kDa. HA tagged GR is detected at 95 kDa. Caveolin-1 protein is at 26 kDa, and was used as 





















Figure 9.5: Transient expression of recombinant human mPRα protein is not detected in the LβT2 
and End-1 cell lines. Endo-cervical cells were seeded into 12-well culture plates in KSF supplemented 
with 10% BPE. LβT2 cells were plated into 12-well plates in DMEM supplemented with 10% serum. 
After a 24 hour incubation period, the medium was replaced for both cell lines and incubated further 
for 24 hours. Thereafter 1 µg of pcDNA3.1/mPRα expression plasmid was transiently transfected and 
were left to grow to 80% confluency. Thereafter the cells were harvested in 50 µl 2x SDS sample 
application buffer. Equal amounts (10 µl) of End-1 and LβT2 whole cell lysates were separated on an 
8% SDS denaturing polyacrylamide gel, transferred to a nitrocellulose membrane and probed with 
anti-mPRα primary antibodies.  Anti-goat HRP conjugate secondary antibodies were used for 
detection of anti-mPRα primary antibodies. Signals were visualised using Amersham 
Chemiluminescence. mPRα exists as a 80 kDa homodimer or a 40 kDa monomer. Loading control 


















Figure 9.6: A representation of sample set RNA integrity for cDNA conversion and subsequent real-
time PCR analysis using gene-specific primers. LβT2 cells were plated into 12-well plates in DMEM 
supplemented with 10% serum. After a 24 hours incubation period, the cells were treated with or 
without 0.2 nM E2 in phenol red-free media supplemented with 10% charcoal stripped serum. After 
48 hours, the cells were treated with 100 nM vehicle (EtOH) or the appropriate ligands or 
combinations thereof in phenol red-free, serum-free media. The cells were stimulated for 8 hours 
prior to harvesting and subsequent RNA extractions. RNA integrity was assessed by electrophoresis 
of RNA sample on a 1% denaturing RNA agarose gel. Image is a representation of sample RNA 

















Figure 9.7: An illustration of where the PR-B and PR-(A+B) primer pairs anneal to the PR-A/B 

















Table 9.1: Summary of hmPRα overexpression study performed in the LβT2 and End-1 cell lines. 
Cell line; Transfection & 






























































































































Yes N.A. Yes No 
LβT2  Fugene HEPES No No Yes No 
End-1 Fugene CREB/ 
HEPES 






Yes No Yes No 
LβT2  Fugene 5x SDS 
(50mM 
DTT) 
No No Yes No 
 
Endo-cervical cells were seeded into 6-well culture plates in KSF supplemented with 10% BPE and 
antibiotics. LβT2 cells were seeded into 6-well culture plates in DMEM supplemented with 10% FCS 
and antibiotics. After 24 hours both cell lines were transiently transfected, using Fugene or DEAE 
Dextran transfection protocols, with 1 and 0.5 µg pcDNA3.1/hmPRα and pCMV-HA-hGR (transfection 
control) respectively, and left to grow to 70% confluency under basal conditions. Thereafter cells 
were harvested using harvesting protocols presented in methods section (Table 1). Equal amounts 
(10 µl) of whole cell lysates were separated on an 8% SDS denaturing polyacrylamide gel, transferred 
to a nitrocellulose membrane and probed with anti-hmPRα and anti-GR specific primary antibodies. 
Anti-rabbit HRP conjugate secondary antibodies were used for detection of GR-specific primary 
antibodies, while anti-goat HRP conjugate secondary antibodies were used for detection of mPRα 
primary antibodies. Mock transfections were used as untransfected (negative) controls. A summary 
of the observations during mPRα over-expression are summarized in table 9.1. Cell lines, tranfection 
protocols and harvesting protocols used are indicated. Observations show observations made during 
Western blot analysis.*Overexpression of mPRα protein is determined by measuring the differences 
between mock tranfected and mPRα transfected cells. If there is no difference in band intersity for 
































Represented above is information regarding primer design and referencing for each gene-specific primer.  
Gene  Species Primer Sequence  Strand  Product Size 
(bp)  




Reference  NCBI Hit  
PR A+B  Mouse GGTGGGCCTTCCTAACGAG  Fwd  121  19 63.2 60  Turgeon et al., 2006  NM_008829.2  
  GACCACATCAGGCTCAATGCT  Revs   21 54.2    
PR B  Mouse GGTCCCCCTTGCTTGCA  Fwd  121  17 64.7 60  Turgeon et al., 2006 NM_008829.2  
  CAGGACCGAGGAAAAAGCAG  Revs   20 55    
ERα  Mouse GTCTGGTCCTGCGAAGGCTGCAA  Fwd  235  23 60.9 60  Schreihofer et al., 2000  NM_007956.4 
  GCCTTCCAAGTCATCTCTCTGACG  Revs   24 54.2    
ERβ  Mouse GCTGTGATGAACTACAGTGTTCCC  Fwd  267  24 50 60  Schreihofer et al., 2000 NM_207707.1  
  TGGACTAGTAAGTCATCTCTCTGACG  Revs   24 54.2    
GRα  Mouse TGCTATGCTTTGCTCCTGATCTG  Fwd  299  23 47.8 52  Thackray et al., 2006 NM_008173.3  
  TGTCAGTTGATAAAACCGCTGCC  Revs   23 47.8    
AR  Mouse GAGAACCCATTGGACTACG  Fwd  544  19 52.6 52  Thackray et al., 2006 NM_013476.3  
  TGAAGAAGACCTTGCAGC  Revs   18 50    
mPRα Human CGTTTCGGTCCACTGATCCCGG Fwd 214 22 64 56 Jaravaza. (Hons Thesis) NM_178422 
  GCGAGAAGACCTTCGGCATGTAGATACG Revs  28 54    
LHβ  Mouse GGCCGCAGAGAATGAGTTCT  Fwd  83  20 55  60  Chen et al., 2009  NM_008497.2  
  CTCGGACCATGCTAGGACAGTAG  Revs   23 56.5    
GnRHR Mouse CCACAGTGGTGGCATCAGGCCTTC Fwd 192 24 63 58 Kotitschke et al., 2009 (PhD) NM_010323.1 
  TAGCGTTCTCAGCCGAGCTCTTGG Revs  24 58    
GAPDH Mouse TTCACCACCATGGAGAAGGC Fwd 263 20 55 58 Kotitschke et al., 2009 (PhD) NM_008084.2 
  GGCATGGACTGTGGTCATCA Revs  20 55    

















PRIMER EFFICIENCY AND REAL-TIME PCR 
11.1 Real-time PCR reproducibility 
 
Figure 11.1 (A-C): Real-time PCR reproducibility using GnRHR primers on pooled LβT2 cDNA 
samples. LβT2 cells were plated in DMEM supplemented with 10% FCS. After 24 hours incubation, 
the cells were treated with or without 0.2 nM E2 in phenol red-free media supplemented with 10% 
charcoal stripped serum. After an additional 48 hours, the cells were treated with 100 nM vehicle 
(EtOH) or the appropriate ligands or combinations thereof. The cells were harvested, RNA was 
extracted, and cDNA was generated. Equal volumes (1 µl) of pooled endogenous cDNA (cDNA Mix #) 
were used to do 4x real time PCR reactions in paralle from the same cDNA pool to determine real-
time reproducibility. Quantitative real-time PCR products were visualised on a 2% agarose gel using 
gel electrophoresis (A) and each product was confirmed using melting curve analysis (B). NTC defines 

















Roto Gene 6000 CorbrettTM software analysis (C). Melting points and CT values are represented in 
Table 11.1. 
Table 11.1: Melting temperatures and CT values for GnRHR real-time PCR reproducibility. 
Table representing primer melt temperatures and CT values determined from real-time PCR run. The 





No. Colour Name Peak 1 No. Colour Name CT Value 
1 
 
GnRHR NTC  1 
 
GnRHR NTC 32.86 
2 
 
GnRHR Mix 1 91.2 2 
 
GnRHR Mix 1 18.79 
3 
 
GnRHR Mix 2 91.2 3 
 
GnRHR Mix 2 18.72 
4 
 
GnRHR Mix 3 91.2 4 
 
GnRHR Mix 3 18.79 
5 
 
GnRHR Mix 4 91.0 5 
 















11.2 ERα primer efficiency 
 
 
Figure 11.2.1 (A-C): Real-time PCR - ERα primer efficiency. LβT2 cells lysates were harvested, and 
subsequent RNA was extracted. cDNA was generated from RNA sample sets and pooled. A dilution 
series was made from pooled endogenous cDNA (concentration of pooled cDNA was 2 ng/µl). cDNA 
was diluted into 1:0, 1:3, 1:7 and 1:11 ratio’s. Subsequent approximate concentrations were 
calculated (as shown on figure) and used to determine gene-specific primer efficiency. Quantitative 
real-time PCR products were visualised on a 2% agarose gel using gel electrophoresis (A) and each 
product was confirmed using melting curve analysis (B). NTC defines the no template control. CT 
values were calculated using Roto Gene 6000 CorbrettTM software analysis (C) with CT values 

















Table 11.2.1: Quantitation information for ERα primer efficiency. 
No. Colour Name CT Approx Conc (ng/µl) Calc Conc (ng/µl) % Var 
1 
 
ERa 1:0 30.13 2.000 2.175 8.8% 
2 
 
ERa 1:0 30.03 2.000 2.349 17.4% 
3 
 
ERa 1:3 31.74 .666 .639 4.0% 
4 
 
ERa 1:3 31.57 .666 .729 9.5% 
5 
 
ERa 1:7 33.44 .222 .177 20.2% 
6 
 
ERa 1:7 33.94 .222 .121 45.5% 
7 
 
ERa 1:11 34.19 .074 .100 35.3% 
8 
 
ERa 1:11 34.27 .074 .094 26.7% 
9 
 
ERa NTC 34.78  .064  
Table showing CT values, relative concentration of cDNA and percentage variance for each cDNA 
dilution obtained from ERα primer efficiency real-time PCR. 
 
Threshold 0.3669 B 31.1542 
Left Threshold 1.000 R Value 0.97572 
Standard Curve Imported No R
2
 Value 0.95203 
m -3.03357 Reaction efficiency [E] 113.621  
 
Figure 11.2.2:  Standard curve CT (cycle number) vs. concentration (ng/µl) to determine primer 
efficiency. CT values collected from Table 11.2.1 above were plotted against their corresponding log 
concentrations, to generate a standard curve. The formula to calculate primer efficiency [E] 
percentage = (10^(-1/m)-1)*100, where m is the gradient of the standard curve. Gradient (m), R2-
value and primer efficiency are represented in table above. Efficiency of ERα primer pair was 




















Figure 11.3.1 (A-C): Real-time PCR – PR (A+B) primer efficiency. LβT2 cells lysates were harvested, 
and subsequent RNA was extracted. cDNA was generated from RNA sample sets and pooled. A 
dilution series was made from pooled endogenous cDNA (concentration of pooled cDNA was 2 
ng/µl). cDNA was diluted into 1:0, 1:3, 1:7 and 1:11 ratio’s. Subsequent approximate concentrations 
were calculated (as shown on figure) and used to determine gene-specific primer efficiency. 
Quantitative real-time PCR products were visualised on a 2% agarose gel using gel electrophoresis 
(A) and each product was confirmed using melting curve analysis (B). NTC defines the no template 
control. CT values were calculated using Roto Gene 6000 Corbrett
TM software analysis (C) with CT 


















Table 11.3.1: Quantitation information for PR(A+B) primer efficiency. 
Table showing CT values, concentration and percentage variance for each cDNA dilution gathered 
from PR-B primer efficiency real-time PCR. 
 
Threshold 0.0603 B 20.13161 
Left Threshold 1.000 R Value 0.99988 
Standard Curve Imported No R
2
 Value 0.99976 
M -4.11204 Reaction efficiency [E] 75.061 
 
Figure 11.3.2:  Standard curve CT (cycle number) vs. concentration (ng/µl) to determine primer 
efficiency. CT values collected from Table 11.3.1 above were plotted against their corresponding log 
concentrations, to generate a standard curve. The formula to calculate primer efficiency [E] 
percentage = (10^(-1/m)-1)*100, where m is the gradient of the standard curve. Gradient (m), R2-
value and primer efficiency are represented in table above. Efficiency of PR(A+B) primer pair was 
calculated to be 75%. 
  
No. Colour Name Ct Given Conc (Copies) Calc Conc (Copies) % Var 
A1 
 
PR (A+B ) 1:0 18.86 2.000 2.039 2.0% 
A2 
 
PR (A+B ) 1:0 18.92 2.000 1.971 1.4% 
A3 
 
PR (A+B ) 1:3 20.81 .666 .684 2.7% 
A4 
 
PR (A+B ) 1:3 20.89 .666 .654 1.7% 
A5 
 
PR (A+B ) 1:7 22.87 .222 .216 2.8% 
A6 
 
PR (A+B ) 1:7 22.83 .222 .221 0.4% 
A7 
 
PR (A+B ) 1:11 24.74 .074 .076 2.1% 
A8 
 
PR (A+B ) 1:11 24.78 .074 .074 0.2% 
B1 
 



















Figure 11.4.1 (A-C): Real-time PCR - GRα primer efficiency. LβT2 cells lysates were harvested, and 
subsequent RNA was extracted. cDNA was generated from RNA sample sets and pooled. A dilution 
series was made from pooled endogenous cDNA (concentration of pooled cDNA was 2 ng/µl). cDNA 
was diluted into 1:0, 1:3, 1:7 and 1:11 ratio’s. Subsequent approximate concentrations were 
calculated (as shown on figure) and used to determine gene-specific primer efficiency. Quantitative 
real-time PCR products were isualised on a 2% agarose gel using gel electrophoresis (A) and each 
product was confirmed using melting curve analysis (B). NTC defines the no template control. CT 
values were calculated using Roto Gene 6000 CorbrettTM software analysis (C) with CT values 

















Table 11.4.1: Quantitation information for GRα primer efficiency. 
No. Colour Name Ct Given Conc (Copies) Calc Conc (Copies) % Var 
A1 
 
GR NTC 26.32  .038  
A3 
 
GR 1:0 21.59 2.000 1.988 0.6% 
A4 
 
GR 1:0 21.79 2.000 1.683 15.8% 
A6 
 
GR 1:3 22.60 .666 .849 27.5% 
A7 
 
GR 1:3 22.75 .666 .751 12.8% 
A8 
 
GR 1:7 24.32 .222 .202 9.1% 
B1 
 
GR 1:7 24.32 .222 .202 9.1% 
B4 
 
GR 1:11 25.52 .074 .074 0.2% 
B5 
 
GR 1:11 25.52 .074 .074 0.4% 
Table showing CT values, concentration and percentage variance for each cDNA dilution gathered 
from GRα primer efficiency real-time PCR. 
 
Threshold 0.0196 B 22.40877 
Left Threshold 1.000 R Value 0.995 
Standard Curve Imported No R
2
 Value 0.99003 
M -2.75592 Reaction efficiency [E] 130.598  
 
Figure 11.4.2:  Standard curve CT (cycle number) vs. concentration (ng/µl) to determine primer 
efficiency. CT values collected from Table 4.1 above were plotted against their corresponding log 
concentrations, to generate a standard curve. The formula to calculate primer efficiency [E] 
percentage = (10^(-1/m)-1)*100, where m is the gradient of the standard curve. Gradient (m), R2-
value and primer efficiency are represented in table above. Efficiency of GRα primer pair was 
















11.5 GnRHR real-time PCR product 
 
 
Figure 11.5.1: A representation of real-time PCR products using GnRHR primers. LβT2 cells were 
plated into 12-well culture plates in DMEM supplemented with 10% FCS. After 24 hours incubation, 
the cells were treated with (+E2) or without (-E2) 0.2 nM E2 in phenol red-free media supplemented 
with 10% charcoal stripped serum. After an additional 48 hours, the cells were treated with 100 nM 
vehicle (EtOH) or the appropriate ligands (Dex, P4, GnRH) or combinations thereof in phenol red-
free, serum-free media. The cells were stimulated for 8 hours prior to harvesting and subsequent 
RNA extractions. cDNA was generated for all mRNA sample sets. Quantitative real-time PCR using 
GnRHR-specific primers was performed. Amplicons were visualised using on a 2% agarose gel using 
gel electrophoresis, with melting curve analysis (data not shown) confirming GnRHR PCR product 
seen at 196 bp. NTC defines the no template control. CT values were calculated using Roto Gene 
















11.6 GAPDH real-time PCR product 
 
 
Figure 11.6.1: A representation of real-time PCR product using GAPDH primers. LβT2 cells were 
plated into 12-well culture plates in DMEM supplemented with 10% FCS. After 24 hours incubation, 
the cells were treated with (+E2) or without (-E2) 0.2 nM E2 in phenol red-free media supplemented 
(Zhao, 2008 #272)with 10% charcoal stripped serum. After an additional 48 hours, the cells were 
treated with 100 nM vehicle (EtOH) or the appropriate ligands (Dex, P4, GnRH) or combinations 
thereof in phenol red-free, serum-free media. The cells were stimulated for 8 hours prior to 
harvesting and subsequent RNA extractions. cDNA was generated for all mRNA sample sets. 
Quantitative real-time PCR using GnRHR-specific primers was performed. Amplicons were visualised 
using on a 2% agarose gel using gel electrophoresis, with melting curve analysis (data not shown) 
confirming GnRHR PCR product seen at 263 bp. NTC defines the no template control CT values were 

















11.7 ERα real-time PCR product 
 
 
Figure 11.7.1: A representation of real-time PCR product using ERα primers. LβT2 cells were plated 
into 12-well culture plates in DMEM supplemented with 10% FCS. After 24 hours incubation, the 
cells were treated with (+E2) or without (-E2) 0.2 nM E2 in phenol red-free media supplemented 
with 10% charcoal stripped serum. After an additional 48 hours, the cells were treated with 100 nM 
vehicle (EtOH) or the appropriate ligands (Dex, P4, GnRH) or combinations thereof in phenol red-
free, serum-free media. The cells were stimulated for 8 hours prior to harvesting and subsequent 
RNA extractions. cDNA was generated for all mRNA sample sets. Quantitative real-time PCR using 
GnRHR-specific primers was performed. Amplicons were visualised using on a 2% agarose gel using 
gel electrophoresis, with melting curve analysis (data not shown) confirming GnRHR PCR product 
seen at 235 bp. NTC defines the no template control CT values were calculated using Roto Gene 6000 
















11.8 PR(A+B) real-time PCR product 
 
 
Figure 11.8.1: A representation of real-time PCR product using PR(A+B) primers. LβT2 cells were 
plated into 12-well culture plates in DMEM supplemented with 10% FCS. After 24 hours incubation, 
the cells were treated with (+E2) or without (-E2) 0.2 nM E2 in phenol red-free media supplemented 
with 10% charcoal stripped serum. After an additional 48 hours, the cells were treated with 100 nM 
vehicle (EtOH) or the appropriate ligands (Dex, P4, GnRH) or combinations thereof in phenol red-
free, serum-free media. The cells were stimulated for 8 hours prior to harvesting and subsequent 
RNA extractions. cDNA was generated for all mRNA sample sets. Quantitative real-time PCR using 
GnRHR-specific primers was performed. Amplicons were visualised using on a 2% agarose gel using 
gel electrophoresis, with melting curve analysis (data not shown) confirming GnRHR PCR product 
seen at 121 bp. NTC defines the no template control CT values were calculated using Roto Gene 6000 
















11.9 GRα real-time PCR product 
 
 
Figure 11.9.1: A representation of real-time PCR product using GRα primers. LβT2 cells were plated 
into 12-well culture plates in DMEM supplemented with 10% FCS. After 24 hours incubation, the 
cells were treated with (+E2) or without (-E2) 0.2 nM E2 in phenol red-free media supplemented 
with 10% charcoal stripped serum. After an additional 48 hours, the cells were treated with 100 nM 
vehicle (EtOH) or the appropriate ligands (Dex, P4, GnRH) or combinations thereof in phenol red-
free, serum-free media. The cells were stimulated for 8 hours prior to harvesting and subsequent 
RNA extractions. cDNA was generated for all mRNA sample sets. Quantitative real-time PCR using 
GnRHR-specific primers was performed. Amplicons were visualised using on a 2% agarose gel using 
gel electrophoresis, with melting curve analysis (data not shown) confirming GnRHR PCR product 
seen at 299 bp. NTC defines the no template control. CT values were calculated using Roto Gene 




















Figure 12.1: Plasmid map of pcDNA3.1/mPRα. The pcDNA3.1/V5/mPRα expression construct was a 
kind gift from Dr. B. Gellersen (Endokrinologikum Hamburg, Germany), however, plasmid 
maps were not provided. The human mPRα cDNA insert was sub-cloned into the pcDNA3.1 
expression vector. The expression construct was sequenced and digested using appropriate 
restriction enzymes and a detailed plasmid map was constructed by the candidate using 
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Figure 12.2: Plasmid map of pcDNA3.1/V5/mPRα. The pcDNA3.1/V5/mPRα expression construct 
was a kind gift from Dr. B. Gellersen (Endokrinologikum Hamburg, Germany), however, 
plasmid maps were not provided. The human mPRα cDNA insert was sub-cloned into the 
pcDNA3.1 expression vector with a 3’ V5-His tag. The expression construct was sequenced 
and digested using appropriate restriction enzymes and a detailed plasmid map was 
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Figure 12.3: Plasmid map of pHA/mPRα. The pcDNA3.1/V5/mPRα expression construct was a kind 
gift from Dr. B. Gellersen (Endokrinologikum Hamburg, Germany), however, plasmid maps 
were not provided. The human mPRα cDNA insert was sub-cloned into a modified pDISPLAY 
expression vector, from which Igκ signal peptide and TMD have been deleted. The 
expression construct was sequenced and digested using appropriate restriction enzymes 
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CALCULATIONS FOR STATISTICAL ANALYSIS  
All statistical analysis for this study was performed using Prism 5, GraphPad Software. 
Statistical analysis included one-way ANOVA, with Dunnett post test, two-way ANOVA with 
Bonferroni post test and a T-test. It must be noted that calculated p values were not 
displayed due to limitations of the software. Instead a p value summery is shown, to 
determine statistical significance. 
Table 13.1: Statistical analysis of TAT-GRE-luc expression in response to hormone 
conditions represented in figure 3.1 
Non-parametric one-way ANOVA (Figure 3.1) 
Dunnett's post-test Mean Diff. 95% CI of diff 
Significant? 
P < 0.05? Summary 
EtOH (1) vs Dex (2) -2.66 -8.457 to 3.138 No ns 
EtOH (1) vs P4 (3) 0.2433 -5.554 to 6.041 No ns 
EtOH (1) vs GnRH (4) -0.457 -6.255 to 5.341 No ns 
EtOH (1) vs GnRH + Dex (5) -15.24 -21.04 to -9.442 Yes *** 
EtOH (1) vs GnRH + P4 (6) -0.2908 -6.088 to 5.507 No ns 
 
Table 13.2: Statistical analysis of endogenous GnRHR mRNA expression in response to 
hormone conditions represented in figure 3.2 
Non-parametric two-way ANOVA (Figure 3.2) 
Source of Variation % of total variation P value P value summary Significant? 
Interaction 2.05 0.9491 ns No 
Treatment 41.95 0.0035 ** Yes 
Priming 0.13 0.7934 ns No 
 
Bonferroni post-tests (Figure 3.2) 
EtOH vs Dex 
Priming EtOH Dex Difference 95% CI of diff. P value Summary 
-E2 1 4.27 3.27 -3.650 to 10.19 P > 0.05 ns 
+0.2 nM E2 1.34 6.052 4.712 -3.278 to 12.70 P > 0.05 ns 
EtOH vs P4 
Priming EtOH P4 Difference 95% CI of diff. P value Summary 
-E2 1 1.36 0.3602 -6.560 to 7.280 P > 0.05 ns 
+0.2 nM E2 1.34 2.259 0.9188 -10.38 to 12.22 P > 0.05 ns 
EtOH vs GnRH 
Priming EtOH GnRH Difference 95% CI of diff. P value Summary 
-E2 1 3.065 2.065 -4.855 to 8.985 P > 0.05 ns 
+0.2 nM E2 1.34 3.205 1.865 -6.125 to 9.855 P > 0.05 ns 















Priming EtOH GnRH + Dex Difference 95% CI of diff. P value Summary 
-E2 1 9.457 8.457 1.537 to 15.38 P<0.01 ** 
+0.2 nM E2 1.34 7.666 6.326 -1.664 to 14.32 P < 0.05 * 
EtOH vs GnRH + P4 
Priming EtOH GnRH + P4 Difference 95% CI of diff. P value Summary 
-E2 1 2.664 1.664 -5.256 to 8.584 P > 0.05 ns 
+0.2 nM E2 1.34 3.028 1.688 -6.302 to 9.678 P > 0.05 ns 
 
Table 13.3: Statistical analysis of ERE-luc reporter expression in response to agonist 
treatment represented in figure 4.3 
T-test (Figure 4.3) 
Receptor EtOH Agonist Difference 95% CI of diff. P value Summary 
ER 1 1.212 0.2122 -1.378 to 1.803 P > 0.05 ns 
 
Table 13.4: Statistical analysis of endogenous ERα mRNA expression in response to 
hormone conditions represented in figure 4.4 
Non-parametric two-way ANOVA (Figure 4.4) 
Source of Variation % of total variation P value P value summary Significant? 
Interaction 4.48 0.2511 ns No 
Treatment 77.17 P<0.0001 *** Yes 
E2 Priming 2.19 0.0741 ns No 
 
Bonferroni post-tests 
EtOH vs Dex 
E2 Priming EtOH Dex Difference 95% CI of diff. P value Summary 
-E2 1 0.8818 -0.1182 -0.5869 to 0.3505 P > 0.05 ns 
+0.2 nM E2 1.035 1.416 0.3809 -0.1603 to 0.9222 P > 0.05 ns 
EtOH vs P4 
E2 Priming EtOH P4 Difference 95% CI of diff. P value Summary 
-E2 1 0.5442 -0.4558 -0.9246 to 0.01290 P < 0.05 * 
+0.2 nM E2 1.035 0.6566 -0.378 -1.143 to 0.3874 P > 0.05 ns 
EtOH vs GnRH 
E2 Priming EtOH GnRH Difference 95% CI of diff. P value Summary 
-E2 1 0.2339 -0.7661 -1.235 to -0.2974 P<0.001 *** 
+0.2 nM E2 1.035 0.2464 -0.7882 -1.329 to -0.2470 P<0.001 *** 
EtOH vs GnRH + Dex 
E2 Priming EtOH GnRH + Dex Difference 95% CI of diff. P value Summary 
-E2 1 0.2185 -0.7815 -1.250 to -0.3127 P<0.001 *** 
+0.2 nM E2 1.035 0.3041 -0.7305 -1.272 to -0.1893 P<0.001 *** 
EtOH vs GnRH + P4 
E2 Priming EtOH GnRH + P4 Difference 95% CI of diff. P value Summary 















+0.2 nM E2 1.035 0.2775 -0.7571 -1.298 to -0.2159 P<0.001 *** 
 
Table 13.5: Statistical analysis of ERE-luc expression in response to 100 nM GnRH priming 
represented in figure 4.5 
Non-parametric two-way ANOVA (Figure 4.5) 
Source of Variation 
% of total 
variation P value P value summary Significant? 
Interaction 0.09 0.8665 ns No 
Agonist 4.22 0.2765 ns No 
GnRH Priming 68.93 0.002 ** Yes 
 
Bonferroni post-tests 
EtOH vs agonist (E2) 
GnRH Priming EtOH E2 Difference 95% CI of diff. P value Summary 
-100nM GnRH 1 0.6368 -0.3632 
-1.499 to 
0.7724 P > 0.05 ns 
+100nM GnRH 2.232 1.962 -0.2697 
-1.285 to 
0.7460 P > 0.05 ns 
 
Table 13.6: Statistical analysis of PRE-luc expression in response to agonist treatment 
represented in figure 5.3 
T-test (Figure 5.3) 
Receptor EtOH Agonist Difference 95% CI of diff. P value Summary 
PR 1 1.231 0.2315 -1.359 to 1.822 P > 0.05 ns 
 
Table 13.7: Statistical analysis of endogenous PR (A+B) mRNA expression in response to 
hormone conditions represented in figure 5.4 
Non-parametric two-way ANOVA (Figure 5.4) 
Source of Variation % of total variation P value P value summary Significant? 
Interaction 11.21 0.4309 ns No 
Treatment 25.44 0.0774 ns No 
E2 Priming 1.32 0.4468 ns No 
 
Bonferroni post-tests 
EtOH vs Dex 
E2 Priming EtOH Dex Difference 95% CI of diff. P value Summary 
-E2 1 0.8783 -0.1217 -1.415 to 1.171 P > 0.05 ns 
+0.2 nM E2 1.09 0.962 -0.1277 -1.956 to 1.701 P > 0.05 ns 















E2 Priming EtOH P4 Difference 95% CI of diff. P value Summary 
-E2 1 0.8873 -0.1127 -1.406 to 1.180 P > 0.05 ns 
+0.2 nM E2 1.09 0.8184 -0.2713 -2.511 to 1.968 P > 0.05 ns 
EtOH vs GnRH 
E2 Priming EtOH GnRH Difference 95% CI of diff. P value Summary 
-E2 1 2.118 1.118 -0.1756 to 2.411 P < 0.05 * 
+0.2 nM E2 1.09 1.434 0.3446 -1.484 to 2.173 P > 0.05 ns 
EtOH vs GnRH + Dex 
E2 Priming EtOH GnRH + Dex Difference 95% CI of diff. P value Summary 
-E2 1 1.99 0.9895 -0.3035 to 2.283 P > 0.05 ns 
+0.2 nM E2 1.09 1.092 0.002326 -1.826 to 1.831 P > 0.05 ns 
EtOH vs GnRH + P4 
E2 Priming EtOH GnRH + P4 Difference 95% CI of diff. P value Summary 
-E2 1 1.45 0.4504 -0.8427 to 1.744 P > 0.05 ns 
+0.2 nM E2 1.09 1.907 0.8173 -1.011 to 2.646 P > 0.05 ns 
 
Table 13.8: Statistical analysis of PRE-luc expression in response to 100 nM GnRH priming 
represented in figure 5.5 
Non-parametric two-way ANOVA (Figure 5.5) 
Source of 
Variation 
% of total 
variation P value P value summary Significant? 
Interaction 7.68 0.045 * Yes 
Agonist 0.31 0.6779 ns No 
GnRH Priming 35.56 P<0.0001 *** Yes 
 
Bonferroni post-tests 
EtOH vs agonist (R5020) 
GnRH Priming EtOH R 5 020 Difference 95% CI of diff. P value Summary 
-100nM GnRH 1 0.791 -0.209 
-0.4866 to 
0.06851 P > 0.05 ns 
+100nM GnRH 1.201 1.34 0.1391 
-0.1385 to 

















Table 13.9: Statistical analysis of PRE-luc expression in response to 0.2 nM E2 priming 
represented in figure 5.5 
Non-parametric two-way ANOVA (Figure 5.5) 
Source of Variation 
% of total 
variation P value P value summary Significant? 
Interaction 0.75 0.4897 ns No 
Agonist 1.37 0.3519 ns No 
E2 Priming 67.74 P<0.0001 *** Yes 
 
Bonferroni post-tests 
EtOH vs agonist (R5020) 
E2 Priming EtOH R5020 Difference 95% CI of diff. P value Summary 
-0.2nM E2 1 0.9761 -0.02385 
-0.3515 to 
0.3038 P > 0.05 ns 
+0.2nM E2 1.708 1.55 -0.1585 
-0.4861 to 
0.1692 P > 0.05 ns 
 
Table 13.10: Statistical analysis of GRE-luc expression in response to agonist treatment 
represented in figure 6.3 
T-test (Figure 6.3) 
Receptor EtOH Agonist Difference 95% CI of diff. P value Summary 
GR 1 4.963 3.963 2.372 to 5.554 P<0.001 *** 
 
Table 13.11: Statistical analysis of endogenous GRα mRNA expression in response to 
hormone conditions represented in figure 6.4 
Non-parametric two-way ANOVA (Figure 6.4) 
Source of Variation % of total variation P value P value summary Significant? 
Interaction 8.88 0.4564 ns No 
Treatment 42.64 0.0054 ** Yes 
E2 Priming 4.6 0.1274 ns No 
 
Bonferroni post-tests 
EtOH vs Dex 
E2 Priming EtOH Dex Difference 95% CI of diff. P value Summary 
-E2 1 0.49 -0.51 -0.9780 to -0.04206 P<0.01 ** 
+0.2 nM E2 0.9277 0.9174 -0.01037 -0.6722 to 0.6514 P > 0.05 ns 
EtOH vs P4 
E2 Priming EtOH P4 Difference 95% CI of diff. P value Summary 
-E2 1 0.5378 -0.4622 -0.9302 to 0.005775 P < 0.05 * 















EtOH vs GnRH 
E2 Priming EtOH GnRH Difference 95% CI of diff. P value Summary 
-E2 1 0.5056 -0.4944 -0.9999 to 0.01106 P < 0.05 * 
+0.2 nM E2 0.9277 0.498 -0.4297 -1.092 to 0.2321 P > 0.05 ns 
EtOH vs GnRH + Dex 
E2 Priming EtOH GnRH + Dex Difference 95% CI of diff. P value Summary 
-E2 1 0.3115 -0.6885 -1.194 to -0.1830 P<0.001 *** 
+0.2 nM E2 0.9277 0.4467 -0.481 -1.143 to 0.1808 P > 0.05 ns 
EtOH vs GnRH + P4 
E2 Priming EtOH GnRH + P4 Difference 95% CI of diff. P value Summary 
-E2 1 0.4604 -0.5396 -1.045 to -0.03415 P<0.01 ** 


















BUFFERS AND SOLUTIONS 
 




2% (w/v) tryptone 
0.5% (w/v) yeast extract 
0.05% (w/v) NaCl 
2.5 mM KCl 
10 mM MgCl2 




1% (w/v) tryptone 
0.5% yeast extract 
1% NaCl 
containing 50 μg/mL ampicillin 
for LB-agar plates add 1,5% agar 
 




1 ml diethyl pyrocarbonate (DEPC) in 1 L dH2O (1:1000 dilution) 
Incubate 2 h at 37°C, autoclave twice to inactivate DEPC 
 
















0.2 M MOPS 
0,05 M sodium acetate 
0,01M EDTA, pH 8.0, adjust pH to 7.0 with 10 M NaOH 
 
Denaturing formaldehyde gel mix (1% 100 ml) 
 
Dissolve 1 g agarose in 70 ml DEPC-treated H2O and bring to boil. Add 10 ml 10X MOPS 
buffer and 20 ml formaldehyde in fume hood. Mix well and pour. 
 
RNA sample loading buffer 
 
1,8 ml DEPC H2O 
0,8 ml Bromophenol blue solution (saturated) 
1 ml glycerol (100%) 
1.5 ml 10x MOPS 
2,6 ml 12.3 M formaldehyde 
7,3 ml formamide 
Add 2,5 μl 10 mg/ml ethidium bromide per 1 ml RNA sample loading buffer just before use. 
 
RNA electrophoresis buffer (500 ml) 
 
50 ml 1x MOPS 
14 ml formaldehyde 

















14.3  Western blot analysis 
 
5X SDS sample buffer 
 
100 mM Tris-HCL, pH 6.8 
5% (w/v) SDS 
20% (v/v) glycerol 
2% (v/v) ß-mercaptoethanol 




25 mM Tris-HCL, pH 7.5 
250 mM glycine 




25 mM Tris, pH 7.5 
200 mM glycine 
10% (v/v) methanol 
 
Tris buffered saline (TBS) 
 
50 mM Tris, pH 7.5 



















50 mM Tris, pH 7.5 
150 mM NaCl 




100 mM ß-mercaptoethanol 
2% (w/v) SDS 
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